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ABSTRACT
Epidemiological Burden of Depression and its Impact on Adherence to Oral
Hypoglycemic Agents and Related Economic Outcomes in Patients with Type 2
Diabetes
Iftekhar D. Kalsekar

Presence of depression in patients with type 2 diabetes may affect their adherence
to oral hypoglycemics and consequently glycemic control and economic outcomes.
These potential effects may be more significant when one considers that depression is
highly prevalent in patients with diabetes. This study involved two phases. Phase one of
the study examined the epidemiological relationship between depression and type 2
diabetes. Phase two of the study examined the impact of depression on patterns of use
and adherence to oral hypoglycemics in newly diagnosed type 2 diabetes patients.
Impact of depression on expenditures related to type 2 diabetes and overall health care
was also estimated. The study also tested the mediating influence of adherence between
depression and type 2 diabetes expenditures. Results of phase one of the study indicated
that depression was more prevalent in patients with type 2 diabetes as compared to a
control group. Results also indicated that females with depression were more likely to
develop type 2 diabetes as compared to those without depression. Phase two results
indicated that patients without depression had a more favorable pattern of oral
hypoglycemic use with a significantly lower proportion of non-depressed patients
switching, augmenting, or discontinuing their oral hypoglycemics as compared to
depressed patients. Depressed patients were also found to have significantly lower
adherence to oral hypoglycemics as compared to non-depressed patients. Multivariate
analyses indicated that patients with depression incurred 21.30% higher type 2 diabetes
related costs as compared to non-depressed patients. This difference was primarily due to
a higher probability of an ER/hospitalization episode in depressed patients. Similarly,
patients with depression had 32.10% higher overall health care costs as compared to
patients without depression. Depression was associated with increased costs in all areas
of health care such as ER/hospitalization, outpatient, and prescription costs. Mediation
analysis indicated that adherence to oral hypoglycemics was not a mediator between
depression and type 2 diabetes related expenditures. Thus, depression could have
potentially impacted type 2 diabetes related outcomes directly through a physiological
effect on glycemic levels or indirectly through its impact on adherence to other behaviors
such as diet or exercise.
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CHAPTER ONE
INTRODUCTION
An estimated 17 million Americans are affected by diabetes. The American
Diabetes Association (ADA) has estimated the total cost attributable to diabetes to be
$132 billion in 2002, which included $ 91.8 billion in direct medical and treatment costs.1
The prevalence rates of diabetes in Medicaid programs have been reported to be nearly
twice that of the US population as a whole. Prevalence based costs of illness studies have
shown that the per capita mean cost of patients with diabetes in Medicaid were nearly
$8,000 per year; approximately four times the annual cost of a Medicaid enrollee without
diabetes.2
Diabetes mellitus can be divided into type 2 diabetes (formerly called non-insulin
dependent diabetes mellitus) and type 1 diabetes (formerly known as insulin dependent
diabetes mellitus). Type 2 diabetes is more prevalent and accounts for more than 90% of
diabetes cases.3 Data from the National Medical Expenditure Panel Survey (MEPS)
showed that inpatient hospital care for diabetes accounted for 63% of the total health care
expenditure for diabetics.4 Although the cost breakdown estimates for Medicaid are not
available, one can assume that even in Medicaid programs, diabetic complications
account for a major fraction of the total costs attributable to type 2 diabetes.
Over the past decade large-scale studies have demonstrated that tight glycemic
control greatly reduces the frequency and severity of long-term diabetes related
complications. In the 10-year United Kingdom Prospective Diabetes Study (UKPDS),
intensive glycemic control resulted in A1C levels that were significantly lower than in
type 2 diabetes patients on conventional therapy.5 The UKPDS data showed a continuous
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relationship between the risks of microvascular complications and glycemia, such that for
every percentage point decrease in A1C there was a 35% reduction in the risk of
complications.
The importance of tight glycemic control has been also recognized by key US
organizations. The National Committee for Quality Assurance (NCQA) and the
Foundation for Accountability (FACCT) encourage health care delivery systems to
provide appropriate diabetes care by maintaining tight glycemic control in their enrollees.
The American Diabetes Association (ADA) recommends measuring A1C every three
months and maintaining this value below 7% to prevent future complications.6 However,
in one study, only 20% of health maintenance organization members with diabetes met
these ADA standards.7
Studies using measures of adherence such as pill count and refill information have
demonstrated associations between drug adherence and glycemic control. Diehl and
associates8 used pill counts to assess adherence to oral hypoglycemics in patients with
type 2 diabetes and found a trend towards higher fasting blood glucose in patients taking
less than 80% of the prescribed doses. In addition, both Chousa and associates9 and
Peterson and associates10 used pill count and self-reported measures of adherence to
demonstrate an association between adherence and A1C levels. In a recent study
conducted by Schectman and associates11 in an indigent population using pharmacy
claims, glycemic control and its improvement over time were strongly associated with
adherence to diabetes medication measured on the basis of refill information. Thus,
evidence in the literature clearly links improved glycemic control through better
adherence to drug therapy in patients with type 2 diabetes.
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Adherence to Oral Hypoglycemics
There is a large literature demonstrating a strong association between adherence
to medication and outcomes. Adverse outcomes resulting from non-adherence including
increased use of emergency room and inpatient services account for a large proportion of
the drug-related morbidity and mortality estimated to cost $ 76.6 billion in the US
annually.12 Non-adherence to oral hypoglycemic agents can also result in dire
consequences for patients with type 2 diabetes. A review of 13,309 patients with type 2
diabetes from the UK Mediphys database documented adherence and clinical events
between 1991 and 1997.13 Patients who discontinued their oral hypoglycemic agents
were approximately twice as likely to experience an emergency medical event and had a
mortality rate that was three times that of continuers. Thus, adherence to oral
hypoglycemic agents assumes great importance in preventing future complications and
controlling health care expenditures in patients with type 2 diabetes.
However, it is increasingly recognized that patients are non-adherent to many
aspects of diabetes self-management including sufficient intake of appropriate oral
antidiabetics. Approximately 10-30% of patients affected by type 2 diabetes withdraw
from their prescribed regimen within one year of diagnosis. Of the remaining patients,
nearly a quarter take insufficient medication thus failing to achieve appropriate glycemic
levels.14 An observational study of subjects enrolled in an HMO suggested that 31% of
type 2 diabetes patients on oral hypoglycemic monotherapy did not refill any drug in the
following year.15 A similar study of a US pharmacy claims database found low 12-month
persistence ranging from 31% for alpha-glucosidase inhibitors to 60% for metformin.16
Similar results were found in a study conducted in Scotland which showed that adherence
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to oral hypoglycemic agents was sub-optimal, with half of patients treated with
metformin and over one third of those treated with sulphonylureas obtaining insufficient
drug supplies for adequate drug coverage.17
Medication non-adherence is a major concern in all chronic conditions especially
in symptom free patients. Studies conducted in other Medicaid populations have found
that newly diagnosed type 2 diabetes patients were less adherent than patients consuming
oral hypoglycemics for a longer period of time.18 This may be due to the lack of diabetic
complications and other symptoms in the initial stages of type 2 diabetes. Newly
diagnosed patients do not feel as vulnerable to the development of complications and
hence are less likely to comply with their medication regimen. Some patients may also
be in a stage of denial and fail to acknowledge the presence of type 2 diabetes leading to
decreased medication adherence. Newer patients may also be less informed and less
supervised regarding their condition by physicians and other health care providers due to
lack of diabetic complications. Thus, newly diagnosed patients are at a considerably
higher risk for non-adherence with diabetes medication, subsequently leading to
inadequate glucose control and diabetic complications.
Impact of Depression on Adherence
There are a plethora of reasons for patients to be non-adherent to their
medications. These reasons may range from their disbelief in the efficacy and adverse
events associated with treatment to various socio-economic constraints. A number of
health behavior models such as the Health Belief Model have tried to examine these
factors related to adherence.19 Specifically in patients with type 2 diabetes, cost of
therapy, severity of diabetes, presence of co-morbid conditions, use of insulin therapy,
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interactions with health care providers, and complexity of drug regimens have been
shown to be factors associated with adherence to oral hypoglycemic therapy, diet and
exercise.8,20-22
In addition to these factors, presence of co-morbid depression can be an important
factor leading to lack of adherence in these patients. The precise mechanism by which
depression might affect medication adherence is complex. Several features of depression
can have detrimental effects on adherence with medications including poor motivation,
decrements in attention, memory, and cognition, decreased self-care, and even intentional
self-harm.23 As depressive symptoms are normally associated with a feeling of
hopelessness and pessimism, they may hinder adherence to medical regimen. In addition,
depression is often accompanied by social isolation and withdrawal thus possibly making
an individual highly susceptible to non-adherent behavior. Also, most importantly
depression may impact an individuals cognitive functioning resulting in forgetfulness to
adhere to complex treatment regimen. Some studies have also indicated that depression
has been associated with greater sensitivity to unpleasant side effects from medications.24
Depression also adversely affects satisfaction with care, which itself predicts poor
adherence to medical regimens.25,26
A few studies have examined the association between depression and treatment
adherence. It is well recognized that adherence to antidepressants is very poor; with only
40% of those receiving an antidepressant prescription completing the nine-month
recommended treatment.27 There is also a lack of adherence to other medical regimen in
patients with depression. A recent meta-analysis of 12 published studies confirmed the
same demonstrating that depressed patients were three times as likely as non-depressed
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patients to be non-adherent to physician recommendations.23 In the only study28
examining the impact of depressive symptoms on adherence in patients with diabetes, the
depressive symptoms were assessed using the Hopkins Symptom Checklist-90 Revised;
adherence was assessed by self-report and by using an automated data collection system
for refills of oral hypoglycemic agents. The results demonstrated that diabetes patients
with higher levels of depressive symptoms had more lapses in filling their prescriptions
for hypoglycemic agents. Assessing the extent to which non-adherence to a medication
regimen for a chronic condition such as type 2 diabetes may be a result of a treatable
condition such as depression can be important in improving patient adherence and finally
improving outcomes of treatment.
Epidemiology of Depression and Diabetes
The potential effects of depression on outcomes associated with management of
type 2 diabetes may be even more significant when one considers that depression is
highly prevalent in patients with diabetes. A recent meta-analysis of 42 studies indicated
that the odds of depression in patients with diabetes were twice that of a comparison
group of patients without diabetes.29 A sub-analysis of seven studies including only
patients with type 2 diabetes indicated that patients with type 2 diabetes were nearly two
and a half times more likely to have co-morbid depression as compared to patients
without type 2 diabetes.
In addition to prevalence of co-morbid depression in patients with type 2 diabetes,
it is also important to consider the epidemiological measure of incidence. Incidence has
the advantage of establishing the temporal order and disentangling the causes of onset
from influences on chronicity. Diabetes causes biochemical changes as well as may
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require psychosocial adjustments that may lead to depression. On the other hand,
depression is related to changes in nutrition and exercise that may contribute to risk for
diabetes; and there may be somatic aspects of depression such as a change in the immune
or vascular system that contributes to enhanced risk for diabetes onset.30,31 Neurohormonal changes induced by depression such as increase in levels of cortisol and
catecholamines can lead to insulin resistance and to the development of type 2 diabetes.
Depressed individuals are less likely to be physically active and eat a healthy diet. These
adverse health behaviors may in turn lead to obesity and subsequently to the development
of diabetes. Evidence from a few prospective studies indicates that depression doubles
the risk of incident type 2 diabetes even after controlling for other risk factors.
Controlling for multiple risk factors, Eaton and colleagues32 have shown that community
respondents with major depression, diagnosed using the National Institute of Mental
Health’s Diagnostic Interview Schedule, had an estimated relative risk of 2.23 of
developing type 2 diabetes over a 13-year period. Kawakami and associates33 also
demonstrated in a sample of 2,764 male employees of an electrical company in Japan that
significant depressive symptoms, measured using the Zung Self-Rating Depression scale,
were associated with a 2.3 times increased risk of developing type 2 diabetes compared to
non depressed employees after controlling for known risk factors. However, these
studies had a small number of incident case (n= 89 and n = 43, respectively) and thus had
limited statistical power. A couple of other studies used data from the National Health
and Nutrition Examination Epidemiologic Follow-up Study (NHEFS) to test the
relationship between depression and incidence of diabetes.34,35 These studies used the
NHEFS cohorts and measured depression using self-reported scales such as the Center
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for Epidemiologic Studies Depression Scale (CES-D) and the General Well-Being
Depression subscale. These studies had variable results with only one of the studies
demonstrating a significant and independent role of depressive symptoms in the
development of diabetes.
Thus, the literature indicates the possibility of higher rates of pre-existing
depression in patients with type 2 diabetes, which may subsequently lead to lack of
adherence with anti-diabetic medications resulting in poorer outcomes. In recent years, a
number of new oral antidiabetics have been approved including acarbose, glimepride,
metformin, miglitol, repaglinide, and troglitazone. These compounds have been shown
to be effective in achieving tight glycemic control as either monotherapy or in
combination with other oral antidiabetics. However, inadequate drug adherence due to
the presence of pre-existing depression would negate the benefits of these expensive
antidiabetic agents. All these findings cause increased concern regarding increased
morbidity, mortality and expenditures associated with the management of new patients
with type 2 diabetes.
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NEED FOR THE STUDY
Epidemiological studies in the literature regarding the association of depression
and diabetes were conducted in a mix of type 1 and type 2 diabetes patients.29 These
issues have not been explored exclusively in type 2 diabetes patients. Also, most of these
studies relied on self-reported data for identification of diabetes and depression.29
Studies in the literature have used a variety of scales to measure the self-report of
depressive symptoms and each scale measures depressive symptoms over a different time
interval.29 These self-reported scales can provide an overestimation of depression as
symptoms related to diabetes may be misclassified as those due to depression. Also,
these measures are not accurate predictors of psychiatric diagnosis as transient depression
symptoms may reflect a situational response to current life events. Some of the selfreported depression scales such as the CES-D scale do not distinguish between general
anxiety and depression and are also inaccurate in identifying patients with major mood
disorders.
These epidemiological studies also suffered from selection bias, as they have been
conducted in specialized settings that treat patients with problematic diabetes. Moreover,
potential confounders such as sex, age, race, or concomitant medical illness were not
addressed. The published studies also had limited statistical power and generalizability
due to low sample sizes. In addition, these prevalence and incidence rates may be
presumably higher in an indigent population such as enrollees in Medicaid. Hence, there
is a need to obtain estimates of clinically diagnosed depression in patients with type 2
diabetes in a population of lower socio-economic status such as Medicaid enrollees.
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Studies of the relationship between depression and adherence have used a variety of
approaches to assess depression or depressive symptomatology (ranging from
questionnaires such as the CES-D or the Beck Depression Inventory, to clinical
interviews). Also, different aspects of adherence (adherence to diet, exercise, glucose
monitoring, and medications), different criteria for defining adherence, and different
approaches to measuring adherence have been used. It is also possible that the
association between depression and adherence is artificially created due to the methods of
measuring adherence. When asked to self-report their levels of adherence, depressed
patients may have poor self-perceptions and underestimate their actual level of
adherence. Thus, it is important to use objective measures of adherence (such as pill
counts or refill information) in assessing the relationship between depression and
adherence. Also, a lower socio-economic population may have greater barriers to
adherence thwarting efforts at improving care and outcomes.11 As patients enrolled in
Medicaid generally have a greater burden of chronic disease, less vigorous treatment, and
poorer disease outcomes, it will be appropriate to focus efforts on improving adherence in
such populations.
Studies in the literature examining the impact of depression on adherence to treatment
regimen were not necessarily restricted to drug therapy and were all co-relational in
nature. Cross sectional studies are not methodologically capable of establishing
directional effects. The patient population in these studies consisted of a mix of both
prevalent and incident type 2 diabetes cases. If such cross-sectional data is used to study
the relation between adherence and depression, the chicken and egg scenario arises,
wherein one is not able to assess whether depression caused a decrease in medication
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adherence or a decrease in adherence with medications aggravated conditions associated
with type 2 diabetes leading to depression. This lack of causality and especially the
biases in model estimation due to presence of endogeneity makes it imperative to observe
the data longitudinally. Also, the adherence behavior of those newly diagnosed with
diabetes and starting treatment for the first time may differ markedly from that of
survivor cohorts (i.e. those patients who stay under treatment). The problem of nonadherence may be especially common in the years immediately after diagnosis when
many patients with newly diagnosed type 2 diabetes may not yet have accepted or
adjusted to their diagnosis.18 Hence, there is a need for large longitudinal studies in
which depression, adherence, and health outcomes are examined and the direct effects of
depression and the indirect effects of depression through patient adherence on health
outcomes are explored in patients with newly diagnosed type 2 diabetes.
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CONCEPTUAL FRAMEWORK
The study will be conducted in two distinct phases.
•

Phase 1 will examine the epidemiological relationship between depression and
type 2 diabetes

•

Phase 2 will examine the impact of depression on adherence with oral
hypoglycemics and establish causal pathways for the impact of depression on
outcomes related to management of type 2 diabetes

Selection of Database
The study will be conducted using claims data, which provides a number of
advantages. Claims databases are typically used for billing purposes and thus have
comprehensive information regarding health care utilization and costs. The presence of
separate files for outpatient visits, emergency room visits, hospitalizations, and pharmacy
records allow the examination of all components of health care and the relationships
between them. Availability of eligibility information also provides the opportunity to
conduct longitudinal studies following continuously eligible patients for extended periods
of time. One of the biggest advantages of claims data is their non-intrusiveness. As the
providers and patients are never contacted, the chances of a Hawthorne effect
(improvement of performance under observation) in the study are minimized. Also,
identification of disease conditions, and utilization parameters are not self-reported and
hence more likely to be accurate. Claims data research is less expensive and time
consuming as compared to other type of research like clinical trials. It also provides large
samples for sufficient power in statistical tests. Thus, claims data provide an opportunity
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for inexpensive, non-intrusive research providing high statistical power in real world
settings.36
West Virginia Medicaid claims data will be used to meet the objectives of this
study. Medicaid enrollees have comprehensive prescription benefits and out-of system
use is rare. Thus, Medicaid prescription data is a more valid and comprehensive source
than either patient recall or physician’s prescribing records. Pharmacy refill data thus
provide a valid approach to measuring drug adherence, which is an important variable in
the methodological framework of our study. In measuring adherence from refill
information, an assumption is made that a filled prescription results in ingestion of a full
supply of the drug. However, as in a population enrolled in Medicaid procurement of
drugs from other sources is highly unlikely, a prescription which is not refilled can be
considered a good indicator of a prescription not taken and thus of non-adherence. There
can also be issues related to the validity of the prescription claims information. However,
a validation study that compared Medicaid data with its primary sources such as
hospitals, physicians, and pharmacies showed that medication data were of high quality.37
In contrast, self reported adherence is prone to recall bias and tends to be overestimated
because of desires of social desirability on the part of the respondents. Also expensive
adherence assessment methods such as Medication Event Monitoring System (MEMS)
caps may be subject to the Hawthorne effects.38
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Phase 1
The conceptual framework regarding the relationship between pre-existing
depression and incidence of type 2 diabetes is demonstrated in Figure 1. Previous
literature indicates the impact of pre-existing depression on increasing the incidence of
type 2 diabetes.39 A possible explanation for this relationship is the presence of detection
bias as individuals with depressive symptoms may be more likely to seek medical care
than individuals without symptoms, and therefore would have a greater opportunity for
being diagnosed with diabetes than those without symptoms leading to an increased
prevalence and incidence of type 2 diabetes among patients with depression.40,41
Another possible explanation is that depression can lead to increased incidence due to
physiological reasons such as neuro-hormonal changes leading to insulin resistance and
increased glucose levels.42,43 Behavioral changes induced by depression such as physical
inactivity, smoking, and unhealthy diet are also considered risk factors for type 2
diabetes.44,45 These adverse health behaviors may also lead to obesity and subsequently
to the development of type 2 diabetes. Being overweight is associated with onset of type
2 diabetes and depressed individuals suffer from problems with appetite and weight gain.
However, one can also view obesity as a mediating variable in the relationship between
depression and onset of type 2 diabetes.
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Figure 1: Conceptual framework for Phase 1
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Patients with depression will be identified in the year 1997. As a comparison
group, a group of Medicaid enrollees without depression will be identified in the year
1997. Patients with type 2 diabetes in the baseline year (i.e.1997) will be excluded from
the analysis. This cohort of patients will be followed till December 31, 2002 and incident
cases of type 2 diabetes will be identified in both the groups. The time frame for
selection of patients and identification of incident cases for phase 1 of the study is shown
in Figure 2.
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Figure 2: Time-line for Phase 1
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Phase 2
As discussed in the introduction, depression may cause poor adherence to oral
hypoglycemics. However, depression can affect type 2 diabetes outcomes in ways other
than through its impact on adherence to oral hypoglycemic agents.39 Depression may
oppose efforts to achieve appropriate glycemic levels via both behavioral and
physiological pathways. Non-adherence with oral hypoglycemics might be just one of
the behavioral mediators.
There is also the issue of aggravation of symptoms wherein patients with
depression report significantly more physical symptoms on medical review of systems
than non-distressed populations when controlling for severity of medical illness.40 Since
co-morbid depression in diabetes is often associated with increased symptom reporting
and amplification of symptoms, it is possible that physicians may order more testing and
follow ups in these patients.41 This may explain findings, which have showed that
diabetes patients with more severe depressive symptoms have significantly higher
medical costs compared to non-depressed diabetes patients, even after controlling for
severity of diabetes and other medical illness.28
In addition, metabolic alterations associated with depression may disrupt normal
glucose metabolism. Studies suggest that depressive disorders lead to increased release
of hormones such as cortisol, which increase insulin resistance and decrease glucose
uptake.42,43 Depression may also worsen diabetes outcomes through its effect on
behavioral pathways. Depression is associated with increased smoking, alcohol
consumption, unhealthy eating, and diminished physical activity.44,45
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In view of the alternate theories of the impact of depression on diabetes, an
important question that needs to be addressed is whether or not poor adherence actually
mediates the relationship between depression and outcomes related to type 2 diabetes.
Our approach to this question is to determine whether the association between depression
and outcome is weakened after adjusting for level of adherence. The conceptual model
in Figure 3 depicts the different factors in addition to pre-existing depression, which may
impact adherence with oral hypoglycemics and outcomes related to type 2 diabetes.
These factors identified from the literature such as socio-demographic characteristics, comorbid conditions, severity of type 2 diabetes, patient-provider relationship, and
complexity of regimen will be statistically controlled in the models to help in estimating
the direct and indirect effects of pre-existing depression on outcomes related to
management of incident type 2 diabetes.
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Figure 3: Conceptual framework for Phase 2
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related outcomes
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The study will examine the impact of preexisting depression on patterns of use of
oral hypoglycemics, drug adherence and outcomes in patients with type 2 diabetes.
Incident cases of type 2 diabetes will be identified between January 1, 1998 and
December 31, 2000. A 12-month pre-period without a diagnosis for type 2 diabetes or a
prescription for an oral hypoglycemic can confirm that the patient is newly diagnosed
with type 2 diabetes. A 12-month pre-period will also be used to identify the diagnosis of
depressive symptoms in these patients. Drug utilization patterns and adherence will be
measured over the period of 12 months post index prescription. The study population
will be limited to patients taking at least one oral agent for type 2 diabetes. Patients will
have to be continuously eligible in both the pre and post periods. Incident type 2 diabetes
patients who do not have preexisting depression but develop depression in the follow up
period will also be excluded in the analysis. The time frame and design for enrollment
and analysis for phase 2 is provided in Figure 4.
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Figure 4: Timeline for Phase 2
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Dec 31, 2002

Evaluation of Outcomes
The study aims to examine the effect of pre-existing depression on adherence with
oral hypoglycemics and subsequently the effect of outcomes related to management of
type 2 diabetes. Thus, the selected cohort of newly diagnosed type 2 diabetes patients
with and without pre-existing depression will be followed for a period of one year to
detect the impact of depression on adherence with medications and other outcomes.
Information on dosage, frequency, length of prescription, and number of tablets
dispensed from the pharmacy claims of the patients will be used to assess refill
information and compute patterns of oral hypoglycemic use and adherence indices.
Examining the pattern of oral hypoglycemic use is especially important in patients newly
diagnosed with type 2 diabetes. The following patterns will be examined:


Augmentation: Augmentation refers to a situation where an initial regimen is
modified by adding another agent of a different class or insulin.



Switching: Switching refers to a situation when an initial regimen of one class of
oral hypoglycemic agent is changed to another class, or insulin.



Discontinuation: Patients discontinuing their oral hypoglycemic therapy



Non-modification: Modification in medication regimen may indicate either
augmentation or switching. Patients who experience no modification in their
medication regimens for the entire follow up period (except discontinuers) will be
designated as non-modifiers.

Sometimes advancement of type 2 diabetes is associated with a progressive loss of
beta cell function and increased insulin resistance caused by persistent hyperglycemia
and possible drug resistance. This is usually referred to as secondary failure wherein there
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is a loss of glycemic control in patients with type 2 diabetes whose disease has been
initially well controlled with a single oral hypoglycemic agent. In our study,
augmentation or switching will be used as proxies for secondary failure. In addition,
survival analysis techniques will be used to estimate the impact of preexisting depression
on time to secondary failure.
Another proxy of secondary failure is the switching of type 2 diabetes to insulin,
as patients are typically switched to insulin therapy if they are on maximum oral
hypoglycemics and still unable to control their blood glucose levels. Survival analysis
techniques will also be used to estimate the impact of pre-existing depression on time to
insulin switch.
Adherence indices will be derived separately for the different oral hypoglycemic
agents used over the follow up period. Adherence will be modeled as the mean
adherence for all antidiabetic drugs taken by each patient. Adherence to insulin will not
be computed, as utilization of insulin through an administrative dataset is difficult to
compute due to frequent changes in dosage instructions without proper documentation.
Adherence indices such as the Medication Possession Ratio (MPR) will be used in the
study.
The above adherence related outcomes could be termed as intermediate outcomes,
which may in turn affect the final outcomes related to management of type 2 diabetes.
Claims data can be used effectively to measure these final outcomes in terms of
healthcare service utilization and costs for type 2 diabetes. Number of physician office
visits, diabetes prescriptions, and Emergency room/hospitalization episodes specifically
for type 2 diabetes will be measured. Overall type 2 diabetes costs and their breakdowns
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in terms of outpatient, inpatient, and pharmacy costs will also be computed. However,
due to the nature of type 2 diabetes, it is highly likely that there is a high proportion of
healthcare utilization and costs which is diabetes related but not directly attributable to
type 2 diabetes. Hence, overall healthcare utilization and costs irrespective of diagnosis
codes will also be computed. Appropriate econometric techniques will be used to
estimate the impact of pre-existing depression on these intermediate and final outcomes
controlling for the effect of factors mentioned in the conceptual model. In addition, the
impact of preexisting depression on final outcomes directly and indirectly in the form of
drug adherence as a mediating variable will be estimated using path analytic methods.
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GOALS OF THE STUDY


Phase 1: To estimate the epidemiological burden (in terms of prevalence and
incidence) of depression and type 2 diabetes.



Phase 2: To estimate the impact of pre-existing depression on adherence with
oral hypoglycemics and establish causal pathways for the impact of depression on
outcomes related to management of type 2 diabetes.

SPECIFIC OBJECTIVES
Phase 1
Objective 1: To estimate the prevalence of co-morbid depression in patients with type 2
diabetes.
Null Hypothesis A: There is no difference between the prevalence of co-morbid
depression in patients with type 2 diabetes and without type 2 diabetes.

Objective 2: To estimate the incidence of type 2 diabetes in patients with pre-existing
depression.
Null Hypothesis B: There is no difference in the incidence rate of type 2 diabetes in
patients with pre-existing depression as compared to patients without pre-existing
depression.
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Phase 2
Objective 3: To examine the impact of pre-existing depression on patterns of oral
hypoglycemic use in new patients with type 2 diabetes.
Null hypothesis C: There is no difference in the pattern of oral hypoglycemic use
between newly diagnosed type 2 diabetes patients who have pre-existing depression and
those who do not have pre-existing depression.

Objective 4: To examine the impact of pre-existing depression on secondary failure with
oral hypoglycemics.
Null Hypothesis D: There is no difference in the rate of secondary failure with oral
hypoglycemics between newly diagnosed type 2 diabetes patients who have pre-existing
depression and those who do not have pre-existing depression.

Objective 5: To estimate the impact of pre-existing depression on initiation of insulin
therapy in patients with type 2 diabetes.
Null Hypothesis E: There is no difference in the rate of initiation of insulin therapy
between newly diagnosed type 2 diabetes patients who have pre-existing depression and
those who do not have pre-existing depression.

Objective 6: To estimate the impact of pre-existing depression on adherence to oral
hypoglycemic agents.
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Null Hypothesis F: There is no difference in adherence to oral hypoglycemics between
newly diagnosed type 2 diabetes patients who have pre-existing depression and those
who do not have pre-existing depression.

Objective 7: To estimate the impact of pre-existing depression on type 2 diabetes related
utilization and costs.
Null Hypothesis G: There is no difference in type 2 diabetes related utilization and costs
between newly diagnosed type 2 diabetes patients who have pre-existing depression and
those who do not have pre-existing depression.

Objective 8: To estimate the impact of pre-existing depression on overall health care
utilization and costs.
Null Hypothesis H: There is no difference in overall health care utilization and costs
between newly diagnosed type 2 diabetes patients who have pre-existing depression and
those who do not have pre-existing depression.

Objective 9: To examine the causal pathways between pre-existing depression,
adherence, and outcomes such as resource utilization and costs for type 2 diabetes.
Null Hypothesis I: Adherence to oral hypoglycemics is not a mediating variable between
the presence of pre-existing depression and outcomes related to management of type 2
diabetes.
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SIGNIFICANCE OF THE STUDY
The results of this study can help prioritize risk factors for disorders perhaps
leading to efforts of prevention. The results might indicate a benefit to screen a select
population for adults with diabetes. This is important as screening of all primary care
patients is not shown to be cost-effective and screening hence should be restricted to only
a high-risk population. Also, if the results indicate poorer outcomes and higher costs of
diabetes management in patients with co-morbid depression then early detection and
treatment of depression could potentially decrease total cost of diabetes care.
If a relationship between adherence and depression is demonstrated it may explain
the high morbidity and mortality rates in depressed patients. It would also call for
improving the detection and treatment of depression. Although a majority of the
depressed patients present in primary care clinics, there is substantial evidence that
depression is under detected and inadequately treated in such settings.46,47 Increased
efforts to detect and treat depression may be associated with better glycemic control. For
patients who are beginning their courses of treatment for chronic diseases, screening for
depression might prove to be a useful identifier of possible future non-adherence and
might suggest closer monitoring and assistance to achieve adherence. On the other hand,
clear non-adherence with a specified treatment regimen should raise suspicion of comorbid depression. Although it remains to be determined whether treating depression
will result in improved patient adherence, the recognition of depression as a significant
risk factor for non-adherence with medical treatment carries the potential to improve
medical practice, reduce patient disability, enhance patient functioning, and improve
outcomes.
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Research indicating that depression is associated with health outcomes and
additive medical costs in specific chronic illness such as diabetes may lead to changes in
guidelines for diabetes management and encourage national agencies and Health
Maintenance Organizations (HMOs) to screen for depression in patients with such
chronic conditions and to improve the clinical management of depression.
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LIMITATIONS
Inherent limitations of claims database are applicable to the study as well.36
Measuring adherence using prescription refills fails to assess the timing and quantity of
medication taken. Many patients request refills regularly when reminded, even if they
have not run out of drugs and some others stockpile medications or have quantities of
medications in several areas for convenience. In addition, Medicaid enrollees may lack
the economic disincentives to purchase only the medications that they will consume.
However, one can assume that refilling a prescription might be a good indicator of
willingness to adhere to medications. Also, as in a population enrolled in Medicaid
procurement of drugs from other sources is highly unlikely, a prescription which is not
refilled can be considered a good indicator of a prescription not taken and thus of nonadherence. It is also not possible to verify whether the patient discontinued taking the
medication because of lack of efficacy, adequate control through other methods, or
change in therapy by physician. One also misses the most non-adherent patient, i.e. those
who do not fill any oral hypoglycemic medications.
Adherence to medications can be affected by a lot of factors, which will not be
measured in this study such as social support, perceived risk of the outcomes of being
non-adherent, and others. Also, severity of disease is an important predictor of adherent
behavior.48,49 As clinical information is not available, our measures of disease severities
are proxies and could be subject to measurement bias. Lack of clinical information also
prevents us from estimating the impact of adherence on clinical parameters such as blood
glucose or A1C levels. In addition to adherence with oral hypoglycemics, diabetes
control is also affected by factors such as adherence to specified diet and exercise
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regimen. Although one can make an assumption that a patient’s adherence to oral
hypoglycemics can be a valid proxy of adherence to other important self-management
behaviors such as diet and exercise, studies in literature have demonstrated low
correlations between these.50,51
Another major limitation of the study is the issue of undiagnosed/unrecognized
depression.46 This can potentially lead to misclassification bias as patient classified as
non-depressed diabetics could be patients with undiagnosed depression and this could
lead to underestimation of the effect of depression on adherence to medications and
related outcomes. However, one can easily assume that diagnosed patients will have
more severe depressive symptoms as compared to an undiagnosed population. An
alternative would be to identify depression in patients through administration of a self
reported diagnostic measure. However, self reported depression has been consistently
shown to be highly unreliable and especially in patients with chronic conditions such as
diabetes, the severe symptoms of diabetes may be misattributed to depression.
Depressive symptom inventories such as CES-D are found to be overly sensitive to
somatic complaints that may be the result of diabetes rather than depressed mood. Also,
self-reported measures may identify a broader spectrum of depression disorders (e.g
dysthymic disorder or minor or subsyndromal depression) or symptoms that reflect comorbid psychiatric illness (e.g anxiety or substance abuse disorders) or general
distress.52,53
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CHAPTER TWO
LITERATURE REVIEW
Overview of Type 2 Diabetes
Diabetes is a highly prevalent physiological condition involving high blood
glucose levels. There are two classifications of diabetes, type 1 or insulin dependent
diabetes mellitus, and type 2 diabetes or non-insulin dependent diabetes mellitus. 54 Type
1 diabetes affects approximately 10% of the diabetic population in the United States.55 It
is a disease of the beta cells of the pancreatic islets, destroyed by an immunologically
mediated inflammatory reaction. In type 1 diabetes, the pancreas loses its ability to
produce any insulin, resulting in uncontrolled elevations of blood glucose. Although both
type 1 and type 2 diabetes share the common feature of elevated blood glucose levels,
type 2 diabetes typically involves the following three stages in most patients. The first
stage involves the principal underlying defect of insulin resistance. Although insulin can
attach normally to receptors on liver and muscle cells, certain mechanisms prevent
insulin from moving glucose into these cells. The ability of beta cells of the pancreas to
secrete insulin is not affected. However, as the condition progresses there is subsequent
beta cell exhaustion and secretion of insulin is affected. Eventually, the cycle of elevated
glucose further impairs and possibly destroys beta cells, thereby stopping insulin
production and causing full-blown diabetes.56-58
Genetic factors play an important role with regard to both insulin resistance and
impaired beta cell function. However, environmental factors such as high calorie intake
and limited physical activity also play a major role in the incidence and progression of
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type 2 diabetes. Type 2 diabetes patients initially have mild symptoms and after years of
disease may present with complications of diabetes. Symptoms of type 2 diabetes that
are typically seen at diagnosis may be thirst, increased urination, fatigue, and blurred
vision. However, most of the diagnosis is incidental, and up to 50% of type 2 diabetes
patients are relatively asymptomatic at diagnosis.55 However, all type 2 diabetes patients
are at risk of severe complications as the condition progresses. The life expectancy of
patients with type 2 diabetes is reduced by 30-40% for those in the age range of 40-70
years.59 Most of this mortality and morbidity associated with type 2 diabetes can be
attributed to diabetic complications, which can be divided into the following 2 categories:
•

Microvascular complications: These complications affect the smaller blood
vessels and are specific complications of diabetes and do not occur in patients
without diabetes. Microvascular complications can occur in different body sites
such as the eye (retinopathy), the kidney (nephropathy), and the nervous system
(neuropathy). These complications can lead to debilitating conditions such as
blindness, renal failure, and foot problems leading to amputations.60

•

Macrovascular complications: These complications are due to the effect of high
glucose levels on larger blood vessels and are not unique to diabetic patients but
occur to a greater extent in diabetic patients. Macrovascular disorders include
conditions such as cardiovascular disease, cerebrovascular disease, and peripheral
vascular diseases.60,61
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Diagnostic Tests for Type 2 Diabetes
Random plasma glucose or fasting plasma glucose levels are typically used for
diagnosis of diabetes. Measurement of fasting plasma glucose requires the patient to fast
overnight for at least 8 hours. Another test for diagnosis of diabetes, which is not used as
frequently in clinical practice, is the oral glucose tolerance test.62 The American Diabetes
Association (ADA) currently recommends measurement of glycosylated hemoglobin
(A1C) for monitoring of glycemic control in patients and it is widely used by clinicians
both for monitoring and diagnostic purposes.63 A1C levels yield a measure of chronic
glycemia from the slow, posttranslational non-enzymatic glycation of hemoglobin. A1C
provides a moving average of blood glucose levels integrated over time, weighted
proportionally toward recent levels. Clinical studies have shown a strong correlation
between A1C levels and the mean level of blood glucose over the preceding one to three
months.
Treatment Options
Type 2 diabetes is a progressive disease and is typically managed using a “stepped
care approach”.64,65 Patients are initially managed with non-pharmacological options
such as diet and exercise. As the disease progresses, oral pharmacological agents are
used to control blood glucose levels. Typically, these agents maintain blood glucose
levels, and some patients can be maintained on single oral agents for a few years.
However, patients eventually show secondary failure to their treatment regimen,
requiring therapy with a combination of oral hypoglycemics. While combination
therapies lead to better glycemic control, they can also potentially increase the risk of
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side effects of therapy. Once oral combination therapies fail, patients progress to insulin
therapy.
Non-pharmacological therapy
Diet, exercise, and weight loss are the initial treatment modalities in the “stepped
care” approach for type 2 diabetes. These lifestyle behavioral changes not only lower
blood glucose levels, but also help in controlling co-existing risk factors for future
complications. In a meta-analysis of 14 studies66 examining interventions to increase
physical activity among diabetes patients, individuals receiving these interventions had a
mean post study A1C level of 7.7% compared with 8.3% among comparison group
patients. In addition to affecting glycemic control, moderate physical activity improved
other cardiovascular risk factors such as high-density lipoprotein cholesterol and blood
pressure. Unfortunately, most patients are unable to achieve adequate control with
lifestyle changes alone. However, they can play a pivotal role in diabetes management in
conjunction with medical regimen. A controlled diet and regular physical activity are
therefore, recommended for a majority of patients with type 2 diabetes especially those
who are overweight.67,68
Oral hypoglycemic agents
A variety of oral medications for type 2 diabetes with different mechanism of
actions are available. They are typically divided into distinct classes based on their
mechanism of action.69-73
Sulfonylureas: Sulfonylureas have been available in the United States since 1954. They
are further classified into:
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First generation sulfonylureas: including drugs such as chlorpropamide, tolbutamide,
acetohexamide, and tolazamide.
Second generation sulfonylureas: including drugs such as glyburide, glipizide, and
glimepiride. Second generation sulfonylureas are more potent and probably safer than
first generation sulfonylureas but essentially of equal efficacy.
Mechanism of action: Sulfonylureas interact with the pancreatic beta cells leading to a
closure of voltage-dependent potassium adenotriphosphate channels facilitating cell
membrane depolarization, calcium entry into the cell, and insulin secretion. Thus,
sulfonylureas allow for insulin release at lower glucose thresholds than normal.
Side effects: Sulfonylureas are associated with weight gain, typically from five to ten
pounds, problematic in patients already obese at diagnosis. Sulfonylureas also cause
hypoglycemia, especially in elderly, those with worsening renal functioning, and those
with irregular meal schedules.
Indications: Sulfonylureas are approved for use as monotherapy and in combination with
all other oral agent classes (except the non-sulfonylurea secretagogues) and insulin.

Meglitinides: Meglitinides were introduced in the United States in 1998 and comprise a
new class of insulin secretagogues derived from benzoic acid that are structurally and
pharmacologically distinct from oral sulfonylureas. This class includes drugs such as
repaglinide, nateglinide, and mitiglinide.
Mechanism of action: They are also known as non-sulfonylurea insulin secretagogues as
their mechanism of action is similar to that of sulfonylureas: interaction with voltage
dependent potassium adenotriphosphate channels on beta cells. They are different from
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sulfonylureas in having short metabolic half-lives, which result in brief episodic
stimulation of insulin secretion. Thus these newer agents are rapidly metabolized and
shorter acting and better than sulfonylureas in controlling elevation of glucose levels after
meals. Also, since less insulin is secreted several hours after the meal, there is decreased
risk of hypoglycemia during this late postprandial phase.
Side effects: Side effects include diarrhea and headache. Some of these agents such as
repaglinides may pose a slightly increased risk for cardiac events.
Indications: They are approved for use either as monotherapy or in combination with
metformin.

Biguanides: Although available internationally for decades, metformin, a biguanide was
released in the United States only in 1995.
Mechanism of action: It reduces glucose production in the liver and increases tissue
sensitivity to available insulin. These agents may have a beneficial effect on cholesterol,
blood pressure, and clotting factors. Metformin does not cause hypoglycemia or weight
gain and hence is particularly well suited for obese type 2 diabetes patients.
Side effects: More than 30% of metformin users experience gastrointestinal problems
including nausea and diarrhea. Some patients may have excessive weight loss. Rare but
life threatening lactic acidosis is seen primarily in persons with renal insufficiency, which
impairs the clearance of metformin.
Indications: Approved for use as monotherapy and in combination with sulfonylureas and
other secretagogues, thiazolidenediones, and insulin.
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Thiazolidenediones: In 1997, troglitazone was the first thiazolidenedione that was
introduced in the United States but was withdrawn after reports of liver toxicity in March
of 2000. The other agents in this class, which are currently used, are pioglitazone and
rosiglitazone.
Mechanism of action: Thiazaolidenediones reduce insulin resistance by activating certain
genes involved in fat synthesis and carbohydrate metabolism. These agents all improve
cholesterol levels, including High Density Lipoprotein (HDL) levels and also may reduce
the risk for blood clots. Thiazolidenediones have a relatively slow onset of action and
lower the glucose level progressively over 16 weeks.
Side effects: Troglitazone (rezulin) was removed from the market owing to its
hepatotoxicity. Although the other thiazolidenediones do not cause liver toxicity, they
are associated with side effects such as weight gain, which can be as great or greater than
that with sulfonylureas. Some patients may also experience anemia and edema.
Indications: Thiazolidenediones are the most expensive class of oral hypoglycemics and
are indicated as monotherapy and in combination with metformin, sulfonylurea, and
insulin (pioglitazone only).

Alpha-glucosidase inhibitors: Includes drugs such as acarbose (Precose, Glucobay) and
miglitol (Glyset). These were introduced in 1996.
Mechanism of action: Alpha-glucosidase inhibitors act by a unique mechanism of
delaying intestinal absorption of carbohydrates. Although their benefit in monotherapy
and combination therapy has been proved, the incremental reduction in A1C is relatively
modest. Their greatest effect is on postprandial glucose levels; whereas, the effect on
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fasting blood glucose levels is small. These agents are non-systematic and hence do not
cause hypoglycemia and weight gain.
Side effects: The most common side effects are gastrointestinal side effects such as
flatulence, bloating, and diarrhea.
Indications: They are approved for use as monotherapy and in combination with
sulfonylureas. However, they are rarely used as monotherapy because of their mild
efficacy.
As mentioned previously, initial therapy with oral hypoglycemics fails to control
blood glucose indefinitely. Results from the UKPDS indicated that after a period of 3
years, only 50% of type 2 diabetes patients were adequately controlled with a single drug,
and after nine years this percentage had decreased to 25%.5 A second oral agent of a
different class is commonly added when initial glucose control begins to fail.
Combination of these agents are often used to increase their effectiveness and are
becoming increasing popular for use before a patient’s transition to insulin therapy.
However, as failure of oral therapy typically coincides with beta cell exhaustion, insulin
use eventually is required in most patients with type 2 diabetes.
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Guidelines for Therapy
Recent guidelines have stressed the importance of strict glucose control in
patients with type 2 diabetes.6,74 The UKPDS has shown that for every 1% decrease in
A1C levels, future micro-vascular complications decrease by 35%.5 The goals of
treatment of type 2 diabetes are to reduce the symptoms of hyperglycemia and to prevent
acute and chronic complications of the disease.
Metformin and sulfonylureas are the mainstay of oral hypoglycemic therapy for
type 2 diabetes.75 As a high fraction of type 2 diabetes patients in the United States are
obese, metformin is typically the favored initial therapy.76 For the obese patients in
whom insulin resistance is a major factor, thiazolidenediones are a suitable alternative
when metformin is not tolerated or is contraindicated because of renal insufficiency.
Sulfonylureas are often considered the first choice for patients who are not significantly
overweight at diagnosis.72
The initial treatment selection for type 2 diabetes depends on the severity of
symptoms and the degree of elevation of glucose.70,71
•

Patients presenting with marked symptoms and acute hyperglycemia with Fasting
Plasma Glucose (FPG) levels greater than 300 mg/dl are most quickly and
effectively treated with insulin. With reduction of glucotoxicity and institution of
a diet and exercise program, insulin therapy can often be withdrawn with
maintenance of good glycemic control. Metformin is particularly to be avoided in
these patients because of the risk of lactic acidosis.

•

Patients with FPG levels of 200 to 300 mg/dl fall in an intermediate group. One
option is to treat them with diet and exercise alone with close-follow up. Failure
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to respond to non-pharmacological methods should quickly lead to initiation of
oral agent monotherapy. If the patient is symptomatic, starting immediately with
diet, exercise, and oral agent monotherapy is most often a successful and better
strategy.
•

Patients with FPG levels of less than 200 mg/dl usually can be treated
successfully with diet and exercise initially. Although diet and exercise
eventually lose effectiveness as the sole therapy, reinforcing the importance of
diet and exercise generally improves the response to oral hypoglycemics.

Treatment Goals
The American Diabetes Association (ADA) recommended targets for glycemic
control include a pre-prandial blood glucose level of 80 to 120 mg/dl, a bedtime blood
glucose level of 100 to 140 mg/dl, and an A1C level of less than 7%. Change in therapy
or additional intervention is typically advised at an A1C level of 8% or more.6 However,
more stringent guidelines have been offered by the American College of Endocrinology
and the American Association of Clinical Endocrinologists: pre-prandial blood glucose
levels less than 110 mg/dl, two-hour post-prandial glucose levels less than 140 mg/dl, and
A1C levels at 6.5%.74
All these recommendations are based on three landmark studies: Wisconsin
Epidemiological Study of Diabetic Retinopathy,60 the Kumamoto study,77 and the
UKPDS,5 which have shown unequivocally that maintaining blood glucose
concentrations as close to normal decreases the incidence of diabetic complications.
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Impact of Glycemic Control on Type 2 Diabetes Outcomes
Epidemiological data from the Wisconsin Epidemiological Study of Diabetic
Retinopathy60 firmly implicate glycemic control in the development of the microvascular
complications associated with type 2 diabetes. In this study baseline A1C levels were
related to incidence and progression of retinopathy, neuropathy, and nephropathy.
Benefits of glycemic control on microvascular complications have also been
demonstrated by a few other randomized trials. The Kumamoto trial77 was conducted in
a relatively small sample of 110 lean Japanese patients with type 2 diabetes randomized
to conventional or intensified insulin therapy. Intensive therapy was associated with a
lower incidence of macrovascular events (0.6 versus 1.3 events per 100 patient-years).
More recently, the results of the large UKPDS5 have confirmed that improved glycemic
control is associated with reduced rates of microvascular complications. However, the
UKPDS did not confirm such a beneficial effect on macrovascular disease. The UKPDS
has the advantage over the Kumamoto trial of including typical overweight and obese
patients who may also have had lesser degrees of insulin deficiency.
The UKPDS and Kumamoto trials clearly showed that the incidence of
complications dramatically decreased at approximately five to ten years from initiation of
intensive glycemic control. An economic analysis of the UKPDS78 found that increased
therapy costs of intensive glycemic control in type 2 diabetes patients are offset by
significantly reduced costs of complications. The net cost of intensive blood glucose
control was recently estimated at 1,435 pounds per patient annually, the cost saved on
complications at approximately 15,000 pounds and the cost per event free year of
intensive blood glucose control at about 1,166 pounds. Within the metformin sub study
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of the UKPDS, another pharmacoeconomic study determined that intensive management
of the overweight was a more cost-effective option. 79 Thus, improving long-term
glycemic control should reduce the costs of treating diabetes-related complications.
These savings would more than offset the costs of interventions required to achieve
glycemic control.
A number of recent studies have shown that the economic benefits of improved
glycemic control accumulate much sooner than the seven-ten year trial period examined
in the UKPDS. A study conducted by Testa and colleagues demonstrated evidence of
short-term cost savings. They compared short-term effects on symptoms, quality of life,
work productivity, and health care use of active hypoglycemic therapy versus placebo in
a randomized trial and found that at 15 weeks, patients who controlled their glycemic
levels reported better health and work productivity and less use of health care services.
The improvements in quality of life were both consistent and substantial across all
domains and were partially due to the reduction in adverse events associated with
hyperglycemia. The study results demonstrated that improved glycemic control (1.8
percentage points lower A1C levels) resulted in increased productivity (12%) within a
period of 12 weeks.80 In a study conducted by Gilmer and associates in a large HMO
over the period of four years, a strong association was demonstrated between baseline
glycemic levels in 1992 and subsequent health care expenditures over the next three
years. Lower baseline levels of A1C were associated with significantly lower charges for
care and after adjusting for age, sex, and co-morbidity, higher baseline levels of A1C
were associated with significantly higher subsequent chares for care. Their model
suggested health care savings ranging from $400 to $4000 per patient over a three-year
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period, with savings increasing depending on the level of baseline A1C.81 Wagner and
colleagues at Group Health Cooperative of Puget Sound demonstrated reductions in
health care utilization and costs within one to two years of improvement of A1C levels.
In a retrospective analysis, better glycemic control (reduction and maintenance of less
than or equal to one percentage point in A1C level) resulted in average cost savings for
the HMO of $685 to $950 per patient per year between 1994 and 1997. The lower end of
the scale corresponded to patients with uncomplicated diabetes whereas the higher end
reflected complicated diabetes.82
Impact of Adherence with Oral Hypoglycemics on Glycemic Control and Type 2
Diabetes Outcomes
A number of studies in the literature have empirically evaluated the association
between medication adherence and diabetes metabolic control. Diehl and colleagues8
used pill counts to assess adherence in 77 patients with diabetes and found a trend
towards higher fasting blood glucose levels in those taking less than 80% of prescribed
dosages. Chousa and associates9 similarly found adherence assessed by pill count to be
associated with metabolic control measured by A1C among 107 patients with type 2
diabetes. Using self-reported adherence plus the pharmacy records of 65 patients with
type 2 diabetes, Peterson and colleagues10 also demonstrated an association between
adherence and a composite measure of metabolic control, including A1C. However,
most of these studies relied on small patient samples and self-report as the measure of
drug adherence. A recent study conducted by Schectman and associates11 examined this
issue in a sample of 810 type 2 diabetes patients receiving medical care from a university
based internal medicine clinic serving low-income population in rural central Virginia.
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The study used refill data to establish adherence with oral hypoglycemics and found that
better metabolic control was associated with better medication adherence. For each 10%
increment in drug adherence, A1C significantly decreased by 0.16%. These results were
duplicated in a prospective assessment of self-reported adherence in a homogenous
cohort of 11,896 type 2 diabetes patients in Europe. The study results indicated that A1C
levels were associated with adherence to medications, with a 1.4% mean difference
between groups with optimal and worst adherence.83
However, conflicting results are present for the effect of medication adherence on
utilization and costs associated with type 2 diabetes. In a retrospective cohort study
conducted in a non-managed care setting, a threshold effect was observed where a target
level of adherence was needed before medical care costs were reduced. Increased
pharmaceutical adherence was associated with fewer emergency department visits and
inpatient admissions, suggesting improved disease control. Similar costs and utilization
patterns were evident for both overall health care and diabetes-related care. The impact
of medication adherence on decreasing the use and cost of non-pharmacy services was
observed at a threshold of 20 to 39% adherence. However, medication adherence was not
associated with decreased overall healthcare costs because medication costs offset
medical care costs savings.84 In another study, which examined a longitudinal cohort of
older adults in the southeastern United States, increased adherence with diabetes
medications was found to be the strongest predictor of overall health care costs. Results
indicated a statistically significant 8.65 to 28.9% decrease in annual costs with every 10%
increase in medication adherence.85
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Non-adherence to oral hypoglycemic agents can also result in dire consequences
for patients with type 2 diabetes. A review of 13,309 patients with type 2 diabetes from
the UK Mediphys database documented patient visits to primary care physicians,
prescription refills, and emergency events between 1991 and 1997. Patients who
discontinued their oral hypoglycemics were approximately twice as likely to experience
an emergency medical event and had a mortality rate that was three times that of
continuers.13 Thus, adherence to oral hypoglycemics assumes great importance in
preventing future complications and controlling health care expenditures in patients with
type 2 diabetes.
Adherence to Oral Hypoglycemics in Patients with Type 2 Diabetes
On the basis of the discussion in the sections above, adherence to oral
hypoglycemics assumes great importance in diabetes management. However, medication
non-adherence is a major problem in all therapeutic areas with estimates of nonadherence rates ranging from 30% to 60% with higher rates in symptom free patients.86
A similar trend is seen in patients with type 2 diabetes especially those who are newly
diagnosed with the condition. A study conducted in Tayside, Scotland of 2,920 type 2
diabetes patients who received a prescription for oral hypoglycemic drugs for at least 12
months between January 1993 and December 1995 showed that adherence to these agents
was suboptimal, with only about one-third of those treated with oral hypoglycemic
obtaining insufficient drug supplies for “adequate” drug coverage (defined as 90%).17
These results are consistent with a recent observational study of subjects enrolled in a
health maintenance organization that suggested that 31% of those receiving sulfonylureas
alone did not purchase any drug in the following year.15 A similar study conducted by
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Skaer and associates estimated that 10-30% of patients with type 2 diabetes withdraw
from their prescribed regimen within one year of diagnosis and of the remainder; nearly
20% administer insufficient medication to facilitate an adequate reduction in blood
glucose.14
A recent analysis of a large administrative pharmacy claims database found
persistence to oral hypoglycemic therapy over a 12-month period to be low, ranging from
31% for alpha glucosidase inhibitors to 60% for metformin, with adherence rates of 7083%. The study results also indicated that the addition of a second agent was observed in
15% of the population with a mean time to augment therapy being approximately four
months. When a composite measure of change in therapy including switching or
augmentation was used, a striking 36% of the patients were found to change therapy over
a 12-month follow up period.16 Similar studies have found even lower adherence rates,
although these differences can be explained by methodological and population
differences. These studies used refill data for measuring adherence where one assumes
that every tablet dispensed is actually taken by the patient. Thus, these adherence rates
may be overestimates, thus providing further evidence that adherence to diabetic regimen
is a cause for concern and an important challenge for health care professionals and
patients with type 2 diabetes.
Factors Affecting Adherence
The nature and determinants of non-adherent behavior are complex and not yet
well understood. It is commonly believed that adherent behavior is a multidimensional
issue, which needs to be defined for each population and disease. The four dimensions
for determination of adherence identified by most researchers are: treatment regimen
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complexities, health status and disease-experience factors, characteristics of the
interaction with healthcare providers, and patient related attributes.18
Regimen factors
Regimen factors greatly affect adherence. Frequency of dosing and the number of
medications (complexity of regimen) have been shown to reduce adherence.20 Other
medication related characteristics such as route of administration could also impact
adherence. Dezii and colleagues87 evaluated differences in adherence and persistence
with prescribed therapy of once-daily (OD) dosing compared with twice-daily (BID)
dosing of glipizide in patients with type 2 diabetes from a pharmacy benefit manager
claims database. Patients new to extended-release gastrointestinal therapeutic system
(GITS) and immediate-release glipizide therapy were identified and followed for one
year. The authors concluded that initiation of OD pharmacotherapy results in better
adherence and persistence compared with a BID regimen, despite a greater daily pill
burden in the OD cohort. These data suggest that dosing frequency exerts a greater
impact on patient adherence and persistence than number of tablets per dose. Schectman
and associates11 saw similar results of improved adherence in patients prescribed OD
dosing as opposed to multiple dosing in the study.
Conflicting results have been found for the association between number of drugs
prescribed and mean adherence. Many studies have reported a positive association
between number of drugs prescribed and mean adherence.88 It is possible that patients on
more medications are more likely to adhere because of greater disease severity, concern,
or knowledge, and a more established regimen. However, Schectman and associates89
reported contrasting finding of an inverse association between number of drugs
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prescribed and minimum adherence levels suggesting lower adherence to individual
drugs in a complex regimen. Similar results were found in a retrospective study by
Dailey and associates,90 comparing patterns of use and persistence in patients with
diabetes initiated on monotherapy versus those on polytherapy. For the patients who had
no modification of their medication regimen, persistence with sulfonylurea or metformin
monotherapy was 65% greater than with polytherapy over a one-year period. Similar
results were seen for adherence with oral hypoglycemics, wherein adherence with
sulfonylurea or metformin monotherapy was 45% greater than with polytherapy.
Relationship factors
Patients may not fear possible medication side effects or drug interaction if they
understand their prescriptions and have an open, communicative relationship with their
health care professional. Researchers have shown that satisfaction with the interpersonal
quality of the patient provider relationship is significantly associated with adherence to
diabetes therapy.91,92 Anderson and colleagues93 state that physicians must be aware of
the likelihood of non-adherence in individual patients and make efforts to persuade
patients of the importance of adherence to a program designed to reach and maintain
therapeutic goals. It is the physician’s responsibility to teach, motivate, and strengthen
the patient to maximize adherence as part of a “therapeutic partnership”.
Health status and disease experience
Anderson and Kirk93 suggested that if an illness has easily recognizable and
unpleasant symptoms that are improved by following treatment recommendation,
adherence is more likely. In diabetes, many of the symptoms are not evident until later in
life. Therefore, many individuals will not feel the urgency of undergoing a treatment
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regimen or making lifestyle changes immediately. Adherence is also more likely if the
patient has experienced the illness previously or has known someone impaired by the
illness in question. Such experience may make patients more vulnerable and make them
proactive regarding taking actions to minimize the risk of disease. Studies in patients with
type 2 diabetes have demonstrated the same showing that newly treated patients are less
adherent than patients taking antidiabetic medications for a longer period of time. Newly
diagnosed patients are usually symptom free and devoid of diabetic complications, thus
having low perceived susceptibility to complications leading to decreased adherence.
Also, if the disease does not affect a patient’s functionality and quality of life, and
diabetes is well controlled through lifestyle changes, then the patient may believe that
medications are not needed. Newly diagnosed patients may also remain for prolonged
periods in a stage of denial and refuse any interventions related to the control of diabetes.
Additionally, newer patients might be less informed about their condition because
providers fail to give adequate counseling until negative treatment outcomes and diabetic
complications become evident.18
Patient related attributes
Socioeconomic factors and patient demographics may play an important role in
non-adherence. Indigent population without insurance may be non-adherent because of
the cost of medications. Lower socioeconomic and minority groups generally have
greater burdens of chronic disease and poorer outcomes. Members of these populations
may also have barriers to adherence that thwart efforts at improving care and outcomes.9496

In addition to economic and access factors, these include lack of social support,

differences in health beliefs and cultural norms, lower disease-specific knowledge and
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educational background, substance abuse and other physical or mental impairment, and
care continuity and physician relationship issues.
Conflicting results have been found in terms of the association between age and
adherence. A study by Schectman and associates89 in patients with diabetes found a 1.8%
increase in mean adherence to oral hypoglycemics per decade of increased age. The
association between age and adherence was consistent with that found by both Billups
and colleagues97 and Bailey and associates98. However, studies by Monane and
colleagues99 and Gurwitz and associates100 conflict with respect to an association between
age and adherence among senior citizens. The association of age and adherence could
stem from training and/or maturing effects that facilitate adherence behavior balanced by
increasing risk for decreased mental and physical functioning that may impair adherence
with advanced age.
Race may also play an important role in affecting the adherence to medications.
Schectman and associates89 reported that African-American diabetes patients averaged
4.1% lower mean adherence than white patients. Medicare studies have shown similar
racial disparities for intervention services after controlling for income.101 AfricanAmerican patients may have different perspectives and experiences with respect to health
care that influences adherence behaviors.102 Others have shown that cultural and
communication barriers, between African-American patients and Caucasian physicians
can lead to less participatory decision making and greater mistrust, leading to lower
adherence.103,104 Lower educational level has also been associated with mistrust of
medical care and therefore potentially lower adherence.105 Because education status of
African-American and white low-income patients may differ, education may confound
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this association between race and adherence. However, a recent survey found that
minority ethnicity was a strong negative predictor of adherence among elderly patients
without prescription coverage, independent of income and education.106
The Sick Role Theory suggests that non-adherent patients do not adopt the sick
role, and fail to conduct behaviors appropriate to their illness. An important factor
involved in the Sick Role Theory is denial, which is in turn associated with a negative
effect on health outcomes, including regimen adherence.48 A significant relationship
between self-perception of health and adherence with health care regimes has also been
demonstrated. In a cross sectional convenience sample study of 106 subjects with a
chronic illness for at least two years, Wichowski and Kubsch studied the relationship
between self-perception of illness and adherence with health care regimens. There was a
significant negative correlation between self-perception of illness and adherence for the
total population. Adults who do not perceive themselves as ill are unlikely to comply
with their treatment regimens.107
Although it is a durable belief that personality traits are predictive of patient
adherence to treatment regimens, this has not been corroborated by the literature.
However, depression has been consistently associated with poor adherence. Depression
may contribute to low motivation, and it may impact directly on the will of the patients to
get better, interfering in the patient’s adherence to the treatment regimen.
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Impact of Depression in Adherence and Outcomes in General
Adherence to pharmacological regimens for depression is very poor, with less
than half of those receiving an antidepressant prescription completing the recommended
treatment.27 However adherence to medications for other conditions is also affected by
depression.39 Depression can affect cognitive focus, energy, and motivation thus a
patient’s willingness and ability to adhere to treatment recommendations including
medication regimens.23 Positive expectations and beliefs in the benefits and efficacy of
treatment have been shown to be essential to patient adherence.108 Depression often
involves an appreciable degree of hopelessness and adherence might be difficult for a
pessimistic patient. Considerable research has shown that presence of a social support
109,110

network aids in improving adherence with regimens.

Depression is often

accompanied by social isolation and withdrawal from the very individuals who would be
essential in providing emotional support and assistance. Also, depression might be
associated with reductions in cognitive functioning essential to remembering and
following through with recommendations. A meta-analysis of 12 published studies
revealed that depressed patients were three times as likely as non depressed patients to be
non adherent to recommendations given by physicians.23 Six of these studies involved
patients with end stage renal disease or renal transplants and six involved other medical
diseases (angina, cancer, arthritis). Patients with a recent Myocardial Infarction (MI)
who dropped out of a recommended cardiac rehabilitation program were found to be
more depressed and socially introverted than those who participated for the prescribed
duration of therapy. Depression and poor motivation were also found to be inversely
related to smoking cessation and increasing exercise activity for patients hospitalized for
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unstable angina or acute MI.111 In another study, elderly patients with depression who
had coronary artery disease adhered less often to prescribed aspirin therapy than patients
without depression.112
Recent studies conducted in primary care patients have found significantly higher
health care costs in patients with depression as compared to patients without depression.
This increase in costs was seen in primarily all categories such as primary care visits,
laboratory test, emergency room visits, hospitalizations and pharmacy costs.113-115 Simon
and associates demonstrated that depressed patients in an HMO had healthcare costs of
approximately $4,246 as compared to costs of $2,371 in a comparison group. These
numbers remained significantly different even after adjustment for presence of other
chronic medical illnesses.113 Callahan and colleagues also found that patients with
depression had mean total outpatient charges of $1,210 over a nine-month period
compared to $752 for a non-depressed population after controlling for medical
diagnoses.114 Similar results were shown by Unetzer and associates in an elderly cohort
of 2,588 patients from a large HMO wherein the total median medical costs over a one
year period for depressed patients was $2,147 as compared to $1,461 for non depressed
patients.115 Primary care studies have also found that patients with major depression are
disproportionately represented among high utilizers of medical care. In a study
conducted in the Group Health Cooperative, it was found that 10% of patients use more
outpatient visits, specialty medical visits, and in-hospital days than the 50% of lowest
utilizers of these clinics. More than half of these high utilizers had significant depressive
symptomatology.116
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Impact of Depression on Adherence and Outcomes in Type 2 Diabetes
Studies have demonstrated that depression can play an important role in affecting
adherence with prescribed regimen and thus directly or indirectly affect management and
outcomes of a number of chronic conditions.23 Similar results are also seen in studies
examining the effect of depression on outcomes related to type 2 diabetes. A metaanalysis was conducted to examine the association of depression with glycemic control in
patients with diabetes.117 The diagnosis of depression was established by using semistructured clinical interviews and diagnostic criteria. Depression was quantified using
self report instruments such as the Beck Depression Inventory (BDI) and Center for
Epidemiological Studies-Depression Scale (CES-D) that measure the severity of recent
depression symptoms, while glycemic control was assessed using a measure of A1C.
The results of the meta-analysis indicated that depression was significantly associated
with hyperglycemia. Although the results demonstrated that depression accounts for a
small amount (3%) of the variance in A1C levels, this is not trivial in clinical practice.
Six studies examining the impact of depression on glycemic levels were restricted to
patients with type 2 diabetes.118-123 Of these, two clearly showed a relationship between
depression and glycemic control.118,119 Van der Does and associates118 found that higher
A1C levels were significantly associated with symptom scores of worse mood on the
Dutch Shortened Profile of Mood states and general well being in the Affect Balance
Scale. Lustman and colleagues119 reported that depressed patients as indicated by the
National Institute of Mental Health Diagnostic Interview Schedule Version Three, had
higher A1C levels compared with those who were never depressed. Wilson and
colleagues120 found that depression as measured by BDI and CES-D was not significantly
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correlated with glycemic control but was significantly associated with self-care behaviors
such as medication adherence, glucose testing, diet and exercise. The remaining three
studies of depression and type 2 diabetes produced equivocal results.121-123 Peyrot and
Rubin121 found that although scores on the CES-D depression scale were higher in
individuals with elevated A1C levels, the relationship was not statistically significant.
If depression is associated with hyperglycemia and hyperglycemia is associated
with diabetes complications, then it follows that depression may also be associated with
diabetic complications. Previous studies have correlated depression with a variety of
diabetes complications such as diabetic neuropathy and cardiovascular disease, yet others
have failed to find an association between depression and diabetic retinopathy and other
diabetic complications. A recent meta-analysis of 27 studies was conducted to examine
the impact of depression on diabetes complications.124 The results of this meta-analysis
revealed a consistently statistically significant relationship between depression and a
variety of diabetes complications. The overall effect size for the meta-analysis was
statistically significant and in the small to moderate range depending on the specific
complications. For each of these complications an increase in depressive symptoms was
associated with an increase in the severity or number of diabetes complications.
These effects of depression on glycemic control and diabetic complications also
translate into differences in health care costs. Data from the Medical Expenditure Panel
Survey (MEPS) 1996 was used by Egede and associates125 to examine differences in
health care expenditures in diabetes patients with and without depression. Expenditures
were adjusted for inflation with the consumer price index to reflect 2001 dollars.
Expenditures for prescription medication were higher in depressed individuals than in
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non-depressed individuals with diabetes ($1,392 versus $666, p<0.0001). There were no
statistically significant differences in other expenditure categories. Co-morbid depression
was associated with an almost fivefold significant increase in total health care
expenditures. Significant differences were obtained even after controlling for age, sex,
race, insurance status, and comorbidity. However, the values reported were unadjusted
and the number of diabetics with depression was a very small proportion (n=85). This
issue was also examined by Black126 in older diabetic Mexican Americans, using
longitudinal data from the Hispanic Established Population for the Epidemiologic Study
of the Elderly (EPSE). The risks of co-morbid myocardial infarction, hypertension,
arthritis, and angina were significantly higher in the presence of concomitant depressive
symptoms, as were the risks of diabetic complications, functional disability, incontinence,
vision impairment, poorer perceived health status, and health care utilization among both
diabetic and non-diabetic individuals. Rates were substantially higher among depressed
individuals with diabetes, however, in comparison to depressed nondiabetic individuals.
The study also demonstrated that the interaction of diabetes and depression was
synergistic predicting greater mortality, greater incidence of both macro-and
microvascular complications over the follow up period of seven years. The study also
demonstrated a gradient response such that the risk of adverse events increases with the
increasing severity of depression. Importantly, these health burdens were evident even
when controlling for socio-demographic risk factors, including sex, age, education,
marital status, immigration status, and living arrangements.
All these studies used self-reported measures for identification of depression and
diabetes. Utilization and costs were also self-reported and were measured and analyzed
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in terms of total health care costs, which also included costs for mental health treatment.
Regardless of whether major depression adversely affects an individual’s physical health,
total costs are expected to be higher for those with major depression due to the costs
associated with mental health treatment. A recent study by Finkelstein and associates127
examined this issue using data from the 1997 Medicare 5% Standard Analytic Files. This
was the first study studying the impact of depression on non-mental health care costs in
patients with diabetes using actual claims data to measure utilization. The study results
indicated that controlling for age, gender, race, and comorbidities, non-mental health care
costs were approximately 21.00% higher for depressed patients with diabetes as
compared to non-depressed patients with diabetes. The authors also concluded that
depressed patients seek treatment for more services and when admitted, spend more time
in inpatient facilities than patients without depression.
The only study which examined the effect of depression on both adherence with
oral hypoglycemics and health care utilization was conducted recently by Ciechanowski
and associates28 in a primary care based sample of 367 patients with type 1 and type 2
diabetes in a staff model HMO. Depressive symptoms were assessed with the Hopkins
Symptom Checklist-90 Revised. The patient population was divided into low, medium,
and high depression tertile categories based on depression scores on the Hopkins
symptom checklist. Adherence was assessed by self-report and by using an automated
data collection system for refills of oral hypoglycemics. The authors found that
depressive symptom severity was significantly associated with decreased adherence to
dietary recommendations and approximately twice as many interruptions in refills of oral
hypoglycemics. Depressive severity was associated with a non-significant increase in
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A1C levels. After controlling for demographics, medical comorbidity, and diabetes
severity, higher levels of depression severity were associated with significantly worse
mental and physical functioning and a significantly greater probability of having an
emergency department, primary care, specialty care, medical inpatient, and mental health
costs compared to patients with low severity depression. The total costs of the high
tertile group were $3,654 versus $ 2,653 in the medium depression tertile and $2,094 in
the low tertile groups after adjusting for diabetes severity and medical co-morbidity.
However, this study was conducted in a small sample of diabetes patients in a
highly specialized clinical setting. There was also the issue of non-response bias as only
62% of the originally contacted diabetes patients agreed to participate in the study. The
study included a mix of type 1 and type 2 diabetes patients with varying durations of
diabetes. As discussed in detail before, adherence issues might be drastically different in
newly diagnosed patients as compared to a survivor cohort and hence need to be
examined separately. Also, measures used to assess depressive diagnosis and a few other
control variables were self-reported. Adherence to oral hypoglycemics was obtained
through pharmaceutical claims data. However, refill data to measure adherence was only
available for a subset of the population (n = 200). Most importantly, total health care
utilization and costs were examined rather than specifically examining diabetes related
outcomes and utilization.
Most of the studies in literature addressing this issue of depression and diabetes
were cross sectional in nature thus not indicating whether depression causes aggravation
of diabetes symptoms or problems with diabetes management lead to depression. This
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presence of endogeneity also can lead to statistical biases in the estimates of the impact of
depression on diabetes related outcomes.
Theories for Impact of Depression on Type 2 Diabetes Outcomes
Speculation regarding the pathways by which depression impacts diabetes falls
into two broad categories: psycho-behavioral and patho-physiological. Depression may
influence diabetes through decreased motivation to maintain behaviors that will protect
against the development or worsening of diabetes, such as proper weight, diet,
medication adherence and exercise.23,28 Depression is associated with increased smoking,
alcohol consumption, and unhealthy eating, and with diminished activity.44,45 People
with diabetes who are depressed care for their diabetes less actively. Remission of
depression may improve glycemic control by reducing unhealthy behaviors and
promoting healthy behaviors. Diabetes patients who are depressed are more likely to
report limited physical functioning and increasing physical activity may be one of the
most important behavioral changes for diabetes patients. Epidemiologic studies have
repeatedly found cross sectional association between low levels of physical activity and
depression. Studies indicate that patients who are more physically active have better
depression symptomatology, and that individuals who are less physically active are more
likely to develop depression.128-130
Alternatively, metabolic alterations associated with depression may disrupt
normal glucose metabolism. The increase risk of negative diabetic outcomes may be the
result of biological changes such as neurohormonal and neurotransmitter changes.
Studies suggest that depressive disorders are accompanied by increased sympathoadrenal
system and hypothalomapituitary adrenal axis activity causing increased release of
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counter regulatory hormones and cortisol, respectively, which increase insulin resistance
and decrease glucose uptake. Lower immune functioning or inhibited cortisol release
may also increase insulin resistance and thus increase vulnerability to diabetic
complications.42,43
It may also be possible that both depression and diabetes share the common
pathogenesis such as actions of the autonomic or sympathetic nervous systems, or
polymorphism of genes associated with obesity. Thus, the link between depression and
diabetes may be the direct or indirect result of risk factors common to both conditions,
such as obesity, inactivity, medication use, and other preexisting psychological and
physical conditions.
In view of the alternate theories for the impact of depression on diabetes, an
important question that needs to be addressed is whether poor adherence actually
mediates the relationship between depression and outcome. One approach to this
question is to determine whether the association between depression and type 2 diabetes
outcomes is weakened after adjusting for adherence. Gary and associates131 found that
presence of depression was associated with higher cholesterol, triglycerides, and glucose
levels in patients with type 2 diabetes. However, adjusting for adherence to diet, physical
activity, smoking, glucose monitoring, and medications did not reduce the effect of
depression. Another approach to determining the role of adherence as a mediator is to
examine whether interventions that reduce depression and improve type 2 diabetes
outcomes also show improvements in adherence. Lustman and associates122,123
conducted two such intervention studies for depression in patients with diabetes. In both
studies, the intervention reduced depression and improved glucose control relative to the
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control condition. However, there was no evidence that reducing depression led to
improved adherence, as measured by the use of home blood glucose monitoring.
However, the Cognitive Behavioral Therapy (CBT) routinely included homework
assignments directing patients to record their thoughts and increase various physical and
social activities. Thus, it is possible that the participation in CBT complicated an already
complex regimen and thus decreased adherence with self-monitoring of blood glucose
levels.
Thus, based on these few studies there is lack of evidence to support the role of
adherence as a mediator in the relationship between depression and diabetes outcomes.
Further research with objective measures of adherence, clear criteria for defining
adherence and depression, and large samples with longitudinal follow-up need to be
conducted.
Epidemiology of Depression and Type 2 Diabetes
These effects of depression on diabetes related outcomes could be highly
detrimental, especially if the rate of occurrence of depression in patients with type 2
diabetes is high. Hence, the epidemiological burden of depression in patients with type 2
diabetes needs to be evaluated and the existing literature on this issue will be discussed in
the following sections.
Prevalence of Depression in Patients with Type 2 Diabetes
A number of studies examining the prevalence of depression in patients with
diabetes have been published in recent years. These studies have used various patient
population, research designs, and diagnostic tools. The varying prevalence rates may
reflect the differences in assessment methods (self-reported depression scales or
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structured diagnostic interviews), sample differences (community based or clinical
samples), and type of diabetes (type 1 or type 2). Also, a few of these studies were
conducted without the presence of a control group. As control groups are essential and
basic to epidemiological research, the following review will focus exclusively on
controlled studies performed in patients with type 2 diabetes.
A recent meta-analysis of 42 studies indicated that the odds of depression in
patients with diabetes were twice that of a comparison group of patients without
diabetes.29 A sub-analysis on the basis of seven controlled studies including only patients
with type 2 diabetes indicated that patients with type 2 diabetes were nearly two and a
half times more likely to have co-morbid depression as compared to patients without type
2 diabetes.32, 132-137 Only two of the seven controlled studies used structured diagnostic
interviews for the assessment of depression.32,137 The structured diagnostic interviews
used were the National Institute of Health’s Diagnostic Interview Schedule (DIS) and the
Clinical Interview Schedule (CIS). The DIS is an instrument for making psychiatric
diagnoses in accordance with criteria specified in the DSM-III of the American
Psychiatric Association, while the CIS reports psychiatric diagnoses according the
International Classification of Disease criteria. Both the interviews have been found to be
reliable and valid in assessing depressive disorders in patients with type 2 diabetes. The
remaining controlled studies used self-reported depression scales such as the Geriatric
Depression Scale (GDS), Zung scale, and the Beck Depression Inventory (BDI).132-136 In
these studies, depression prevalence was equal to the percentage of subjects with scale
scores above a specified threshold value. However, this threshold value varied across the
studies. The method of patient enrollment also differed between the studies. Five
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controlled studies32,132,133,135,137 identified the type 2 diabetes patients and their controls
randomly from a community population, while the remaining two studies134,136 enrolled
the patients and their controls without diabetes from health care clinics, patient support
groups, or physician referrals. The odds of depression were significantly elevated in
patients with type 2 diabetes as compared to control groups irrespective of the method of
depression assessment or patient enrollment. However, only of a few of these studies
explored the effect of concomitant medical illnesses on the association between
depression and type 2 diabetes. This is important as medical conditions in general are a
risk factor for depressive disorders and the presence of type 2 diabetes may not add any
additional risk. Thus, it is possible that the concomitant medical illnesses accompanied
with type 2 diabetes may contribute to this observed increase in prevalence of depressive
diagnosis.
Weyerer and associates137 observed that although patients with type 2 diabetes
had a higher prevalence of depressive symptoms than those with no somatic illness, no
differences were found when diabetes patients were compared to patients with other
somatic illnesses. A recently published study by Pouwer and associates138 displayed
similar results. This community-based study was conducted in elderly Dutch adults.
Depression was assessed using the CES-D scale and diagnosis of type 2 diabetes was
obtained from self-reports and data from general practitioners. The results of this study
indicated that the 20% of the patients with type 2 and other co-morbid chronic conditions
suffered from pervasive depression. Rates of depression were found to be considerably
lower in patients with type 2 diabetes only (8%) and healthy control subjects (9%). Thus,
compared to healthy subjects, the odds for depression are particularly increased in
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patients with type 2 diabetes and other co-morbid diseases, but not in those with type 2
diabetes alone. However, all the studies mentioned above were not population based and
had relatively small sample sizes leading to doubts regarding the stability of the
prevalence estimates.
The only study using claims data to determine prevalence of co-morbid
depression in patients with type 2 diabetes was conducted among enrollees of Kaiser
Permanente Northwest (KPNW).139 The study found unadjusted depression prevalence
rates of nearly 18% in patients with type 2 diabetes. After controlling for confounders
such as age, gender, presence of cardiovascular disease, and weight the results indicated
that patients with type 2 diabetes were slightly more likely to have co-morbid depression
as compared to patients without diabetes (OR=1.187). However, the study failed to
control for co-morbidities other than cardiovascular conditions. Hence there is a
possibility of detection bias as individuals with type 2 diabetes are more likely to have
higher number of co-morbid conditions and thus more likely to seek medical care than
individuals without type 2 diabetes. Thus, individuals with type 2 diabetes would have a
greater opportunity for being diagnosed with depression than those without type 2
diabetes. Also, the study did not examine the interaction effects between demographics
and type 2 diabetes on the prevalence of co-morbid depression. The impact of age on the
relationship between type 2 diabetes and depression is important as the peak period of
onset for depression is generally in the early adult years between 20 and 30 years of age;
while the onset of type 2 diabetes typically occurs after the age of 50. Hence, in addition
to adjusting for age it becomes important to control for a statistical interaction between
age and presence of type 2 diabetes to provide unbiased estimates.
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Incidence of Type 2 Diabetes in Patients with Depression
The studies mentioned in the above section pertained to the concept of prevalence
of depression and were all cross sectional in nature. In addition to prevalence of comorbid depression in patients with type 2 diabetes, it is also important to consider the
epidemiological measure of incidence. In 1684, Thomas Willis, a British physician
suggested that diabetes results from presence of pre-existing depressive disorders.140
Evidence from recent prospective studies have confirmed William’s hypothesis and
indicated that depression doubles the risk of incident type 2 diabetes even after
controlling for other risk factors. This finding is of important significance as recent
research demonstrates the possibility of preventing or delaying the progression from
impaired glucose tolerance to type 2 diabetes through moderate exercise, weight loss,
modification of diet, or intake of metformin. Depressive disorders can affect the
adherence to each of the above preventive activities and thus lead to increased onset of
type 2 diabetes.
Eaton and associates32 conducted the first prospective study examining the effect
of depression on incidence of type 2 diabetes in adult household residents participating in
the Epidemiological Catchment Area (ECA) Program Survey in Baltimore, Maryland.
Results of the study indicated that controlling for age, race, sex, socio-economic status,
education, use of health services, and body weight, community respondents with major
depression diagnosed by using the National Institute of Mental Health’s Diagnostic
Interview Schedule had an estimated relative risk of 2.23 of developing adult onset of
diabetes mellitus over a 13-year period. However, the diagnosis of diabetes was by selfreport and the study failed to control for all the important risk factors for incidence of
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diabetes. Self-reported diagnosis of diabetes could have also led to the problem of
undetected diabetes. It is possible that some people enrolled in the cohort may have had
onset of type 2 diabetes at baseline, thus biasing the study results.
Kawakami and associates33 conducted a methodologically superior study in a
sample of 2,764 male employees of an electrical company in Japan. The study results
indicated that significant depressive symptoms measured according to the Zung SelfRating Depression scale were associated with a 2.3 times increased risk of developing
type 2 diabetes compared to non depressed employees after controlling for known risk
factors over a eight year follow up period. The results of this Japanese study are
presumably more valid as the study used diagnostic measures such as urine tests and oral
glucose tolerance testing for identification of type 2 diabetes. The study also controlled
for important diabetes risk factors such as body mass index, smoking, alcohol
consumption, activity level, and family history of diabetes. Biases due to presence of
undetected diabetes at baseline were also ruled out by consistent results a sub-analysis
excluding cases found in the first half of the follow up period. However, both these
studies had small number of incident cases (n=89 and 43 respectively) and thus had
limited power. The study populations were also not representative of the general US
population.
A couple of studies have recently used data from the National Health and
Nutrition Examination Epidemiologic Follow-up survey (NHEFS) to test the relationship
between depression and incidence of diabetes. This data is nationally representative and
provides a large cohort of participants for follow up over an extended period of time.
One of the studies used the NHEFS cohort34 from the second examination (1982-1984)
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and measured depression using the CES-D. During the follow up period of
approximately nine years, there were 465 incident cases of diabetes. After controlling for
demographic characteristics, the relative hazard (RH) of incident diabetes among those
with high depressive symptoms was 1.27 as compared to those without symptoms.
Additional statistical controlling for known diabetes risk factors such as body mass index
and physical activity further decreased the strength of the association (RH= 1.11). Both
these values were statistically insignificant at p< 0.05 and thus the study failed to find any
significant effect of depressive symptoms on diabetes incidence. However, a subsequent
study conducted in the NHEFS cohort35 from the first examination (1971-1975)
measuring depressive symptoms using the General Well-Being Depression subscale
suggested a significant and independent role of depressive symptoms in the development
of diabetes. Over an average of 15.6 years of follow-up, 369 participants developed
diabetes. The incidence of diabetes was highest among participants reporting high
numbers of depressive symptoms (7.3 per 1,000 person-years) and did not differ between
persons reporting intermediate and low numbers of symptoms (3.4 and 3.6 per 1,000
person-years, respectively). The association between depressive symptoms and incidence
of diabetes was especially stronger in participants with low education levels. These
results also persisted in multivariate models after adjusting for demographics (age,
gender, and race), health behaviors (smoking, alcohol use, and physical activity), and
baseline body mass index.
Most of these studies relied on self-reported data for identification of diabetes and
depression. Each study exploring the relationship has used a different scale to measure
the self-report of depressive symptoms and each scale measures depressive symptoms
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over a different time interval. Also, the studies using data from the NHEFS cohort were
not specific to incidence of type 2 diabetes and failed to adequately address the issues of
undetected diabetes at baseline. Additionally, studies reported in the literature assessed
depressive symptoms only once at baseline and hence during the follow-up period a nondepressed subject could have developed depressive symptoms and subsequent type 2
diabetes resulting in misclassification bias. This bias could be significant especially due
to the long follow-up periods in these studies ranging from eight to 16 years.
Overview of the Medicaid Program
As the study will be conducted using claims data for enrollees of West Virginia
Medicaid, it will be helpful to understand the structure and functioning of this health care
system. Medicaid is a federally sponsored health insurance program for low-income,
disabled and members of families with dependent children initiated in 1965. The federal
government provides the fiscal assistance and the basic framework of regulations,
guidelines, and operation policies.141 However, the state governments are typically
responsible for administration of the Medicaid program. Benefits provided by Medicaid
include coverage for physician visits, inpatient and outpatient hospitalizations, laboratory
testing, nursing home care, family planning services and supplies, and home health care.
The federal government mandates these health care benefits. Additionally, there are
optional services that are left to the discretion of each state. Although optional, all states
provide reimbursement for prescription costs.
In recent years there has been widespread concern regarding the tremendous
growth in health spending through Medicaid. Total federal and state Medicaid
expenditures including administrative costs increased form $58 billion in 1989 to $194.7
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billion in 2000. One of the major reasons for this increase in expenditures is the increase
in size of the Medicaid eligible population. In 1990, there were 25.3 million enrollees,
which increased to 36.3 million in 1995 and more than 44 million in 2000.142,143 A similar
trend is also seen in West Virginia Medicaid with total number of recipients in the
program increasing from 178,254 in 1982 to 354,326 in 2000. This growth in number of
recipients has resulted in a dramatic increase in expenditures from $121 million in 1982
to over 1.391 billion in 2000.143 This can also be interpreted as an increase in average
spending per recipient from $678.84 to approximately $3,900. Thus, it becomes
important to identify areas of cost-containment; effect of depression on other chronic
conditions such as type 2 diabetes being one such area.
West Virginia’s Medicaid program consists of three components: 144
•

Physician Assured Access System (PAAS); a primary care case management
program wherein individuals enrolled in PAAS receive case management and
education services not available to individuals enrolled in the fee-for-service
program. Under the program, participants select a primary care provider who
coordinates care and whose approval is required for most health care services.

•

Mountain Health Trust (MHT); a capitated program similar to being enrolled in a
Health Maintenance organization (HMO).

•

Traditional fee-for-service program

In 2002, 281,526 individuals were enrolled in West Virginia’s Medicaid program. As
of June 2002, 97,174 Medicaid recipients were enrolled in PAAS. In 1996, Mountain
Health Trust (MHT) was developed under a subsequent 1915(b) waiver that allowed the
state to require a majority of its Medicaid recipients including individuals with
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disabilities to enroll within an HMO. As of June 2002, 48,189 Medicaid recipients who
qualify through Temporary Assistance for Needy Families (TANF) were enrolled in
MHT, and Medicaid recipients who qualified through the supplementary security income
(SSI) were eligible for the primary care case management program and not the capitated
program.145
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CHAPTER THREE
METHODOLOGY
Data Source
West Virginia Medicaid claims data
State Medicaid programs provide health care coverage to poor, aged, and disabled
individuals. The Bureau for Medical Services of the West Virginia Department of Health
and Human Resources has been responsible for the management of the West Virginia
Medicaid Program (WVMP). The West Virginia Medicaid Bureau contracts with
Consultec, Inc. (Atlanta, Georgia), to serve as its claims processor. Consultec maintains
and operates the Medicaid Management Information Systems (MMIS), which processes
provider claims and payments. MMIS data comprises of three files - provider files,
recipient files, and claims (medical and pharmacy) files. The following is a description
of these files and the specific fields (variables) contained in each file.
The provider file contains specific information about all health care providers
eligible to deliver services to Medicaid recipients. It primarily contains the provider’s
name, specialty, Medicaid eligibility, and tax related information. The recipient file
contains detailed information about Medicaid recipients. Important fields in this file
include recipient’s Medicaid number, period of Medicaid eligibility, period of managed
care eligibility, unique identification number, date of birth, gender, race, and county of
residence. The claims file stores detailed information specific to processed claims. For
each medical claim, the file contains fields such as invoice type, provider number,
recipient number, International Classification of Disease 9th edition (ICD-9)146 code of
diagnosis for which the service was provided, Common Procedural Terminology (CPT)
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code for procedures and services provided, Diagnostic Related Group (DRG) codes, date
claim was submitted, date of adjudication, through-date of service, coordination of
benefit code, primary carrier code, extract indicator, and total amount paid. The medical
claims are further classified into two files: outpatient claims and emergency
room/hospitalization claims. For pharmacy claims, the file contains fields such as
number of days supply, metric quantity, National Drug Classification (NDC) code,
generic code, therapeutic class code, refill number, provider ID number, and amount
paid.
Study Population
West Virginia Medicaid data was extracted for the period 01/01/1997 to
12/31/2002. Thus, final data used for the study included all paid claims data for all
individuals eligible for West Virginia Medicaid during the study period. Since Medicaid
recipients aged 65 years and older are eligible for coverage under both Medicaid and
Medicare, the subjects of this research were limited to all Medicaid recipients who were
younger than 65 years to avoid the issue of coverage under both Medicaid and Medicare.
For similar reasons, Medicaid recipients who were part of managed care were not
included in the study.
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Data Extraction
The West Virginia Medicaid claims data obtained from Consultec is loaded on the
server maintained by West Virginia University’s Rational Drug Therapy Program
(RDTP). The data needed for this study was extracted through the software
BrioIntelligence and converted into Statistical Package for Social Sciences (SPSS) data
sets. The extraction process involved identifying the study subjects using specific
selection criteria and the fields/variables needed were downloaded for the defined study
time period.
Data Cleaning
As mentioned previously, the medical claims files are aggregated into two
separate files of outpatient claims and ER/hospitalization claims. It is preferable to
separate the ER claims from the hospitalization claims to get a better distribution of these
health care costs. A variable termed as hospitalization Extract Indicator (EXTIND) in the
ER/hospitalization claims classifies the claims as those belonging to an ER visit or a
hospitalization episode. This variable along with the information provided by the
Diagnosis Related Group (DRG) codes and CPT codes was used to separate ER and
hospitalization claims. The following algorithm was used to separate claims into “ER”
and “Hospitalization” files:
•

Hospitalization claims from the ER/hospitalization file were identified on the
basis of a DRG code greater than 0. These claims were separated and classified
into the “Hospitalization” file.
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•

ER claims were identified on the basis of the EXTIND code. All claims with
EXTIND=2 are indicative of an ER visit. These claims along with all claims with
the same date of service were separated and classified into the “ER” file

•

The outpatient files contain a few claims, which are related to ER episodes.
These files were identified on the basis of CPT codes ranging from 99281 to
99285. These claims along with all claims with the same date of service were
separated and transferred to the “ER” file.

•

If the ER events lead to hospitalization, the ER event was considered as a
component of the subsequent hospitalization episode to prevent double counting.
Claims from the “ER” file with the same date as a hospitalization claim were
identified as indicative of ER episodes subsequently leading to hospitalization and
were transferred to the “Hospitalization” file.

•

A large proportion of claims in the ER/ hospitalization files included services,
which are outpatient but performed in a hospital setting and hence needed to be
aggregated as outpatient claims. After the algorithm mentioned above was used
to classify claims into ER or hospitalization claims, the remaining claims in the
ER/hospitalization files were classified as outpatient claims and were transferred
to the outpatient files.
In addition, there was also the issue of duplication of claims in the medical and

pharmacy files that had to be addressed. These duplications were primarily due to initial
rejection of claims. If a claim was rejected, it was followed up with a negative claim.
Both these negative and positive claims were deleted from the database.
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Selection Criteria
Type 2 diabetes
ICD-9 CM diagnosis codes from medical claims were used to identify patients
with type 2 diabetes. The type 2 diabetic patients were identified on basis of ICD-9 CM
diagnoses codes from 250.0x through 250.9x, where x is the fifth digit with a value of 0
or 2. Individuals having diagnosis codes with a missing fifth digit cannot be classified as
type 1 or type 2 diabetes patients and a decision was made on their inclusion depending
on their use of oral hypoglycemics. The following criteria for classification was used: at
least one inpatient admission for which the principal diagnosis was recorded as type 2
diabetes, or at least two inpatient admissions or two outpatient facility or physician office
visit claims for which any diagnoses was recorded as type 2 diabetes. Claims for
laboratory, pathology or radiology services were not used to identify individuals with
diabetes, since their use could incorrectly identify individuals as having diabetes based on
diagnostic procedures such as screening.
Depression
The depressive diagnoses considered in this study included single episode major
depressive disorder (ICD-9 CM diagnoses codes 296.20 through 296.26), recurrent
episode major depressive disorder (ICD-9 CM diagnoses code 296.3), neurotic
depression/chronic depression/dysthymia (ICD-9 CM 300.4), and depression not
otherwise specified (ICD-9 CM 311). As mental disorders such as depression are
associated with issues of initial misdiagnosis, at least one inpatient admission for which
the principal diagnosis was recorded as depression, or at least two inpatient admissions or
two outpatient facility or physician office visit claims for which any diagnoses was
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recorded as depression was needed. Patients with inadequate number of depressive
diagnoses were excluded from the analysis to prevent any misclassification bias.
The methods for the 2 phases of the study are described in more detail below:

Phase 1
Objective 1
Prevalence of co-morbid depression in patients with type 2 diabetes

Prevalence rate =
per 100,000

Number of type 2 diabetic patients with
co-morbid depression during the year 2000 x 100,000
Number of patients with type 2 diabetes
during the year 2000

Patients in West Virginia Medicaid with a diagnosis of type 2 diabetes in year
2000 were identified based on the specified selection criteria. Among these patients with
type 2 diabetes, presence of co-morbid depression was identified based on the selection
criteria for depression.
In addition, a group of Medicaid enrollees without type 2 diabetes diagnosis or
prescription of diabetic agents was identified in year 2000. Presence of co-morbid
depression was also determined for this group of patients. In addition to uni-variate chisquare analyses, multivariate logistic regression analyses were conducted to control for
effect of confounders such as age, gender, race, and co-morbidity. Interaction effects of
the main independent variables with age and gender were also included in the model as
the associations between type 2 diabetes and depression may differ based on age and
gender. As interaction terms were used in the model, the independent variable “age” was
centered about the average age in the population for ease of interpretation. To separate
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the effects of type 2 diabetes and the presence of related co-morbidities on the prevalence
of depression, a block-wise logistic model was created consisting of the following blocks
of co-variates entered sequentially in the model.
Block 1: Demographic variables: age, gender, race, interaction term of age and
diabetes, interaction term of gender and diabetes
Block 2: Presence of chronic co-morbidities unrelated to type 2 diabetes: Cancer,
asthma, and chronic liver conditions.
Block 3: Number of physician office visits and presence of chronic co-morbidities
related to type 2 diabetes (Cardiovascular conditions, cerebro-vascular conditions,
nephropathy, retinopathy, neuropathy and endocrine/metabolic disorders).
The analysis was restricted to patients who were continuously Medicaid eligible
and had no Medicaid HMO eligibility in the year 2000. Only patients between the ages
of 18 and 64 were included in the analysis to exclude children and enrollees who were
also eligible for Medicare.

Objective 2
Incidence of type 2 diabetes in patients with pre-existing depression
Number of new cases of type 2 diabetes in patients with
Incidence rate = preexisting depression occurring between 1998-2000
x 100,000
per 100,000
Number of patients with depression between 1997

Patients with depression were identified on the basis of the inclusion criteria for
depression in the year 1997. As a comparison group, a group of Medicaid enrollees
without depression diagnosis or prescription of antidepressants was identified in the year
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1997. Patients with a medical claim for type 2 diabetes or a prescription for a
hypoglycemic agent in the year 1997 were excluded from the analysis. These patients
were then followed till the December 31, 2002 to identify incident cases of type 2
diabetes in both the groups. In addition to univariate chi-square analyses, multivariate
logistic regression analyses were conducted to control for effect of confounders such as
age, gender, race, and co-morbidity.
The analysis was restricted to patients who were continuously Medicaid eligible
and had no Medicaid HMO eligibility in the period 1997-2002. Only patients between
the ages of 18 and 60 were included in the analysis to exclude children and enrollees who
were also eligible for Medicare.

Phase 2
To examine the impact of preexisting depression on patterns of use of oral
hypoglycemics, drug adherence, and outcomes in patients with type 2 diabetes, the
following methodology was employed:
Incident cases of type 2 diabetes were identified using the selection criteria
mentioned before. The first prescription for an oral hypoglycemic agent was treated as
an index prescription. A 12-month pre period without a diagnosis for type 2 diabetes or a
prescription for an oral hypoglycemic was used to confirm that the patient is newly
diagnosed with type 2 diabetes. A 12-month pre period was also used to identify the
diagnosis of depressive symptoms in these patients. Drug utilization patterns and
adherence was measured over the period of 12 months post index prescription. Incident
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type 2 diabetes patients who do not have preexisting depression but develop depression in
the follow up period were excluded from the analysis.
Exclusion Criteria for Phase 2


Troglitazone belongs to the thiazolidenedione class of oral hypoglycemics. It was
shown to have liver toxicity and hence required regular monitoring. Due to its
toxic side effects the drug was finally removed from the market in the year
2000.70 Thus, while observing the patterns of use and adherence in the database,
one might attribute any switch from troglitazone as failure of therapy or lack of
adherence. This can lead to misinterpretation of the results and hence patients
who had any prescription for troglitazone in the study period were excluded from
the analysis.



Patients receiving antidepressant therapy without any depressive diagnoses were
excluded from the analysis to prevent any misclassification bias.



Patients with brief depressive reaction (ICD-9 CM 309.0), prolonged depressive
reaction (ICD-9 CM 309.1), psychotic depression (ICD-9 CM 298.0) were
excluded because these are etiologically different from major depressive episodes
or chronic depression.



In addition, patients with a diagnosis of schizophrenia (ICD-9 CM 295.10295.30,295.60, 295.90), bipolar disorder (ICD-9 CM 296.0, 296.1, 296.4, 296.6),
dementia (ICD-9 CM 294.1, 294.9), conditions involving cerebral degeneration
such as Alzheimer’s disease (330.XX, 331.XX), neurotic disorders such as
anxiety, hysteria, phobic disorders, obsessive compulsive disorders and others
(ICD-9 CM 300.XX except 300.4X) were also excluded from the analysis to
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avoid confounding of the effect of other mental disorders on adherence to oral
hypoglycemics and related outcomes. These stringent criteria will help minimize
misclassification bias for majority of the objectives of the study.


Patients in long-term care facility, intermediate care facility or skilled nursing
facility are a select population who are more severe and may demonstrate a high
amount of adherence as they are under constant supervision. Hence, patients in
such facilities in the follow up period were also excluded from the analysis.



Patients who are not continuously eligible in the follow up periods for specific
objectives were excluded from the study.

Measurement of Variables
Main independent variable:
Co-morbid depression
Co-morbid depression will be a categorical variable classified as follows:
•

No diagnosis of depression

•

Diagnosis of depression

A multivariate framework was used to estimate the impact of depression on adherence
and other type 2 diabetes outcomes. All the multivariate models controlled for
confounding factors such as demographics, co-morbidity, diabetes severity, complexity
of regimen, and interaction with health care providers. Multiple variables were used to
measure each of these confounding factors and are described in detail below:
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Demographics
Age: Age was obtained by calculating the difference between the recipient’s date of birth
and the index date of the study.
Gender: The field “recipient gender” in the Medicaid recipient data was utilized to
identify patient’s gender.
Race: The field “recipient race” in the Medicaid recipient data was utilized to identify
patient’s race. Patient’s race was classified into 2 categories: whites and non-whites
Geographical location: Patient’s geographical location was categorized on basis of their
county of residence. The 2003 Rural-urban Continuum Codes were used to classify the
county of residence as rural or urban.
These codes form a classification scheme that categorizes counties by size and
degree of urbanization and proximity to urban areas. Counties all across the nation have
been subdivided into three metro and six non-metro categories, resulting in a nine-part
county codification. This scheme was originally developed in 1974. This scheme of
coding allows researchers to break county data into finer residential groups as per
convenience. The Census Bureau made a radical shift in determining rural-urban
boundaries by changing and liberalizing the procedures for delineating urbanized areas of
50,000 or more people, and abandoning place boundaries in measuring urban or rural
population. The procedures used in defining Urbanized Areas were extended down to
clusters of 2,500 or more people, based solely on population density per square mile.147
Year of index date: As our enrollment period spanned a period of three years (i.e. 19982000) a control variable for the year of index date was included to account for differences
in treatment and diagnosis practices over time. This variable also accounts for
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introduction of oral hypoglycemics and marketing strategies that vary and thus affect
prescribing behavior.

Co-morbidity
Multiple variables were used to measure baseline co-morbidity for newly diagnosed type
2 diabetes patients. The Charlson co-morbidity index148 based on medical claims in the
12-month period prior to the index date was used to measure co-morbidity. In addition to
the Charlson co-morbidity index, co-morbidity was measured using a mix of variables
identifying the presence of specific co-morbid conditions and those related to utilization
of health care services in the 12-month pre-period before the index date of an oral
hypoglycemic agent.
Charlson co-morbidity index: The Charlson Index is a list of 19 medical conditions.
Each condition has a weight assigned from one to six, which is derived from relative risk
estimates of proportional hazard regression models using clinical data. The Charlson
index is the sum of weights for all prevalent conditions during a specified time period.
The index has been shown to have a strong monotonic association of approximately a two
fold increase in mortality per increment in index level. There are a variety of indices that
are primarily based on the Charlson comorbidity index. The version by D’Hoore and
associates,149 which is one of the few Charlson indices for use with administrative claims
data, was used in our study. As coding of the ICD-9 codes in administrative databases
after the decimal places is not reliable, the Charlson index by D’Hoore and associates is
based on only the first three digits of ICD-9 codes. Diagnosis codes related to
depression and diabetes were excluded in the computation of this index.
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Utilization related variables: These variables measured overall utilization in the 12month pre-period excluding utilization accrued due to depression or antidepressants. The
following utilization variables were used:
•

Number of ER/hospitalization visits

•

Total health care costs

•

Distinct number of therapeutic medication classes for management of chronic
conditions.

Specific co-morbid conditions: The presence of the following co-morbid conditions was
identified in the 12-month pre period on the basis of their prevalence in the study
population and their impact on outcomes related to diabetes management.
•

Presence of cardio-vascular conditions (including hypertension and
hyperlipidemia)

•

Presence of Asthma

•

Presence of Ulcers

•

Presence of Cancer

Complexity of drug regimen
The following variables will be used in the model to control for the confounding effect of
complexity of drug regimen on diabetes related outcomes:
Mean daily number of pills of oral hypoglycemic agents: This computation was based
on the first oral hypoglycemic prescription. The fields “Qty dispensed” and “days
supply” were used to compute number of pills per day.
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Number of prescriptions for chronic medications: All the available therapeutic classes
of medication were categorized as those used for acute or chronic conditions on basis of
clinical literature. Therapeutic classes such as Non-Steroidal Inflammatory Drugs
(NSAIDs), which can be used for either chronic or acute purposes, were conservatively
classified as those for acute conditions. Number of prescriptions for chronic conditions
other than depression in the pre period was computed.
Mean daily number of pills of other chronic medications: Mean number of pills per day
was computed for chronic medications other than those used for diabetes or depression.
This analysis was restricted to prescriptions for orally ingested tablets or capsules in the
60-day period before the index date. This was computed by multiplying the mean
number of pills per day for each prescription of a chronic medication with the number of
prescriptions with unique generic codes in the 60-day pre period.

Interaction with healthcare providers
Physician Assured Access System (PAAS) enrollment: Individuals enrolled in PAAS
receive case management and education services not available to individuals enrolled in
the fee-for-service program. Under the program, participants select a primary care
provider who coordinates care and whose approval is required for most health care
services. Hence, a dummy variable indicating whether the patient is enrolled in PAAS or
is under the traditional fee for service system was used as a proxy for interaction with the
health care provider.
Pharmacy patronage: In addition to interaction with their physician, patient’s interaction
with their pharmacist can also affect adherence to medications and related outcomes.
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Pharmacy patronage measured in terms of number of pharmacies visited in the six-month
pre period was used as a proxy for interaction with pharmacists. The variable was
categorized as:
•

No pharmacy use

•

Single pharmacy use

•

Multiple pharmacy use

Severity of diabetes
Although all patients were newly diagnosed with type 2 diabetes, there might be
differences in diabetes severity, which was controlled using the following variables:
Initiation on monotherapy/polytherapy: A medication regimen was referred to as
monotherapy when patients received therapy with a single class of oral hypoglycemic
medication, and polytherapy when patients simultaneously received two or more classes
of oral hypoglycemics. A pattern of use was classified as initial poly-therapy if one of
the following criteria was satisfied:
•

Index prescription was for a fixed combination therapy and the patients received
at least two more prescriptions for the combination therapy in the follow up
period; or

•

The patient had a prescription claim for a second oral hypoglycemic agent/insulin
(different class) within 15 days of the index fill date of the index prescription and
received at least two more prescriptions for each of the drugs in the follow up
period.
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Class of the index oral hypoglycemic agent: Class of the index oral hypoglycemic
prescription can indicate the severity of diabetes and also predict diabetes outcomes
through its efficacy and side effect profile. The index oral hypoglycemic prescription
was classified into one of the following class of oral hypoglycemic:
First generation/second generation sulfonylurea, biguanide, thiazolidenedione,
meglitinide, or alpha glucosidase inhibitor.
Specialty of the prescribing physician: Specialty of the physician who prescribes the
index oral hypoglycemic prescription can be predictive of diabetes severity, access
issues, and/or diabetes related outcomes. This variable was categorized as index
prescription provided by: a specialist (endocrinologist), an internist, or a family
physician.
Gap between diagnosis and medication therapy: Type 2 diabetes patients in our study
may have varying lengths of time between initial diagnosis of type 2 diabetes and
initiation of oral hypoglycemic therapy. This gap between diagnosis and initiation of
medication therapy was controlled in our study as a continuous variable measured in
days.
Diabetes related utilization: Although the study population consisted of only patients
newly diagnosed with type 2 diabetes, the index date of the study period was the date of
the initial prescription of oral hypoglycemic. Hence, diabetes related utilization was
available for patients who had a gap in therapy between initiation of pharmacotherapy
and initial diagnosis of type 2 diabetes and served as a good proxy for diabetes severity.
The following variables were used to measure diabetes related utilization in the 12-month
pre period:
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•

Total type 2 diabetes related costs

•

Number of type 2 diabetes related ER/hospitalizations
The variables described above were used as independent control variables in all

the multivariate models to examine the impact of depression on type 2 diabetes outcomes.
A variety of outcomes such as adherence with oral hypoglycemics, and utilization related
to type 2 diabetes management were evaluated. The measurement of the outcomes is
described in detail below:
Patterns of oral hypoglycemic use
Patterns of oral hypoglycemic use could be classified in any of the following categories
based on utilization of prescriptions in the follow-up period.
•

Discontinuation
A patient was deemed as a discontinuer in the 12-month follow up period after

initiation of oral hypoglycemic therapy if he/she ends therapy on an oral
hypoglycemic/insulin and does not receive a refill within x days of supply exhaustion
where x equals 250% of the days supply of the last fill.
•

Augmentation

Augmentation refers to a situation where an initial regimen is modified by adding
another agent of a different class or insulin. Addition of another oral hypoglycemic agent
was defined as starting a non-index medication belonging to a class other than the index
prescription, while obtaining a refill for the index drug within a specified window [index
drug fill date + 2.5 * (days supply of index drug fill)] and at least one more prescription
for each of the drug classes in the follow up period. [Patients on initial poly-therapy were
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initially excluded to facilitate the distinction between augmentation and initial polytherapy]
•

Switching
Agent switching was defined as starting a different class of oral hypoglycemic

than the index prescription while not obtaining a refill for the index drug in the follow
up period.
•

Non-modification
Modification in medication regimen may indicate either augmentation or

switching. Patients who experience no modification in their medication regimens for
the entire follow up period (except discontinuers) were designated as non-modifiers.
Dose changes were not classified as modification. Also changing specific drugs
within the same class of oral hypoglycemic was not defined as modification.

If patients could not be categorized in any of the above patterns, then their
prescription patterns were manually inspected to determine their status. Also, the
outpatient pharmacies do not record prescriptions dispensed during an inpatient
admission. These patients may be incorrectly classified as discontinuers due to the lack
of prescription refill information during the length of their hospitalization. Hence, during
the time spent in the hospital it was assumed that the medications are supplied by the
hospital, and therefore the numbers of days of hospitalization were added as days supply
in calculating drug utilization patterns.
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Adherence with oral hypoglycemics
Patients initiating either mono-therapy or poly-therapy involving insulin were
excluded from the computation of adherence indices. For the rest of the patients who
may have insulin use in the form of a switch or augmentation, all their insulin
prescriptions were excluded from the calculation of adherence indices. This exclusion
criterion was used, as only adherence to oral hypoglycemic agents was computed in the
study. Also utilization of insulin through an administrative dataset is difficult to compute
due to frequent changes in dosage instructions without proper documentation.
Medication Possession Ratios150 were used as proxies for measurement of drug adherence
in the study. Two different indices were computed and referred to as MPR-1 and MPR-2.
•

Medication Possession Ratio-1 (MPR-1)
The Medication Possession Ratio-1 (MPR-1) was a proxy measure of medication

adherence in the period between the first and last prescription fills. It is defined as the
sum of days supply for all fills divided by the number of days of therapy between the first
and last fills plus days supply for the last fill.

MPR-1 =

Sum of days supply

(Number of days between the first and last fills) + days supply of the last fill

To account for possible early refills, any excess in the days supply due to early
refill in the previous interval was allocated to the following interval.
This index assesses the proportion of days during the treatment that the patient
possessed an adequate quantity of medication. Since the denominator of the ratio is the
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period during which the patient is in possession of medication, this measurement of
adherence does not capture adherence as a consequence of premature discontinuation of
therapy.
Also, as MPR-1 cannot be computed for patients not filling more than one
prescription, these indices were not computed for patients who discontinue their oral
hypoglycemic agents. The above formula for MPR-1 can be easily applied to nonmodifiers. However, if there are drugs from multiple classes consumed over the time
period (i.e for switchers, augmenters, and those on initial poly-therapy) then MPR-1
should be computed separately for each class of drug. This weighted MPR-1 value was
termed as Reg MPR-1 and was computed as follows:

Sum of {MPR-1 * [(Number of days between the first and last fills) days
Reg MPR-1 =
supply of the last fill]} for all drugs
Sum of (Number of days between the first and last fills) + days supply of
the last fill) for all drugs
If the admit and discharge dates of hospitalizations are included between the first
and last fill dates of a particular class of drug, then the number of days of hospitalizations
was added to the days supply of drugs for that particular class.
The formulas for MPR-1 and Reg MPR-1 mentioned above are restricted to
computing adherence between two prescription refills. In addition, adherence indices
were computed for the period between the index prescription and the end of the follow up
period. In the first case, all gaps are embedded within a series of fills. In the second
case, a terminal gap may be present after the last refill. Both measures assume that the
gaps are due to reduced adherence rather than due to clinician instructions for temporary
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(in the case of “embedded gaps”) or permanent (in the case of “terminal gaps”) drug
cessation.
When computing adherence indices using the end of follow up period as the end
point instead of last refill, all the patients including discontinuers were used in the
analysis. Here, the assumption made would be the fact that discontinuation is because of
failure to comply and not due to control by diet and exercise. These adherence indices
were denoted as MPR-2 and included discontinuers in their computation as opposed to
MPR-1 and Reg MPR-1 wherein all the discontinuers were excluded.
•

Medication Possession Ratio-2 (MPR-2)
The MPR-2 is a proxy measure of medication adherence in the period between the

first prescription and end of the follow up period. It is defined as the sum of days supply
for all fills divided by the number of days in the follow up period (i.e 365 days).

MPR-2 =

Sum of days supply
Number of days in the follow up period (i.e 365 days)

To account for possible early refills, any excess in the days supply due to early refill in
the previous interval was allocated to the following interval.
The above formula for MPR-2 can be easily applied to non-modifiers and
switchers. However, if there are drugs from multiple classes consumed over the time
period (i.e for augmenters, and those on initial poly-therapy) then MPR-2 should be
computed separately for each class of drug. However, these rules might differ a bit for
MPR-2. Reg MPR-2 was computed as follows:
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Sum of {MPR-2* [(Number of days between the first fill and end
of follow up period) for all drugs}
Reg MPR-2 =
Sum of (Number of days between the first fill and end of follow
period) for all drugs
If the admit and discharge dates of hospitalizations are included between the first
fill date and end of follow up period for a particular class of drug, then the number of
days of hospitalizations is added to the days supply of drugs for that particular class.

Computation of costs
•

Total health care costs were computed irrespective of the diagnoses codes. The
components of outpatient, emergency room (ER), hospitalizations, and
prescription costs were separately computed.

•

Diabetes related costs were computed by summing paid amounts for claims with a
primary or secondary diagnosis code for type 2 diabetes. Prescriptions for oral
hypoglycemics and insulin were identified on basis of National Drug
Classification (NDC) Code. Diabetic supplies such as syringes, needles, and
glucose testing equipment were also identified using NDC codes.

•

In case of outpatient, prescription, and ER costs, costs were computed from
Medicaid’s perspective using the amount paid by Medicaid for each claim. In
case of claims for hospitalizations, the amount reimbursed by Medicaid for each
claim was not included in the dataset. Hence, average 2001 West Virginia
Medicaid reimbursement rates on the basis of Diagnosis Related Groups (DRG)
were used for computation of hospitalization costs. For DRG codes that did not
have a reimbursement value from WV Medicaid, the relative weight of the DRG
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was used to assign hospitalization costs. On the basis of these averages, the
average reimbursement assigned per unit DRG weight = $ 4,632.66 per unit
weight.
The above section discussed in detail the measurement of independent and dependent
variables examined in the study. The following sections will describe the methodology
and statistical methods used to meet each specific study objective:
Objective 3
Patterns of oral hypoglycemic use
Univariate analyses such as chi-squares were used to examine the differences in
patterns of oral hypoglycemic (i.e non-modification, switching, augmentation, or
discontinuation) between patients with and without depression. In addition, as the
dependent variable had four possible categories, multivariate multinomial logistic
regression techniques were used to estimate the impact of preexisting depression on the
pattern of oral hypoglycemic use controlling for other confounding factors. A
Multinomial logistic regression model simultaneously estimates binary logistic regression
models for all possible comparisons among the outcomes categories, which enforces the
logical relationship among the parameters and uses the data more efficiently.151 Patients
receiving insulin therapy alone or in combination with oral hypoglycemics at the start of
treatment were excluded from this analysis.
Pattern (non-modification, switching, augmentation, discontinuation) = constant
+β(

Preexisting depression

+ Demographics + Drug regimen and complexity +

Co-morbidity + Diabetes severity + Interaction with health care providers) + error term
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Objective 4
Secondary failure with oral hypoglycemic therapy
Augmenting or switching from the initial class of oral hypoglycemic agent is
indicative of secondary failure with initial pharmacotherapy. A chi-square test statistic
was used to examine the differences in secondary failure with initial oral hypoglycemic
medication between patients with and without depression. A multivariate logistic
regression analysis was used to examine the impact of preexisting depression on
secondary failure controlling for other confounding factors. Patients who discontinued
the use of oral hypoglycemic agents were excluded from the analysis.
Secondary failure (Yes/No)= constant +β (

Preexisting depression

+

Demographics + Drug regimen and complexity + Co-morbidity + Diabetes severity +
Interaction with health care providers) + error term

In addition, survival analysis techniques were used to estimate the impact of
preexisting depression on time to secondary failure. As the outcome in this scenario is
time-to-event data, one encounters the issue of censoring where the response is not
observed for a portion of the subjects due to lack of follow-up time. Also, the frequency
distribution of the response measurements is not normally distributed. Due to these
characteristics of time-to-event data, the standard statistical methods are not appropriate
for estimation. Univariate Kaplan Meier survival analysis and Cox proportional hazard
models controlling for confounding factors were used for estimation of such data.
Proportions hazards regression is a semi parametric model wherein the regression
coefficients are estimated using partial likelihood procedures.152
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Mathematically, the Cox proportional hazard model can be written as:
h(t) = ho(t) * exp {βX}
Where the hazard function h(t) is determined by a set of predictor variables
collectively represented by X. Analogous to the intercept in an Ordinary Least Squares
(OLS) model, the Cox model has a baseline hazard function {ho(t)} which is estimated
non-parametrically. Thus, the model is essentially an OLS regression of the logarithm of
the hazard on the variables X with the baseline hazard being the intercept that varies with
time. The covariates act multiplicatively on the hazard at any point in time, thus leading
to the important assumption of proportional hazards rates between levels of variables.
Therefore, prior to a multivariate analysis each predictor variable was tested for
proportionality. This assumption can be tested by plotting Kaplan Meier survival
estimates versus time, for the different levels of a variable, and checking whether the
curves are linear with a constant proportion between each of the levels. In addition to
these graphical techniques, significance tests provided by statistical software STATA will
also be used for testing proportional hazards assumptions.
Time to Secondary failure = constant +β (

Preexisting depression

+

Demographics + Drug regimen and complexity + Co-morbidity + Diabetes severity +
Interaction with health care providers) + error term
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Objective 5
Initiation of insulin therapy
A chi-square test statistic was used to examine the differences in initiation of
insulin therapy between patients with and without depression. A multivariate logistic
regression analysis was used to estimate the impact of preexisting depression on initiation
of insulin therapy controlling for other confounding factors.
Insulin use (Yes/no) = constant +β (

Preexisting depression

+

Demographics + Drug regimen and complexity + Co-morbidity + Diabetes severity +
Interaction with health care providers) + error term
In addition, survival analysis techniques were used to estimate the impact of
preexisting depression on time to initiate insulin therapy. Univariate Kaplan Meier
survival analysis and Cox proportional hazard models controlling for other factors were
used for estimation.
Time to insulin use = constant +β (

Preexisting depression

+

Demographics + Drug regimen and complexity + Co-morbidity + Diabetes severity +
Interaction with health care providers) + error term
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Objective 6
Adherence with oral hypoglycemic therapy
This objective was examined using different indices for adherence such as the
Reg MPR-1 and Reg MPR-2. Univariate analyses such as t-tests were employed to
examine differences in adherence between patients with and without depression.
Ordinary Least Squares (OLS) regression techniques were used to estimate the impact of
preexisting depression on adherence with oral hypoglycemic medications controlling for
other factors. If the distributions of the adherence indices were skewed then
transformations such as log transformations were performed on the indices.
These adherence scores were also categorized to examine the extremities in
adherence levels and to estimate the relative impact of extreme adherence behavior on
outcomes. Univariate chi-square tests were used to examine differences in adherence.
As multiple categories of adherence were created, multivariate multinomial logistic
regression analysis was used to estimate the impact of preexisting depression on these
categories of adherence controlling for other confounding factors. Patients receiving
insulin therapy alone or in combination with oral hypoglycemics at the start of treatment
were excluded from this analysis. As insulin use in the follow up period can be a
consequence of decrease in adherence, it was not controlled in the model.
Adherence = constant +β (

Preexisting depression

+ Demographics +

Drug regimen and complexity + Co-morbidity + Diabetes severity + Interaction with
health care providers) + error term
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Objective 7
Utilization and costs associated with type 2 diabetes
Claims including either a primary or secondary diagnosis code for type 2 diabetes
and prescriptions for insulin, oral hypoglycemics and diabetic supplies were identified in
assessing total resource utilization associated with type 2 diabetes. The costs were also
examined separately in terms of hospitalization/ER costs, outpatient costs, and pharmacy
costs.
Parametric and non-parametric univariate tests such as t-tests and Mann-Whitney
U tests were used depending on the distribution of the dependent variables. Ordinary
Least Squares (OLS) regression techniques were used for the estimation of the impact of
preexisting depression on total costs associated with type 2 diabetes controlling for other
confounding factors. As the patients were selected over the period of a few years, the
costs were inflated to 2002 costs using the medical care and prescription price index.153
If the distributions of the costs were skewed then transformations such as log
transformations were performed to normalize the data.
In case of semi-log OLS models, empirically researchers have misinterpreted the
estimates of the coefficients of the dummy variables by assuming that the parameter is
estimated with no uncertainty. The coefficient of the primary independent variable was
estimated using the correction of Halverson and Palmquist with a modification by
Kennedy.154,155 This implies that an estimate for the coefficient of the dummy variable is
Corrected Estimate = {Exp (original estimate – 0.5(Standard error of estimate)2 } - 1
Estimates from semi-log OLS models also need to interpreted in terms of dollar values.
However, one cannot simply simulate costs by taking the anti-log of the fitted values.
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This value is subjected to retransformation bias, which is addressed using a smearing
estimator. This estimate for semi-log OLS models is generally the mean of the anti-log
of the residuals, which is multiplied by the fitted value to correct it for retransformation
bias.
In models where the dependent variables are specific costs such as those due to
ER/hospitalization visits and outpatient costs, there is a possibility of null values for the
dependent variable for some of the observations. As a logarithmic transformation cannot
be employed, a two-part model was used in this case to estimate the impact of depression
on ER/hospitalization and outpatient costs. An initial multivariate logistic regression
model was used to estimate the probability of having an ER/hospitalization or outpatient
visit and a subsequent semi-logarithmic OLS model was conducted only on those patients
incurring these specific costs in the follow up period.
Regression models will be analyzed to examine the impact of preexisting
depression on events such as number of ER/hospitalization visits, and outpatient visits.
As the dependent variable in this case is count data, the use of OLS can result in
inefficient, inconsistent, and biased estimates. Hence, a Poisson regression analysis was
conducted to meet these objectives. In a Poisson regression, the probability of a count is
determined by a Poisson distribution, which has the defining characteristic that the
conditional mean of the outcome is equal to the conditional variance. However, if the
models were overdispersed (i.e the variance being greater than the mean) with a high
proportion of zero counts, a negative binomial model was used for estimation.
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Type 2 diabetes related events and expenditures = constant +

β (

Preexisting depression

+ Demographics + Co-morbidity + Diabetes

severity + Interaction with health care providers) + error term

Objective 8
Overall utilization and health care costs
All medical and prescription claims in the 12-month follow up period were
identified for this analysis, irrespective of diagnosis codes. The costs were also examined
separately in terms of hospitalization/ER costs, outpatient costs, and pharmacy costs.
Ordinary Least Squares (OLS) regression analysis was used for the estimation of the
impact of preexisting depression on total health care costs. Regression models were also
used to examine the impact of preexisting depression on events such as number of
ER/hospitalization visits, outpatient visits, or prescriptions. Appropriate econometric
methods as explained in objective 7 were used to estimate the impact of preexisting
depression on overall utilization and health care costs.
Overall health care events and expenditures = constant +

β (

Preexisting depression

+ Demographics + Co-morbidity + Diabetes

severity + Interaction with health care providers) + error term
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Objective 9
Causal pathways between depression, adherence, and type 2 diabetes outcomes
Mediation analysis was conducted to meet this objective using the criteria
suggested by MacKinnon.156 The following three equations were estimated to identify
whether adherence with oral hypoglycemics mediates the relationship between
depression and type 2 diabetes outcomes.

Equation 1
Type 2 diabetes related events and expenditures = constant +
(α) Preexisting depression

+ Demographics + Co-morbidity + Diabetes severity +

Interaction with health care providers + error term 1

Equation 2
Type 2 diabetes related events and expenditures = constant +
(β) Preexisting depression

+ Adherence + Demographics + Co-morbidity +

Diabetes severity + Interaction with health care providers + error term 2

Equation 3
Adherence = constant +

Preexisting depression

+ Demographics + Co-

morbidity + Diabetes severity + Interaction with health care providers + Complexity of
regimen + error term 3
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The following four steps can establish mediation:
Step 1: If depression is a significant predictor of outcomes in equation 1
Step 2: If depression significantly predicts adherence in equation 3
Step 3: If adherence significantly predicts outcomes while controlling for depression in
equation 2. It is not sufficient to show that adherence and outcomes are correlated as
they may be correlated because they are both caused by depression
Step 4: To establish that adherence completely mediates the relationship between
depression and outcomes, the effect of depression on outcomes controlling for adherence
in equation 2 (i.e. β) should be zero.
If all the four steps are met then the data is consistent with the hypothesis that
adherence completely mediates the relationship between depression and outcomes, and if
the first three steps are met but the fourth step is not met, them partial mediation is
indicated. The presence of mediation will be tested by comparing the estimated effects of
depression on type 2 diabetes outcomes with and without controlling for adherence in the
estimation models (i.e. α and β). These differences in the estimates will be statistically
tested using a Hausman type statistic.157
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CHAPTER FOUR
RESULTS AND DISCUSSION
Previous chapters provided an overview of the issue of depression in patients with
type 2 diabetes and discussed the available literature in this area. The specific objectives
and the conceptual framework of the study were outlined. Data sources and detailed
methodology employed to meet the study objectives were also provided. This chapter
presents the results and discusses the findings of each study result. The results chapter is
sub-divided on the basis of the two phases of the study.

Phase 1
Results for Objective 1
To estimate the prevalence of co-morbid depression in patients with type 2 diabetes
Patients in West Virginia Medicaid with a diagnosis of type 2 diabetes in the year
2000 were identified based on the specified selection criteria. Among these patients with
type 2 diabetes, presence of co-morbid depression was identified based on the selection
criteria for depression.
Patients with type 2 diabetes:
• Number of patients with continuous Medicaid eligibility and HMO non-eligibility
between the ages of 18 and 64 in the year 2000: 10,742
•

Number of type 2 diabetes patients who had co-morbid depression in 2000: 2,644
(24.60%)
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Prevalence rate =
per 100,000

Number of type 2 diabetic patients with
co-morbid depression during the year 2000 x 100,000
Number of patients with type 2 diabetes
during the year 2000

Prevalence rate =
per 100,000

2644 x 100,000 = 24,613.66
10742

In addition, a group of Medicaid enrollees without type 2 diabetes diagnosis or
prescription for oral hypoglycemic agent was identified in the year 2000. Presence of
co-morbid depression was also determined for this group of patients.
Patients without type 2 diabetes:
•

Number of patients with continuous Medicaid eligibility and HMO non-eligibility
between the ages of 18 and 64 in the year 2000: 9,364

•

Number of patients without type 2 diabetes who had co-morbid depression in
2000: 1,911 (20.40%)
A Chi-square value of 50.50 was found to be significant (p= 0.001) indicating that

co-morbid depression was more prevalent in patients with type 2 diabetes as compared to
Medicaid enrollees without type 2 diabetes. However, this effect could also be a result of
confounders such as demographics and presence of co-morbid conditions. Hence, a
multivariate logistic regression was also performed controlling for age, gender, race, and
co-morbidities. To separate the effects of type 2 diabetes and the presence of related comorbidities on the prevalence of depression, a block-wise logistic regression model was
created consisting of the following blocks of co-variates entered sequentially in the
model.
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Block 1: Demographic variables: age, gender, race, interaction term of age and
diabetes, interaction term of gender and diabetes.
Block 2: Presence of chronic co-morbidities unrelated to type 2 diabetes: Cancer,
asthma, and ulcer.
Block 3: Number of physician office visits and presence of chronic co-morbidities
related to type 2 diabetes (Cardiovascular conditions, cerebro-vascular conditions,
nephropathy, retinopathy, neuropathy and endocrine/metabolic disorders).
All three logistic regression models were found to be significant and the model
results are summarized in Tables 1A-1C. Use of blocks of covariates shows that
prevalence of depression in patients with type 2 diabetes was significantly higher than
patients without type 2 diabetes after controlling for demographic characteristics such as
gender, age, race, and their interactions (Odds Ratio = 1.259; p = 0.000). The association
remained significant after additionally controlling for presence of major chronic
conditions unrelated to type 2 diabetes (Odds Ratio = 1.181; p=0.000). However,
presence of type 2 diabetes did not retain its statistically significant impact on presence of
co-morbid depression when presence of chronic conditions related to type 2 diabetes and
number of physician office visits were controlled in the model (Odds Ratio = 0.924; p
=0.089).

107

Table 1A: Logistic regression model to examine the relationship between type 2
diabetes and presence of co-morbid depression (Model 1)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper

Type 2 diabetes

0.230

0.044 0.000*

1.259

1.156

1.371

Block 1
Age**

0.006

0.002 0.003*

1.006

1.002

1.010

-0.710

0.055 0.000*

0.492

0.441

0.548

0.347

0.079 0.000*

1.415

1.211

1.653

Interaction of diabetes and
age

-0.029

0.003 0.000*

0.971

0.966

0.977

Interaction of diabetes and
gender

0.029

0.076 0.704

1.029

0.887

1.194

-1.374

0.082 0.000

0.253

Males (ref: females)
Whites (ref: non-whites)

Constant
*significance at the 0.05 level

**Age is centered at the average value of age for the sample (40 years)

Model fit statistics:
Pseudo R-square = 4.1%
-2 Log Likelihood = 20411.304; χ2 = 532.630, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 41.850; p=0.000
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Table 1B: Logistic regression model to examine the relationship between type 2
diabetes and presence of co-morbid depression (Model 2)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper

Type 2 diabetes

0.174

0.044 0.000*

1.190

1.092

1.298

Block 1
Age**

0.003

0.002 0.188

1.003

0.999

1.007

-0.678

0.056 0.000*

0.507

0.455

0.566

0.333

0.080 0.000*

1.396

1.193

1.633

Interaction of diabetes and
age

-0.027

0.003 0.000*

0.973

0.967

0.979

Interaction of diabetes and
gender

0.038

0.076 0.622

1.038

0.894

1.206

Block 2
Asthma

0.652

0.042 0.000*

1.919

1.767

2.083

Cancer

0.139

0.077 0.071

1.149

0.988

1.336

Ulcers

0.555

0.075 0.000*

1.742

1.505

2.016

-1.518

0.084 0.000

0.219

Males (ref: females)
Whites (ref: non-whites)

Constant
*significance at the 0.05 level

**Age is centered at the average value of age for the sample (40 years)

Model fit statistics:
Pseudo R-square = 6.4%
-2 Log Likelihood = 20098.353; χ2 = 845.581, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 29.280; p=0.000
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Table 1C: Logistic regression model to examine the relationship between type 2
diabetes and presence of co-morbid depression (Model 3)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper

Type 2 diabetes

-0.072

0.047 0.124

0.931

0.850

1.020

Block 1
Age**

-0.004

0.002 0.067

0.996

0.992

1.000

Males (ref: females)

-0.598

0.057 0.000*

0.550

0.492

0.614

0.328

0.081 0.000*

1.388

1.185

1.626

Interaction of diabetes and
age

-0.022

0.003 0.000*

0.978

0.972

0.984

Interaction of diabetes and
gender

0.001

0.077 0.991

1.001

0.860

1.165

Block 2
Asthma

-0.111

0.079 0.164

0.895

0.766

1.046

Cancer

0.350

0.077 0.000*

1.419

1.221

1.649

Ulcers

0.483

0.043 0.000*

1.621

1.489

1.764

Block 3
Diabetic complications

0.457

0.049 0.000*

1.579

1.434

1.738

0.040

0.003 0.000*

1.041

1.036

1.046

-1.971

0.090 0.000

0.139

Whites (ref: non-whites)

Number of physician office
visits
Constant
*significance at the 0.05 level

**Age is centered at the average value of age for the sample (40 years)

Model fit statistics:
Pseudo R-square = 9.5%
-2 Log Likelihood = 19678.563; χ2 = 1265.371, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 21.570; p= 0.006
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Discussion for Objective 1
Our results demonstrated that 24.6% of type 2 diabetes patients in West Virginia
Medicaid had co-morbid depression. Previous studies have found depression prevalence
rates ranging from 6.1% to 49.3% in patients with type 2 diabetes.29 The populationbased study conducted in KPNW had a prevalence rate of 17.6%.139 Our rates may be
higher due to an indigent and younger population with a higher proportion of females.
The association of type 2 diabetes and co-morbid depression was significant after
controlling for confounders indicating that patients with type 2 diabetes have higher odds
of co-morbid depression as compared to patients without type 2 diabetes. However,
when the logistic regression model was reanalyzed with the presence of type 2 diabetes
related co-morbidities as independent variables, the odds of co-morbid depression were
not significantly different for patients with type 2 diabetes as compared to patients
without type 2 diabetes. These results are interesting in the fact that they suggest that
higher observed rates of co-morbid depression in patients with type- 2 diabetes are
primarily due to the higher number of co-morbid conditions associated with type 2
diabetes. However, one can attribute these co-morbid conditions and subsequent
depression to type 2 diabetes and thus reasonably conclude that type 2 diabetes is
associated with a higher prevalence of co-morbid depression. Similar results were
obtained in a study by Pouwer and associates,138 which suggested that the prevalence of
co-morbid depression is higher in patients with type 2 diabetes and co-morbid disease(s),
but not in patients with type 2 diabetes only. A variety of other studies have found that
while medical conditions in general are risk factors for psychological disturbance, type 2
diabetes carries no unique risk.121 The comprehensive review by Anderson and associates
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contained two studies that compared rates of depression between people with diabetes
and those with other medical conditions; neither found a significant difference.29 These
results suggest that factors involved in the general burden of illness contribute to the
observed elevated prevalence of co-morbid depression in patients with type 2 diabetes.

Results for Objective 2
To estimate the incidence of type 2 diabetes in patients with pre-existing depression
Patients with depression were identified on the basis of the inclusion criteria for
depression in the year 1997. As a comparison group, a group of Medicaid enrollees
without depression diagnosis or prescription of antidepressants was identified in the year
1997. Patients with a medical claim for type 2 diabetes or a prescription for an oral
hypoglycemic agent in the year 1997 were excluded from the analysis. These patients
were then followed till December 31, 2002, to identify incident cases of type 2 diabetes
in both the groups.
Patients with depression:
•

Number of patients with a diagnosis of depression: 12,589

•

Number of depressed patients without type 2 diabetes in 1997: 11,345

•

Number of eligible patients (Medicaid eligible 97-2002; HMO non eligible 972002; age greater than or equal to 18 and age less than or equal to 60 as on
January 1, 1998): 4,472

•

Number of depressed patients who had incident type 2 diabetes in the follow-up
period (1998-2002): 704 (15.70%)
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Number of new cases of type 2 diabetes in patients with
Incidence rate = preexisting depression occurring between 1998-2002
per 100,000 Number of patients with depression in 1997
Incidence rate =
per 100,000

704 x 100,000
4,472

x 100,000

= 15,742.39

Patients without depression:
•

Number of patients without a diagnosis of depression: 52,653

•

Number of non-depressed patients without type 2 diabetes in 1997: 50,798

•

Number of eligible patients (Medicaid eligible 97-2002; HMO non eligible 972002; age greater than equal to 18 and age less than equal to 60 as on January 1,
1998): 5,195

•

Number of non-depressed patients who had incident type 2 diabetes in the followup period (1998-2002): 606(11.70%)

A univariate chi-square analysis was performed to determine the association
between the presence of pre-existing depression and incidence of type 2 diabetes patients.
Approximately 15.7% of depressed patients developed type 2 diabetes as compared to
11.70% of non-depressed patients. A Chi-square value of 34.104 was found to be
significant with a p-value of 0.000. These numbers indicate that the incidence of type 2
diabetes was slightly higher in patients with pre-existing depression. However, this effect
could also be a result of confounders such as demographics and presence of co-morbid
conditions. Hence, a multivariate logistic regression was performed to determine the
association of pre-existing depression and incidence of type 2 diabetes controlling for
age, gender, race, and presence of cardio-vascular co-morbidities at baseline.
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The logistic regression model was found to be significant with a Nagelkerke Rsquare value of 7.10%. The model results are summarized in Table 2. A significant
adjusted odds ratio indicates that the association between presence of pre-existing
depression and incidence of type 2 diabetes is still significant and that patients with preexisting depression are more likely to develop type 2 diabetes as compared to enrollees
without pre-existing depression.
Due to the use of interaction effects, the odds of developing incident type 2
diabetes in patients with depression as compared to patients without depression needs to
be computed separately for males and females. The interaction term for gender and
presence of pre-existing depression was significant, suggesting that the odds of
developing incident type 2 diabetes in patients with depression differs for males and
females. The results of logistic regression estimate that a 40 year old female with preexisting depression is nearly one and a half times more likely to develop incident type 2
diabetes as compared to a 40 year old female without depression after controlling for age,
gender, race, and cardiovascular co-morbidity at baseline. However, 40 year old males
do not show a relationship between presence of pre-existing depression and development
of incident type 2 diabetes (Odds Ratio for Females= 1.479; Odds Ratio for
Males=0.997).
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Table 2: Logistic regression model to examine the relationship between pre-existing
depression and incidence of type 2 diabetes
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper

Depression

0.392

0.086 0.000*

1.479

1.250

1.751

Age**

0.039

0.004 0.000*

1.040

1.032

1.048

-0.024

0.091 0.791

0.976

0.816

1.168

0.135

0.157 0.389

1.145

0.841

1.558

Interaction of depression and
age

-0.019

0.006 0.001*

0.981

0.969

0.993

Interaction of depression and
gender

-0.394

0.138 0.004*

0.674

0.515

0.884

Cardiovascular co-morbidity

0.760

0.067 0.000*

2.139

1.877

2.438

-2.400

0.166 0.000

0.091

Males (ref: females)
Whites (ref: non-whites)

Constant
*significance at the 0.05 level

**Age is centered at the average value of age for the sample (40 years)

Model fit statistics:
Pseudo R-square = 7.1%
-2 Log Likelihood = 7003.420; χ2 = 370.605, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 7.142; p= 0.521
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Table 3: Logistic regression model to examine the relationship between pre-existing
depression and incidence of type 2 diabetes (excluding cases of incident type 2
diabetes in the first 2 years of follow up)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper

Depression

0.410

0.114 0.000*

1.507

1.205

1.884

Age**

0.030

0.005 0.000*

1.030

1.019

1.041

Males (ref: females)

0.078

0.121 0.519

1.081

0.853

1.371

Whites (ref: non-whites)

0.212

0.213 0.320

1.236

0.814

1.875

Interaction of depression and
age

-0.011

0.008 0.155

0.989

0.974

1.004

Interaction of depression and
gender

-0.371

0.179 0.038*

0.690

0.486

0.979

Cardiovascular co-morbidity

0.704

0.088 0.000*

2.022

1.703

2.401

-3.103

0.225 0.000

0.045

Constant
*Significance at the 0.05 level

**Age is centered at the average value of age for the sample (40 years)

Model fit statistics:
Pseudo R-square = 4.4%
-2 Log Likelihood = 4592.426; χ2 = 164.520, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 11.245; p= 0.188
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Discussion for Objective 2
Evidence from a few prospective studies indicates that depression doubles the risk
of incident type 2 diabetes even after controlling for other risk factors. Controlling for
multiple risk factors in relatively small samples, Eaton and associates32 and Kawakami
and associates33 have shown that presence of depressive symptoms more than doubled the
risk of developing type 2 diabetes. A couple of other studies have used data from the
NHEFS34,35 to test the relationship between depression and incidence of diabetes.
However, these studies using the NHEFS cohort were not specific to incidence of type 2
diabetes and had inconclusive results.
The study results indicated a significant interaction between gender and presence
of pre-existing depression. Pre-existing depression was not significantly associated with
incident type 2 diabetes in males; while females with pre-existing depression were one
and a half times more likely to develop incident type 2 diabetes as compared to females
without pre-existing depression controlling for demographics and presence of
cardiovascular co-morbidity at baseline.
However, this impact of pre-existing depression on incidence of type 2 diabetes
may be confounded by factors such as obesity. Being overweight is associated with onset
of type 2 diabetes and depressed individuals suffer from problems with appetite and
weight gain. One can also view obesity as a mediating variable in the relationship
between depression and onset of type 2 diabetes. However, controlling for the presence
of chronic medical conditions such as cardiovascular problems, cerebrovascular
conditions and metabolic/endocrine disorders at baseline failed to attenuate the
relationship between depression and incidence of diabetes. Another possible explanation
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for this relationship is the presence of detection bias as individuals with depressive
symptoms may be more likely to seek medical care than individuals without symptoms.
Therefore, they would be more likely to be diagnosed with diabetes than those without
symptoms leading to an increased prevalence and incidence of type 2 diabetes among
patients with depression. In this study, an attempt was made to reduce the bias by
controlling for the number of physician office visits at baseline (year 1997). The
presence of pre-existing depression maintained a significant impact on the incidence of
type 2 diabetes after controlling for this ascertainment bias.
Another important limitation of the study is the problem of undetected type 2
diabetes. Diabetic disturbance in glucose metabolism may start 5-10 years before the
diagnosis of type 2 diabetes. It is possible that symptoms due to the presence of
undetected diabetes could have led to depression at baseline. Also, depressive symptoms
may worsen glycemic control exclusively among those who already had diabetic
metabolic disturbance. These factors can lead to an artificial effect of a higher incidence
of type 2 diabetes in patients with depression as compared to patients without depression.
To avoid this problem of undetected diagnosis, a sub-analysis was conducted by
excluding cases of incident diabetes in the first two years of the follow-up period. The
results of this sub-analysis were highly comparable to the original results confirming the
higher incidence of type 2 diabetes in female patients with depression (Table 3).
Also, the peak onset of depression usually occurs during early adulthood between
the ages of 20 and 30; while the onset of type 2 diabetes typically occurs much later.158,159
On the basis of this alone, one would expect depressive symptoms to precede the
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incidence of type 2 diabetes. Hence, a statistical interaction between presence of
depression and age at baseline become highly important control variables in the model.
There is also the possibility of misclassification bias as there might be individuals
at baseline who have depression symptomatology but have not sought treatment or
medical attention and are hence classified as patients without depression. However, this
misclassification would only lead to an underestimation of the effect of depression on
incidence of type 2 diabetes. As significant results are obtained even with
underestimation we can easily conclude that there is a significant positive relationship
between presence of pre-existing depression and incidence of type 2 diabetes.

Phase 2
In phase 2 of the study, patients newly diagnosed with type 2 diabetes were
identified. The date of the first prescription for an oral hypoglycemic agent was identified
for these patients and treated as the index date for the study. Patients were then followed
for a period of 12 months post index date.
Sample selection
In the three-year enrollment period between January 1, 1998 and December 31,
2000, 27,676 patients with a medical diagnosis for type 2 diabetes were identified. Of
these, 9,116 patients were newly diagnosed with type 2 diabetes in the enrollment period.
Only about 50% of these newly diagnosed patients received any type of oral
hypoglycemic prescription in the period between January 1, 1998 and December 31,
2002. Of these 4,459 newly diagnosed type 2 diabetes patients, 1,021 patients had preexisting depression and the remainder had no diagnosis of depression in the entire study
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period. After excluding patients on the basis of other criteria, the final cohort consisted
of 1,326 type 2 diabetes patients (471 patients with depression and 855 patients without
depression). A detailed algorithm of sample attrition for the cohort followed for 12
months post index date is provided in Figure 5.
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Figure 5: Algorithm for sample attrition of patients with newly diagnosed type 2
diabetes (12 month follow up period)
Diagnosis of type 2 diabetes between 1998-2000
(N= 27,676)

Patients with incident type 2 diabetes*
(N= 9,116)

Patients receiving oral hypoglycemic therapy
(N= 4,459)

Patients with pre-existing depression**
(N =1,021)

Patients with no depression diagnosis
(N=3,296)

Medicaid eligibility; HMO non-eligibility;
Age > 18 and < 64 years (N= 774)

Medicaid eligibility; HMO non-eligibility;
Age > 18 and < 64 years (N= 1,756)

Absence of other mental disorders
(N= 544)

Absence of other mental disorders
(N= 981)

Absence of a prescription for Rezulin
(N= 510)

Absence of a prescription for Rezulin
(N= 943)

Absence of nursing home visits
(N= 505)

Absence of nursing home visits
(N= 922)

Prescription of index oral hypoglycemic
prescription in 1998-2001
(N= 471)

Prescription of index oral hypoglycemic
prescription in 1998-2001
(N= 855)

*Incident diabetes is identified by absence of diagnosis codes for diabetes or antidiabetic medications in the 12 month period prior to
index date of diabetes in 98-2000; coupled with Medicaid eligibility and non-HMO eligibility in the 12 month pre-index date
**Pre-existing depression is identified by the presence of a depression diagnosis or use of an antidepressant in the period before
incidence of type 2 diabetes
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Baseline characteristics of newly diagnosed type 2 diabetes patients
To meet the study objectives of examining differences in adherence and health
care expenditures between patients with and without depression, a number of baseline
demographic and clinical variables were controlled to prevent any bias in the validity of
the study results. The comparison of these baseline characteristics between patients is
provided in Table 4. The baseline characteristics were grouped into factors such as
demographic characteristics, complexity of regimen, co-morbid conditions, provider
interaction, and diabetes severity. A Mann Whitney U test was used to compare
continuous variables, while a chi-square test was used to compare differences between
categorical variables.
Demographic characteristics:
Patients with pre-existing depression were significantly younger as compared to
patients without pre-existing depression. Mean age for patients with depression was
46.87 years (+9.35) as compared to a mean age of 49.12 years (+10.65) for patients
without depression. A significantly higher percent of depressed patients were female
(81.5%) as compared to non-depressed patients (53.6%). Depressed and non-depressed
patients did not differ significantly on other demographic characteristics such as race,
geographical location, and year of index prescription.
Complexity of regimen
Patients with depression consumed significantly higher number of pills per day
for chronic medications (3.72 +3.62) as compared to non-depressed patients (2.74 +3.31).
Depressed patients also filled a greater number of prescriptions for chronic medications
(11.63 +10.07) as compared to non-depressed patients (9.27 +3.30). However, the two
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groups did not differ significantly in the number of pills per day for oral hypoglycemic
agents.
Co-morbid conditions
Baseline co-morbid conditions other than depression were evaluated for patients
with type 2 diabetes. Health care utilization variables identifying the presence and
severity of co-morbid conditions (excluding those due to depression) such as total health
care costs, number of ER/hospitalization episodes, and number of therapeutic classes of
chronic medications indicated that patients with depression had a significantly higher
presence of co-morbid conditions as compared to patients without depression. Scores on
the Charlson co-morbidity index indicated greater co-morbidity in depressed patients
(0.76 +1.22) as compared to non-depressed patients (0.55 +1.19). Also co-morbid
conditions such as asthma, ulcer, and cardiovascular conditions occurred more frequently
in depressed patients as compared to non-depressed patients.
Provider interaction
There were no differences in the fraction of patients enrolled in PAAS between
depressed and non-depressed patients. However, a greater fraction of non-depressed
patients (52.3%) used a single pharmacy in the last six months as compared to depressed
patients (38.9%), implying greater pharmacy patronage for non-depressed patients.
Diabetes severity
As the study population consisted of a group of newly diagnosed type 2 diabetes
patients, drastic differences in terms of diabetes severity were not expected. However, as
our study index date was the date of the first prescription for an oral hypoglycemic, there
could be potentially a gap between initiation of oral hypoglycemic therapy and initial
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diagnosis of type 2 diabetes thus leading to differences in diabetes severity. Baseline
comparisons demonstrated that depressed and non-depressed patients did not have
significant differences in diabetes severity as measured on the basis of type of prescribing
physician, initiation on polytherapy, gap between diagnosis and therapy, and number of
diabetes related ER/hospitalization episodes. The only differences were seen in terms of
diabetes related costs in the pre 12-month period and the class of the index oral
hypoglycemic agent. Depressed patients had significantly higher diabetes related costs
($899.35 + 3,275.30) than non-depressed patients ($629.42 + 2,751.92). Also, in terms
of the class of index oral hypoglycemic agent, the most notable difference was that a
higher fraction of depressed patients (2.8%) were prescribed an alpha-glucosidase
inhibitor as compared to non-depressed patients (0.8%). Also, a slightly higher fraction
of depressed patients (2.5%) were prescribed meglitinides as compared to non-depressed
patients (1.1%).
Overall, the results demonstrated distinct differences between patients with and
without pre-existing depression. Depressed patients were significantly younger and
included a higher proportion of females. Depressed patients had a significantly higher
number of co-morbid conditions and a more complex drug regimen at baseline. Level of
diabetes severity was not too different between the two groups. However, differences in
the index class of oral hypoglycemic agent was possibly indicative of a higher fraction of
depressed patients being obese as compared to non-depressed patients. This was deduced
on the basis of clinical information indicating that alpha-glucosidase and meglitinides are
typically prescribed to obese patients as opposed to sulfonylurea due to the absence of
any side effects of weight gain due to these medications.
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These baseline variables were used in the multivariate framework to estimate the
impact of depression on type 2 diabetes outcomes adjusting for these baseline
characteristics. The effect of the individual constructs such as demographics, comorbidity, provider interaction, complexity of regimen, and diabetes severity on type 2
diabetes outcomes were not an objective of the study. Hence, in all the results and
discussions of study objectives, the effect of these baseline control variables on type 2
diabetes outcomes will not be discussed. Only the effect of depression on type 2 diabetes
outcomes controlling for these baseline variables will be examined and discussed.
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Table 4: Baseline characteristics of newly diagnosed type 2 diabetes patients
Depressed
(n=471)

Non-depressed
(n=855)

Test
Statistic

Sig.
(p)

Demographic Characteristics
Age (in years)

46.87 +9.35*

49.12 +10.65*

M=169467.00

0.000**

Gender
• Males
• Females

18.53%
81.47%

46.63%
53.37%

χ2 = 101.30

0.000**

Race
• Whites
• Non-whites

95.91%
4.09%

93.64%
6.36%

χ2 = 3.11

0.078

Residence
• Urban
• Rural

93.03%
6.97%

92.05%
7.95%

χ2 = 0.39

0.534

Year of index prescription
• 1998
21.00%
• 1999
32.11%
• 2000
36.83%
• 2001
10.06%

25.32%
32.04%
35.14%
7.50%

χ2 = 4.81

0.186

Complexity of regimen
Number of pills per day
for chronic medications

3.72 + 3.62*

2.74 + 3.31*

M= 164214.00

0.000**

Number of prescriptions 11.63 + 10.07*
for chronic medications

9.27 + 3.30*

M= 165250.00

0.000**

Number of pills per day
for oral hypoglycemics

1.44 + 0.69*

M=195228.00

0.301

1.49 + 0.73*
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Table 4: Baseline characteristics of newly diagnosed type 2 diabetes patients
(Contd.)
Depressed
(n=471)

Non-depressed
(n=855)

Test
Statistic

Sig.
(p)

1.09+2.16*

M=162948.00

0.000**

Baseline Co-morbid conditions
Number of ER/
hospitalizations
(Excluding those
due to depression)

2.03 +3.47*

Total health costs
(Excluding those
due to depression)

7,623.21
+ 10,942.62*

5,318.42
+ 11,378.92*

M=136320.00

0.000**

Charlson
co-morbidity

0.76 + 1.22*

0.55 + 1.19*

M= 177512.00

0.000**

Number of
therapeutic classes
of medications

2.86 + 1.90*

2.12 + 1.82*

M=153958.00

0.000**

Presence of co-morbid conditions
• Cardio-vascular 64.10%
• Cancer
5.92%
• Asthma
21.24%
• Ulcers
5.12%

58.13%
3.91%
14.62%
1.83%

χ2 = 4.55
χ2 = 3.01
χ2 = 9.42
χ2 = 11.88

0.033**
0.083
0.002**
0.001**

12.74%

11.13%

χ2 = 0.78

0.377

Number of pharmacies seen
in last 12 months
• No pharmacy
0.82%
• Single
38.91%
• Multiple
60.27%

7.05%
52.22%
40.73%

χ2 = 59.93

0.000*

Provider interaction
PAAS enrollment
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Table 4: Baseline characteristics of newly diagnosed type 2 diabetes patients
(Contd.)
Depressed
(n = 471)

Non-depressed
(n = 855)

Test
Statistic

Sig.
(p)

1.52%
30.14%
68.44%

χ2 = 0.70

0.705
0.080

Baseline diabetes severity
Index oral hypoglycemic
prescribed by:
• Endocrinologist
• Internal medicine
• Family practitioner

1.92%
31.53%
66.55%

Number of diabetes
0.21 + 0.59*
related ER/hospitalizations

0.14 + 0.44*

M=194630.00

Total diabetes related
costs

629.42
+ 2,751.92*

M=186703.00 0.020**

Gap between diagnosis
and index prescription
Initial polytherapy

899.35
+ 3,275.30*
117.16
+ 236.23*

97.29 M= 191107.50 0.105
+ 214.15*

6.21%

8.92%

Index class of oral hypoglycemic
• Sulfonylurea
49.72%
• Thiazolidenedione
7.22%
• Biguanides
35.00%
• Alpha-glucosidase
2.81%
• Sulfonylurea-biguanide 2.83%
• Meglitinides
2.42%

55.02%
5.81%
34.60%
0.82%
2.72%
1.13%

*Mean + S.D.
**significance at the 0.05 level
M= Mann-Whitney U Test; χ2 = Chi-square test
PAAS = Physician Assured Access System
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χ2 = 3.11

0.078

χ2 = 14.40

0.013**

Results for Objective 3
To examine the impact of pre-existing depression on patterns of oral hypoglycemic use in
new patients with type 2 diabetes
Patients initiating polytherapy or insulin therapy were excluded from this
analysis. Univariate results for patterns of oral hypoglycemic therapy are presented in
Table 5. Results indicated that a significantly higher fraction of depressed patients
(39.50%) discontinued oral hypoglycemic therapy as compared to non-depressed patients
(32.90%). Only 37.20% of depressed patients non-modified their index oral
hypoglycemic therapy as compared to 50.90% of non-depressed patients who remained
on their original therapy for the entire 12 month follow up period. Of the patients who
modified their index oral hypoglycemic therapy, 9.20% depressed patients switched
therapy as compared to 6.30% non-depressed patients. The fraction of patients
augmenting their index therapy by adding another oral hypoglycemic agent or insulin to
their drug regimen was also significantly higher for depressed patients (14.1%) as
compared to non-depressed patients (9.9%). A univariate chi-square value of 22.95 was
found to be significant with a p-value of 0.000. These numbers indicate that the patterns
of oral hypoglycemic use were significantly favorable for non-depressed patients
indicating better management of type 2 diabetes.
However, this effect could also be a result of confounders such as demographics,
co-morbidity, diabetes severity, complexity of regimen, and interaction with health care
providers. Hence, a multivariate multinomial logistic regression was performed to
determine the impact of depression on patterns of oral hypoglycemic use controlling for
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baseline confounding factors. Non-modification was used as the reference category for
all comparisons in the multinomial logistic model framework.
The multinomial logistic regression model was found to be significant with a
Nagelkerke R-square value of 16.1%. The model results are summarized in Table 6A6C. Results of the multivariate model indicated that controlling for confounding
covariates, patients with depression were nearly one and a half times more likely to
discontinue oral hypoglycemic therapy in the 12 month follow up period as compared to
patients without depression (p= 0.004). Results also demonstrated that depressed patients
were 1.7 times more likely to switch (p=0.046) and two times more likely to augment
therapy (p=0.003) as compared to patients without depression.
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Table 5: Pattern of use of oral hypoglycemics in the 12-month follow up period
Depressed
(n= 446)
Non-modification

Non-depressed Total
(n= 791)
(n= 1237)

37.22%
(166)

50.95%
(403)

46.00%
(569)

9.19%
(41)

6.32%
(50)

7.36%
(91)

14.13%
(63)

9.86%
(78)

11.40%
(141)

39.46%
(176)

32.87%
(260)

35.25%
(436)

Test
statistic

Sig.
(p)

χ2 = 22.95

0.00*

Modification
•
•

Switching
Augmentation

Discontinuation
*significance at the 0.05 level
χ2 = Chi-square test
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Table 6A: Multinomial Logistic regression for the impact of depression on pattern
of oral hypoglycemic use (Switching vs. Non-modification)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.544
0.270 0.044*
1.724 1.016 2.924
Depression
Demographic characteristics
Age (in years)

0.006

0.013 0.674

1.006

0.980

1.032

Males (ref: females)

0.223

0.260 0.391

1.249

0.751

2.078

Whites (ref: non-whites)

1.156

0.777 0.137

3.178

0.692 14.588

Urban (ref: rural)

0.180

0.462 0.697

1.197

0.484

2.957

Year of index prescription (ref: 2001)
-0.911
• 1998
-0.614
• 1999
-0.261
• 2000

0.634 0.151
0.589 0.297
0.559 0.640

0.402
0.541
0.770

0.116
0.171
0.258

1.394
1.716
2.301

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.051

0.064 0.428

1.052

0.928

1.193

Total health costs

0.000

0.000 0.256

1.000

1.000

1.000

-0.051

0.144 0.722

0.950

0.716

1.260

0.077

0.131 0.556

1.080

0.835

1.397

-0.395

0.274 0.149

0.674

0.394

1.152

Cancer

0.446

0.630 0.479

1.563

0.455

5.372

Asthma

0.290

0.358 0.418

1.336

0.662

2.696

Ulcers

0.728

0.601 0.225

2.072

0.638

6.724

0.347 0.234

1.512

0.765

2.986

Number of pharmacies visited (ref: multiple pharmacies)
-0.568
0.801 0.479
• No pharmacy
-0.212
0.249 0.395
• Single pharmacy

0.567
0.809

0.118
0.496

2.726
1.318

Charlson co-morbidity
Number of therapeutic classes
of medications
Cardio-vascular

Provider interaction in the pre period
PAAS enrollment
0.413
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Table 6A: Multinomial Logistic regression for the impact of depression on pattern
of oral hypoglycemic use (Switching vs. Non-modification) (Contd.)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
Complexity of regimen
Number of pills per day for
-0.035
0.059 0.557
0.966 0.859 1.085
chronic medications
Number of prescriptions for
chronic medications

-0.005

0.024 0.849

0.995

0.949

1.044

Number of pills per day for
oral hypoglycemics

0.122

0.217 0.575

1.129

0.738

1.728

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
1.355
0.885 0.126
3.876
• Endocrinologist
0.335
0.255 0.189
1.398
• Internal medicine

0.684 21.956
0.848 2.305

Total diabetes costs

0.000

0.000 0.720

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.311

0.305 0.309

1.364

0.750

2.481

-0.001

0.001 0.167

0.999

0.998

1.000

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.327
0.447 0.465
• Thiazolidenedione
-0.324
0.330
0.327
• Biguanides
1.166
0.739 0.115
• Alpha-glucosidase
0.377
0.808 0.641
• Meglitinides

1.386
0.724
3.208
1.457

0.577 3.331
0.379 1.383
0.753 13.658
0.299 7.107

Gap between index diagnosis
and prescription

Constant

-3.118

1.302 0.017
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Table 6B: Multinomial Logistic regression for the impact of depression on pattern
of oral hypoglycemic use (Augmentation vs. Non-modification)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.659
0.220 0.003*
1.933 1.256 2.975
Depression
Demographic characteristics
Age (in years)
-0.008

0.011 0.452

0.992

0.972

1.013

Males (ref: females)

-0.018

0.218 0.933

0.982

0.640

1.507

Whites (ref: non-whites)

0.744

0.552 0.178

2.104

0.713

6.207

Urban (ref: rural)

0.436

0.406 0.283

1.547

0.698

3.429

0.559 0.558
0.523 0.989
0.502 0.505

0.720
0.993
1.398

0.241
0.356
0.523

2.156
2.767
3.738

0.047 0.003*

1.151

1.051

1.262

0.000

0.000 0.052

1.000

1.000

1.000

-0.248

0.154 0.108

0.781

0.577

1.056

0.201

0.109 0.065

1.222

0.988

1.512

-0.152

0.226 0.503

0.859

0.551

1.339

Cancer

0.143

0.617 0.817

1.153

0.344

3.867

Asthma

0.049

0.336 0.885

1.050

0.543

2.029

Ulcers

0.367

0.635 0.564

1.443

0.416

5.012

0.300 0.279

1.384

0.769

2.489

Number of pharmacies visited (ref: multiple pharmacies)
0.650
0.532 0.222
• No pharmacy
0.060
0.208 0.773
• Single pharmacy

1.915
1.062

0.675
0.706

5.429
1.598

Year of index prescription (ref: 2001)
-0.328
• 1998
-0.007
• 1999
0.335
• 2000
Co-morbid conditions in the pre period
Number of ER/hosp visits
0.141
Total health costs
Charlson co-morbidity
Number of therapeutic classes
of medications
Cardio-vascular

Provider interaction in the pre period
PAAS enrollment
0.325
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Table 6B: Multinomial Logistic regression for the impact of depression on pattern
of oral hypoglycemic use (Augmentation vs. Non-modification) (Contd.)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
Complexity of regimen
Number of pills per day for -0.018
0.048 0.705
0.982 0.895 1.078
chronic medications
Number of prescriptions for -0.014
chronic medications

0.020 0.486

0.986

0.947

1.026

Number of pills per day for
oral hypoglycemics

0.168 0.067

1.359

0.978

1.887

0.307

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
1.469
0.698 0.035*
4.347
• Endocrinologist
0.152
0.217 0.484
1.164
• Internal medicine

1.107 17.072
0.761 1.781

Total diabetes costs

0.000 0.032*

1.000

1.000

1.000

Number of diabetes related -0.348
ER/Hosp visits

0.291 0.232

0.706

0.399

1.250

0.000

0.001 0.508

1.000

0.998

1.001

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.133
0.419 0.750
• Thiazolidenedione
-0.089
0.257
0.730
• Biguanides
-0.505
0.888 0.569
• Alpha-glucosidase
-1.095
0.926 0.237
• Meglitinides

1.143
0.915
0.603
0.335

0.503
0.553
0.106
0.054

2.598
1.515
3.442
2.056

Gap between index diagnosis
and prescription

Constant

0.000

-3.016

1.048 0.004
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Table 6C: Multinomial Logistic regression for the impact of depression on pattern
of oral hypoglycemic use (Discontinuation vs. Non-modification)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.454
0.157 0.004*
1.575 1.157 2.144
Depression
Demographic characteristics
Age (in years)
-0.013

0.007 0.065

0.987

0.973

1.001

Males (ref: females)

-0.053

0.150 0.723

0.948

0.706

1.273

Whites (ref: non-whites)

-0.056

0.295 0.850

0.946

0.531

1.685

0.077

0.259 0.767

1.080

0.650

1.795

0.385 0.042*
0.366 0.019*
0.351 0.140

0.458
0.424
0.596

0.215
0.207
0.299

0.973
0.869
1.186

0.037 0.000*

1.159

1.079

1.246

Urban (ref: rural)

Year of index prescription (ref: 2001)
-0.782
• 1998
-0.859
• 1999
-0.518
• 2000
Co-morbid conditions in the pre period
Number of ER/hosp visits
0.148
Total health costs

0.000

0.000 0.218

1.000

1.000

1.000

Charlson co-morbidity

0.077

0.082 0.343

1.080

0.921

1.268

Number of therapeutic classes
of medications

0.083

0.080 0.300

1.087

0.929

1.271

-0.311

0.156 0.046*

0.732

0.539

0.995

Cancer

0.429

0.392 0.273

1.536

0.713

3.310

Asthma

0.290

0.215 0.178

1.337

0.877

2.038

Ulcers

0.051

0.415 0.903

1.052

0.467

2.370

0.216 0.843

1.044

0.683

1.595

Number of pharmacies visited (ref: multiple pharmacies)
0.377
0.340 0.267
• No pharmacy
-0.186
0.145 0.201
• Single pharmacy

1.458
0.830

0.749
0.624

2.838
1.104

Cardio-vascular

Provider interaction in the pre period
PAAS enrollment
0.043
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Table 6C: Multinomial Logistic regression for the impact of depression on pattern
of oral hypoglycemic use (Discontinuation vs. Non-modification) (Contd.)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
Complexity of regimen
Number of pills per day for
0.032
0.033 0.327
1.033 0.968 1.102
chronic medications
Number of prescriptions for
chronic medications

-0.060

0.016 0.000*

0.942

0.913

0.971

Number of pills per day for
oral hypoglycemics

0.103

0.126 0.414

1.109

0.866

1.421

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.312
0.694 0.653
1.366
• Endocrinologist
0.171
0.151 0.259
1.187
• Internal medicine

0.350
0.882

5.321
1.597

Total diabetes costs

0.000

0.000 0.639

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

-0.296

0.222 0.182

0.744

0.481

1.149

Gap between index diagnosis
and prescription

-0.001

0.000 0.027*

0.999

0.998

1.000

1.099
1.136
0.694
0.776

0.610
0.793
0.201
0.246

1.980
1.627
2.400
2.444

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.094
0.300 0.753
• Thiazolidenedione
0.127
0.183 0.487
• Biguanides
-0.366
0.633 0.564
• Alpha-glucosidase
-0.254
0.586 0.664
• Meglitinides
Constant

1.042

0.667 0.118

*significance at the 0.05 level
PAAS = Physician Assured Access System

Model fit statistics:
Pseudo R-square = 16.1%
-2 Log Likelihood = 2616.299; χ2 = 189.814; p= 0.00
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Discussion for Objective 3
Depression can play an important role in diabetes management as it can decrease
adherence with medications leading to inadequate glucose control and thus affect patterns
of use of oral hypoglycemics. Results from our study indicated the same with a
significantly higher fraction of depressed patients switching, augmenting, and
discontinuing therapy. There are no studies in literature to compare these results as no
other study has examined the impact of depression on patterns of oral hypoglycemic use.
However, there are a few studies, which examine the patterns of oral hypoglycemic use in
newly diagnosed type 2 diabetes patients.
A large administrative database study by Boccuzzi and associates16 using
pharmacy claims of millions of Americans, found that the rate of discontinuation for
newly diagnosed type 2 diabetes patients in the 12-month follow up period was 11.3%.
Nearly 15% augmented therapy while 10% switched from the index oral hypoglycemic
agent in the 12-month follow up period. A similar study conducted by Skaer and
associates14 estimated that 10-30% of patients with type 2 diabetes withdraw from their
prescribed regimen within 1 year of diagnosis. In a study conducted by Dailey and
associates90 in Medi-Cal patients who were newly diagnosed with type 2 diabetes,
patterns of oral hypoglycemic use indicated that nearly 16% of patients failed to refill
their index oral hypoglycemic prescription in the one-year follow up period. Donnan and
associates17 conducted a population-based study in Tayside, Scotland following up newly
diagnosed type 2 diabetes patients for varying time periods with a median follow up time
of 588 days. Results from the study indicated that nearly 70.00% of patients did not
modify their original oral hypoglycemic therapy, 5.40 % augmented therapy, and around
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18.00% switched therapy in the follow up time period. Surprisingly, only 0.50% of the
newly diagnosed type 2 diabetes patients discontinued pharmacotherapy.
The overall rates of switching (7.40%) and augmentation (11.40%) found in this
study are comparable to the findings in literature. The results showed lower rates of nonmodification with 46.00% of newly diagnosed patients maintaining therapy on the index
oral hypoglycemic agent, as compared to non-modification rates of 60-70% in the
literature. The largest discrepancy, however, was in terms of discontinuation rates. The
rates of 35.00% were much higher than most reported studies. The differences in these
patterns can be attributed to differences in algorithm used for classification of these
patterns and/or variations in length of follow-up periods. These differences can also be
attributable to a difference in the health care system, as some of the studies in literature
were based in Europe. Also, a number of these studies had the strict inclusion criteria of
at least two prescriptions for oral hypoglycemics in the follow up as opposed to our
criteria of a diagnosis of type 2 diabetes and at least one prescription for an oral
hypoglycemic agent. This difference in inclusion criteria can possibly be the most logical
reason for higher discontinuation rates in this study. However, similar studies conducted
to examine patterns of use for antihypertensive medications have detected high
discontinuation rates comparable to this study results with 40-50% of new users of
antihypertensive medications discontinuing use by 6 months.160
Patterns of use of oral hypoglycemics have been used in the literature to examine
management of patients with newly diagnosed type 2 diabetes. They can be highly
indicative of success of oral hypoglycemic therapy in controlling blood glucose levels in
these patients. Non-modification of the initially prescribed oral hypoglycemic therapy
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can be an indication of adequate blood glucose control. Modification of therapy in terms
of either switching or augmenting therapies is typically seen when the index oral
hypoglycemic therapy fails to maintain blood glucose levels. This inadequate control of
blood glucose can occur due to the natural course of the disease over time. However,
frequently it is a result of lack of adherence to either medications, diet or exercise
regimen. The act of switching/augmentation typically indicates secondary failure with
initial therapy. However, such a conclusion cannot be drawn for patients discontinuing
pharmacotherapy. The reasons for discontinuing therapy are not captured in a claims
database. The adverse effects of oral hypoglycemic agents can affect patient’s quality of
life, which in turn can result in discontinuation of treatment. Thus, these patients may be
discontinuing therapy in spite of inadequate blood glucose control, which may cause a
number of diabetic complications in the future. It is also possible that patients
discontinue pharmacotherapy as their blood glucose levels are controlled through other
methods such as diet and exercise. However, a review of 13,309 patients with type 2
diabetes from the UK Mediphys database, demonstrated that patients who discontinued
their oral hypoglycemics were approximately twice as likely to experience an emergency
medical event and had a mortality rate that was three times that of continuers.13 These
results indicate that a large fraction of type 2 diabetes patients who discontinue therapy
need to maintain pharmacotherapy for adequate management of their diabetes.
Although no studies are available in the literature to examine the impact of
depression on patterns of oral hypoglycemic use, studies have demonstrated an
association between depression and adherence to diabetes medications.28 Patterns such as
switching, augmentation, and especially discontinuation can be indicative of lack of
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adherence. Results of this study demonstrated that patterns of oral hypoglycemic use
were much more favorable in non-depressed patients as compared to depressed patients
after adjusting for the effect of confounders. This study demonstrates that even in a
population with complete insurance coverage, there may be issues of avoidance of
therapy partly due to presence of co-morbid depression.

Results for Objective 4
To examine the impact of pre-existing depression on secondary failure with oral
hypoglycemics
Augmenting or switching from the initial class of oral hypoglycemic agent can be
considered together as modification of therapy, indicative of secondary failure with initial
pharmacotherapy. Objective 4 was to estimate the impact of depression on the rate of
modification and the time to modification with index therapy in the 12-month follow up
period. Patients initiated on polytherapy or insulin therapy were excluded from the
analysis. Patients who discontinued therapy in the 12-month follow up period were also
excluded from the analysis.
Univariate results are presented in Table 7. The results indicated that a
significantly higher percent of depressed patients (38.47%) modified their index oral
hypoglycemic therapy as compared to non-depressed patients (24.08%). Higher rates of
modification were also accompanied with a relatively shorter time period to modification
for depressed patients (282.57 + 7.54) compared to non-depressed patients (307.63 +
4.99). A univariate Kaplan Meier analysis indicated that this time to modification was
significantly higher for depressed patients with a log rank test statistic of 16.65
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(p=0.000). These results can also be seen in terms of a better survival distribution for
non-depressed patients in the Kaplan Meier survival curves for time to modification of
pharmacotherapy (Figure 6). However, this effect could also be a result of confounders
such as demographics, co-morbidity, diabetes severity, complexity of regimen, and
interaction with health care providers. Hence, a multivariate logistic regression and Cox
proportional hazards model was performed to determine the impact of depression on rate
and time to modification of oral hypoglycemic use controlling for baseline confounding
factors. The logistic regression model was found to be significant with a Nagelkerke Rsquare value of 11.40%. The model results are summarized in Table 8. Results of the
multivariate model indicated that controlling for confounding covariates, patients with
depression were nearly 1.7 more likely to modify oral hypoglycemic therapy in the 12
month follow up period as compared to patients without depression (p= 0.003). An
initial multivariate Cox proportional hazards model to estimate the impact of depression
on time to modification of index oral hypoglycemic therapy failed to satisfy the
proportional hazard assumption. Hence, on the basis of the cumulative Kaplan Meier
survival functions that indicated 2 different hazards, an extended Cox-proportional
hazards model was estimated to examine the effect of depression on time to modification
in the first six months and the latter six month follow up period. The extended Cox
proportional hazards model was found to be significant and the model fit and results are
summarized in Table 9. The model indicated that the hazard to modify therapy was 2.4
times more for depressed patients as compared to non-depressed patients in the latter six
months of the follow-up period (p=0.001). No significant differences were observed
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between the patients for the first six months after the index oral hypoglycemic
prescription.
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Table 7: Modification of oral hypoglycemics in the 12-month follow up period
Depressed Non-depressed Total
(n= 270)
(n= 531)
(n= 801)
Non-modification
Modification
Time to modification
(in years)
(Mean + Standard Error)

61.53%
(166)

75.92%
(403)

71.02%
(569)

38.47%
(104)

24.08%
(128)

28.98%
(232)

282.57
(+ 7.54)

307.63
(+ 4.99)

*significance at the 0.05 level
χ2 = Chi-square test
LR = Log rank test
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299.18
(+ 4.19)

Test
statistic

Sig.
(p)

χ2 = 18.07

0.000*

LR=16.65 0.000*

Figure 6: Kaplan-Meier Survival Curves for time to modification of oral
hypoglycemic therapy
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Table 8: Logistic regression for the impact of depression on modification of oral
hypoglycemic agents
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.568
0.188 0.003*
1.764 1.220 2.551
Depression
Demographic characteristics
Age (in years)
-0.004

0.009 0.663

0.996

0.978

1.014

Males (ref: females)

0.071

0.180 0.694

1.073

0.754

1.528

Whites (ref: non-whites)

0.801

0.485 0.098

2.228

0.861

5.763

Urban (ref: rural)

0.321

0.332 0.333

1.379

0.719

2.643

Year of index prescription (ref: 2001)
-0.721
• 1998
-0.426
• 1999
0.007
• 2000

0.470 0.125
0.438 0.331
0.418 0.986

0.486
0.653
1.007

0.194
0.277
0.444

1.221
1.541
2.284

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.110

0.045 0.015*

1.116

1.022

1.219

Total health costs

0.000

0.000 0.028*

1.000

1.000

1.000

-0.174

0.119 0.145

0.840

0.665

1.062

0.174

0.095 0.068

1.190

0.987

1.434

-0.257

0.196 0.190

0.773

0.527

1.135

Cancer

0.295

0.512 0.564

1.344

0.493

3.665

Asthma

0.125

0.273 0.647

1.133

0.663

1.937

Ulcers

0.594

0.494 0.229

1.810

0.688

4.764

0.253 0.097

1.522

0.927

2.499

Number of pharmacies visited (ref: multiple pharmacies)
0.075
0.472 0.874
• No pharmacy
-0.060
0.175 0.732
• Single pharmacy

1.077
0.942

0.427
0.668

2.716
1.328

Charlson co-morbidity
Number of therapeutic classes
of medications
Cardio-vascular

Provider interaction in the pre period
PAAS enrollment
0.420
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Table 8: Logistic regression for the impact of depression on modification of oral
hypoglycemic agents (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

0.040 0.465

0.971

0.897

1.051

Number of prescriptions for -0.012
chronic medications

0.018 0.514

0.988

0.954

1.024

0.292

0.153 0.056

1.340

0.993

1.808

Complexity of regimen
Number of pills per day for -0.030
chronic medications

Number of pills per day for
oral hypoglycemics

95% C.I. for
Odds ratio
Lower Upper

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
1.533
0.647 0.018*
4.633
• Endocrinologist
0.212
0.183 0.245
1.237
• Internal medicine

1.303 16.473
0.865 1.769

Total diabetes costs

0.000

0.000 0.200

1.000

1.000

1.000

Number of diabetes related -0.030
ER/Hosp visits

0.232 0.896

0.970

0.615

1.530

Gap between index diagnosis -0.001
and prescription

0.001 0.187

0.999

0.998

1.000

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.181
0.344 0.598
• Thiazolidenedione
-0.234
0.227 0.302
• Biguanides
0.348
0.663 0.600
• Alpha-glucosidase
-0.261
0.664 0.694
• Meglitinides

1.199
0.791
1.416
0.770

0.611
0.507
0.386
0.210

2.351
1.234
5.191
2.829

Constant

-2.093

0.893 0.019

*significance at the 0.05 level
PAAS = Physician Assured Access System

Model fit statistics:
Pseudo R-square = 11.4%
-2 Log Likelihood = 871.997; χ2 = 64.944, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 8.157; p=0.418
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0.123

Table 9: Extended Cox proportional hazards model for the impact of depression on
time to modification of oral hypoglycemic agent
Beta
S.E. Sig.
Hazard
95% C.I. for
(p)
ratio
Hazard ratio
Lower Upper
0.168
0.181 0.353
1.183 0.829 1.688
Depression (0 –6 months)
0.855
0.246 0.001*
2.350 1.451 3.806
Depression (6 –12 months)
Demographic characteristics
Age (in years)
-0.004

0.008 0.623

0.996

0.982

1.011

Males (ref: females)

0.028

0.150 0.852

1.028

0.767

1.379

Whites (ref: non-whites)

0.749

0.434 0.084

2.115

0.904

4.948

Urban (ref: rural)

0.319

0.286 0.265

1.375

0.785

2.409

0.385 0.115
0.358 0.358
0.343 0.901

0.545
0.720
1.044

0.256
0.357
0.532

1.160
1.451
2.045

0.033 0.001*

1.114

1.044

1.189

0.000

0.000 0.018*

1.000

1.000

1.000

-0.200

0.102 0.048*

0.818

0.671

0.999

0.137

0.076 0.072

1.147

0.988

1.333

-0.172

0.158 0.276

0.842

0.617

1.148

Cancer

0.221

0.403 0.583

1.248

0.567

2.747

Asthma

0.191

0.224 0.396

1.210

0.779

1.879

Ulcers

0.623

0.373 0.095

1.865

0.897

3.878

0.199 0.147

1.335

0.904

1.970

Number of pharmacies visited (ref: multiple pharmacies)
0.022
0.392 0.955
• No pharmacy
-0.077
0.144 0.590
• Single pharmacy

1.022
0.926

0.474
0.698

2.205
1.227

Year of index prescription (ref: 2001)
-0.607
• 1998
-0.329
• 1999
0.043
• 2000
Co-morbid conditions in the pre period
Number of ER/hosp visits
0.108
Total health costs
Charlson co-morbidity
Number of therapeutic classes
of medications
Cardio-vascular

Provider interaction in the pre period
PAAS enrollment
0.289
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Table 9: Extended Cox proportional hazards model for the impact of depression on
time to modification of oral hypoglycemic agent (Contd.)
Beta
S.E. Sig.
Hazard
95% C.I. for
(p)
ratio
Hazard ratio
Lower Upper
Complexity of regimen
-0.020
0.033 0.543
0.980 0.918 1.046
Number of pills per day for
chronic medications
Number of prescriptions for
chronic medications

-0.009

0.015 0.541

0.991

0.962

1.020

Number of pills per day for
oral hypoglycemics

0.217

0.118 0.066

1.242

0.986

1.566

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
1.037
0.424 0.015*
2.821
• Endocrinologist
0.135
0.147 0.359
1.144
• Internal medicine

1.228
0.858

6.481
1.526

Total diabetes costs

0.000

0.000 0.101

1.000

1.000

1.000

-0.014

0.180 0.938

0.986

0.693

1.404

0.000

0.000 0.246

1.000

0.999

1.000

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.152
0.274 0.580
• Thiazolidenedione
-0.236
0.187
0.207
• Biguanides
0.198
0.485 0.682
• Alpha-glucosidase
-0.238
0.517 0.645
• Meglitinides

1.164
0.790
1.219
0.788

0.680
0.547
0.472
0.286

1.994
1.139
3.153
2.171

Number of diabetes related
ER/Hosp visits
Gap between index diagnosis
and prescription

* significance at the 0.05 level
PAAS = Physician Assured Access System

Model fit statistics:
-2 Log Likelihood = 2863.587; χ2 = 72.07, p= 0.001
Global test of proportional hazards : χ2 = 43.45, p= 0.467
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Discussion for objective 4

Modification to treatment regimens may be indicative of poor blood glucose
control, lack of tolerance of the drug, or the onset of concomitant conditions. Failure to
achieve glycemic control or the onset of co-morbid conditions may prompt physicians to
step up the treatment regimen by: (1) substituting a more potent medication or (2) adding
another oral hypoglycemic agent, or (3) initiating insulin therapy.
Depression can decrease adherence with medications leading to inadequate
glucose control and thus lead to modification of oral hypoglycemic therapy. The study
results indicated the same with a significantly higher percent of depressed patients
modifying their index oral hypoglycemic therapy as compared to non-depressed patients.
No studies examining the impact of depression on modification of therapy are available
in the literature. However, one can compare our overall rates of modification with
findings from other studies. Results from the study conducted by Donnan and
associates17 in Tayside Scotland, indicated that around 28.00% of newly diagnosed type 2
diabetes patients modified their index oral hypoglycemic therapy over the median follow
up time period of 588 days. A similar rate for modification of therapy (32.00%) was
observed over a 12-month follow up period in a study conducted in Medi-Cal.90 A more
recent study conducted by Bocuzzi and associates16 in a large administrative dataset used
a composite measure of change in therapy including switching or augmentation and
found that a striking 36.00% of the patients changed therapy over a 12-month follow up
period with a crude time to modification of therapy being around 170 days. Overall rates
from this study for modification of 29.00% were similar to findings from previous
studies. However, time to modification of therapy was longer (300 days) in this study as
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compared to the crude rates estimated from the study by Bocuzzi and associates16 (~ 170
days).
Multivariate results indicated that controlling for baseline characteristics, patients
with depression were nearly 1.8 times more likely to modify index therapy as compared
to non-depressed patients. Similarly, the hazard to modify therapy was 2.4 times more
for depressed patients as compared to non-depressed patients in the latter six-month
follow-up period.

Results for Objective 5
To estimate the impact of pre-existing depression on initiation of insulin therapy in
patients with type 2 diabetes

The univariate results are presented in Table 10. Results indicated that a
significantly higher percent of depressed patients (5.30%) initiated insulin therapy as
compared to non-depressed patients (2.90%). Higher rates of insulin initiation were also
accompanied with a relatively shorter time period to begin insulin therapy for depressed
patients (355.92 days) compared to non-depressed patients (358.71 days). A univariate
Kaplan Meier analysis indicated that this time to insulin initiation was significantly
higher for depressed patients with a log rank test statistic of 4.68 (p = 0.030). These
results can also be seen in terms of a better survival distribution for non-depressed
patients in the Kaplan Meier survival curves for time to initiation of insulin therapy
(Figure 7).
However, these differences between the two groups were not found to be
significant in the multivariate framework after adjusting for confounders such as
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demographics, co-morbidity, diabetes severity, complexity of regimen, and interaction
with health care providers. The logistic regression model to predict the impact of
depression on the likelihood of initiating insulin therapy was found to be significant with
a Nagelkerke R-square value of 14.40%. The model results are summarized in Table 11.
Results of the multivariate model indicated that controlling for confounding covariates,
there were no significant differences in the rate of initiation of insulin therapy in the 12month follow up period. The Cox proportional hazards model was found to be
significant and satisfied the assumptions of proportional hazards. The model fit and
results are summarized in Table 12. The model indicated that the time to initiate insulin
therapy was not significantly different between depressed and non-depressed patients
after adjusting for baseline covariates.
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Table 10: Initiation of insulin therapy in the 12-month follow up period
Depressed
(n= 471)

Initiation of insulin therapy
• Insulin use
•

No insulin use

5.30%
(25)
94.70%
(446)

Time to initiation of
355.92
insulin
(+ 2.09)
(in years)
(Mean + Standard Error)

Non-depressed Total
Test
(n= 855)
(n= 1326) statistic

2.90%
(25)

3.80%
(50)

97.10%
(830)

96.20%
(1276)

358.71
(+ 1.43)

357.71
(+ 1.17)

*significance at the 0.05 level
χ2 = Chi-square test
LR = Log Rank test
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χ2 = 4.76

Sig.
(p)

0.030*

LR = 4.68 0.032*

Figure 7: Kaplan-Meier Survival Curves for time to initiation of insulin therapy
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Table 11: Logistic regression for the impact of depression on initiation of insulin
therapy
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.521
0.341 0.126
1.684 0.864 3.283
Depression
Demographic characteristics
Age (in years)
-0.015

0.017 0.355

0.985

0.953

1.017

Males (ref: females)

-0.164

0.349 0.637

0.848

0.428

1.680

Whites (ref: non-whites)

1.029

1.040 0.323

2.798

0.364 21.505

Urban (ref: rural)

0.243

0.588 0.679

1.275

0.403

4.039

0.908 0.621
0.826 0.660
0.807 0.905

0.638
1.438
0.908

0.108
0.285
0.187

3.785
7.255
4.421

0.047 0.920

1.005

0.916

1.102

Year of index prescription (ref: 2001)
-0.449
• 1998
0.363
• 1999
-0.096
• 2000
Co-morbid conditions in the pre period
Number of ER/hosp visits
0.005
Total health costs

0.000

0.000 0.200

1.000

1.000

1.000

Charlson co-morbidity

0.292

0.158 0.064

1.340

0.984

1.825

Number of therapeutic classes
of medications

0.255

0.163 0.117

1.290

0.938

1.775

Cardio-vascular

-0.455

0.350 0.194

0.634

0.319

1.261

Cancer

-2.187

1.281 0.088

0.112

0.009

1.381

Asthma

-0.498

0.457 0.276

0.608

0.248

1.489

Ulcers

-1.009

1.098 0.358

0.365

0.042

3.137

0.448 0.705

1.185

0.492

2.852

1.677
0.468

0.474
0.236

5.930
0.929

Provider interaction in the pre period
PAAS enrollment
0.169

Number of pharmacies visited (ref: multiple pharmacies)
0.517
0.644 0.422
• No pharmacy
-0.759
0.350 0.030*
• Single pharmacy
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Table 11: Logistic regression for the impact of depression on initiation of insulin
therapy (Contd.)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
Complexity of regimen
-0.071
0.079 0.369
0.932 0.798 1.087
Number of pills per day for
chronic medications
Number of prescriptions for
chronic medications

-0.034

0.035 0.338

0.967

0.902

1.036

Number of pills per day for
oral hypoglycemics

0.379

0.232 0.102

1.461

0.927

2.301

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.568
1.094 0.604
1.765
• Endocrinologist
0.582
0.315 0.065
1.789
• Internal medicine

0.207 15.068
0.965 3.318

Total diabetes costs

0.000

0.000 0.777

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits
Gap between index diagnosis
and prescription

0.197

0.349 0.573

1.218

0.614

2.414

0.000

0.001 0.655

1.000

0.998

1.002

Initial polytherapy

0.917

0.499 0.066

2.502

0.941

6.653

1.635
0.351
0.467
0.000
0.483

0.604
0.147
0.051
0.000
0.049

4.424
0.837
4.301
.
4.755

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.491
0.508 0.333
• Thiazolidenedione
-1.046
0.443 0.018*
• Biguanides
-0.762
1.133 0.501
• Alpha-glucosidase
• Sufonylurea biguanide -19.08 6477.240 0.998
-0.728
1.167 0.533
• Meglitinides
Constant

-4.174

1.710 0.015

*significance at 0.05 level
PAAS = Physician Assured Access System

Model fit statistics:
Pseudo R-square = 14.4%
-2 Log Likelihood = 370.174; χ2 = 53.058, p= 0.015
Hosmer and Lemeshow’s goodness of fit: χ2 = 2.828; p=0.945
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0.015

Table 12: Cox proportional hazards model for the impact of depression on time to
initiation of insulin therapy
Beta
S.E. Sig.
Hazard
95% C.I. for
(p)
ratio
Hazard ratio
Lower Upper
0.494
0.328 0.132
1.639 0.861 3.118
Depression
Demographic characteristics
Age (in years)
-0.015

0.016 0.355

0.985

0.955

1.017

Males (ref: females)

-0.170

0.335 0.613

0.844

0.437

1.629

Whites (ref: non-whites)

0.993

1.024 0.332

2.698

0.363 20.079

Urban (ref: rural)

0.183

0.550 0.739

1.201

0.409

3.532

Year of index prescription (ref: 2001)
-0.607
• 1998
-0.329
• 1999
0.043
• 2000

0.385 0.115
0.358 0.358
0.343 0.901

0.545
0.720
1.044

0.256
0.357
0.532

1.160
1.451
2.045

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.000

0.042 0.997

1.000

0.921

1.086

Total health costs

0.000

0.000 0.241

1.000

1.000

1.000

Charlson co-morbidity

0.260

0.144 0.071

1.297

0.978

1.719

Number of therapeutic classes
of medications

0.238

0.155 0.124

1.269

0.937

1.719

Cardio-vascular

-0.414

0.334 0.215

0.661

0.343

1.272

Cancer

-1.997

1.229 0.104

0.136

0.012

1.510

Asthma

-0.435

0.431 0.314

0.647

0.278

1.508

Ulcers

-0.948

1.067 0.375

0.388

0.048

3.138

0.429 0.681

1.193

0.515

2.763

1.628
0.488

0.487
0.252

5.441
0.942

Provider interaction in the pre period
PAAS enrollment
0.176

Number of pharmacies visited (ref: multiple pharmacies)
0.487
0.616 0.428
• No pharmacy
-0.718
0.336 0.033*
• Single pharmacy
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Table 12: Cox proportional hazards model for the impact of depression on time
to initiation of insulin therapy (Contd.)
Beta
S.E. Sig.
Hazard
95% C.I. for
(p)
ratio
Hazard ratio
Lower Upper
Complexity of regimen
0.076 0.414
0.940 0.811 1.090
Number of pills per day for -0.062
chronic medications
Number of prescriptions for -0.032
chronic medications

0.034 0.347

0.968

0.906

1.035

0.393

0.218 0.071

1.481

0.966

2.270

Number of pills per day for
oral hypoglycemics

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.562
1.041 0.589
1.755
• Endocrinologist
0.559
0.301 0.063
1.749
• Internal medicine

0.228 13.491
0.969 3.156

Total diabetes costs

0.000

0.000 0.712

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.157

0.329 0.633

1.170

0.614

2.232

Gap between index diagnosis
and prescription

0.000

0.001 0.639

1.000

0.998

1.001

Initial polytherapy

0.856

0.465 0.066

2.354

0.946

5.854

1.471
0.353
0.493
0.451

0.577
0.150
0.059
0.049

3.750
0.828
4.142
4.132

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.386
0.477 0.419
• Thiazolidenedione
-1.042
0.436
0.017*
• Biguanides
-0.708
1.086 0.515
• Alpha-glucosidase
-0.797
1.130 0.481
• Meglitinides
*significance at the 0.05 level
PAAS = Physician Assured Access System

Model fit statistics:
-2 Log Likelihood = 662.481; χ2 = 54.049, p= 0.012
Global test of proportional hazard: χ2 = 31.86; p= 0.5237
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Discussion for Objective 5

Initiation of insulin therapy can be a proxy for failure to control blood glucose
with oral hypoglycemic therapy. Depression can decrease adherence with medications
leading to inadequate glucose control and cause a subsequent need for insulin therapy.
Although significant differences were observed at the univariate level, these differences
were not seen when the objective was examined in a multivariate framework. One reason
for this may be the length of the follow up period. Usually insulin therapy is initiated
when oral hypoglycemics and their combinations fail to control blood glucose and is not
seen in a large fraction of newly diagnosed type 2 diabetes within a year of therapy.
There are no studies in literature examining the role of depression in initiation of
insulin therapy in patients with type 2 diabetes. However, studies have examined the
issue of insulin initiation extensively. These studies have reported a high variation in
rates of progression to insulin therapy in newly diagnosed patients. This was primarily
due to studies having a small sample sizes and being conducted in specialized settings
such as diabetes clinics. In a study conducted by Spoelstar and associates161 in a Dutch
general health care system, the cumulative incidence of switching to insulin therapy was
36% over a 4.5-year period. Results from the United Kingdom Prospective Database
study report insulin initiation rate of 30% over a nine year follow up period.162 One of
the large population based studies examining this issue was conducted by Donnan and
associates163 using retrospective claims data in incident type 2 diabetes patients in
Tayside, Scotland. The newly diagnosed type 2 diabetes had varying times of follow up
with a median length for the total cohort being 588 days. Overall, 9.40% of subjects
switched to insulin with a median time of switching being approximately six months after
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initiation of oral hypoglycemic therapy. The annual rate of switching was computed to
be 5.84%. These rates in literature are comparable to annual insulin initiation rate of
3.80% found in this study.

Results for Objective 6
To estimate the impact of pre-existing depression on adherence to oral hypoglycemic
agents

Adherence to oral hypoglycemics was computed using refill information from claims
data. Patients initiating either mono-therapy or poly-therapy involving insulin were
excluded from the computation of adherence indices. All insulin prescriptions were
excluded from the calculation of adherence indices. This objective was examined using
different indices for adherence such as the Reg MPR-1 and Reg MPR-2. Univariate ttests were conducted to examine the differences in adherence indices.
Univariate results are presented in Table 13. Results indicated that patients with
depression had significantly lower adherence to oral hypoglycemics than non-depressed
patients on the basis of both Reg MPR-1 and Reg MPR-2. However, although the
differences were significant the magnitude of difference was not large with patients with
depression being only 3% and 6% less adherent to oral hypoglycemics than nondepressed patients on the Reg MPR-1 and Reg MPR-2 index respectively. A multivariate
Ordinary Least Squares (OLS) regression was performed to determine the impact of
depression on adherence (Reg MPR-1 and Reg MPR-2) to oral hypoglycemic use
controlling for baseline confounding factors. Results of the multivariate OLS models are
presented in Tables 14 and 15. The multivariate results were exactly similar to the
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univariate analysis wherein the depressed patients were found to be significantly less
adherent than non-depressed patients. The magnitude of difference in adherence after
adjusting for baseline covariates was similar to unadjusted differences with depressed
patients being approximately 3% and 7% less adherent than non-depressed patients as
measured by Reg MPR-1 and Reg MPR-2.
However, this multivariate OLS model was estimated on the assumption that
depression has a linear effect on adherence. Also, in objective 9, which estimates the
impact of adherence on health care expenditures, a continuous adherence score could not
be used as the independent variable as literature indicates a possible non-linear
relationship between adherence to medications and health care expenditures. Hence, we
categorized Reg MPR-1 and Reg MPR-2 to examine the impact of depression on
categories of adherence levels. Categories of adherence were computed on the basis of
recommendations from clinical experts and on the basis of distribution of adherence rates
in the study data.
Adherence measured by both Reg MPR-1 and Reg MPR-2 was divided into the
following categories:
•

Very low adherence: (Reg MPR-1 and Reg MPR-2 greater than or equal to 0 and

less than or equal to 0.55)
•

Low adherence: (Reg MPR-1 and Reg MPR-2 greater than 0.55 and less than or

equal to 0.7)
•

Average adherence: (Reg MPR-1 and Reg MPR-2 greater than 0.70 and less

than or equal to 0.85)
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•

Good adherence: (Reg MPR-1 and Reg MPR-2 greater than 0.85 and less than or

equal to 1.0)
•

Over adherence: (Reg MPR-1 and Reg MPR-2 greater than 1.0).

Univariate distributions of depressed and non-depressed patients on the basis of these
categories are presented in Table 13.
As multiple categories of adherence were created, multivariate multinomial
logistic regression analysis was used to estimate the impact of preexisting depression on
these categories of adherence controlling for other confounding factors. Good adherence
was used as the reference category for all comparisons in the multinomial logistic model
framework. Separate multinomial logistic regression models were estimated for the
impact of depression on Reg MPR-1 and Reg MPR-2. The multinomial logistic
regression model for the impact of depression on Reg MPR-1 and Reg MPR-2 were
found to be significant with a Nagelkerke R-square value of 26.10% and 20.00%,
respectively. The model results are summarized in Tables 16A-16D and Table 17A-17D.
Results of the multivariate model for Reg MPR-1 indicated that controlling for
confounding covariates, patients with depression were 1.9 times more likely to have low
adherence to oral hypoglycemics as compared non-depressed patients in the 12 month
follow up period (p= 0.031). Results from the model for Reg MPR-2 demonstrated that
depressed patients were 1.6 times more likely to be in the very low adherence group as
compared to non-depressed patients (p=0.004). No other comparisons in the multinomial
logistic regression models were found to be significant.
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Table 13: Adherence indices in the 12-month follow up period
Reg MPR-1: Based on adherence between index prescription and the last oral
hypoglycemic prescription fill
Depressed
Non-depressed
Total
Test
Sig.
(n = 295)
(n=595)
(n=890)
Statistic
(p)
Mean Reg MPR-1
(Mean + S.D.)

0.86 + 0.14

0.89 + 0.13

0.88 + 0.13 t = -3.38

0.001*

Categories of Reg MPR-1
Very low adherence

3.05%(9)

1.85%(11)

2.25%(20)

Low adherence

11.53%(34)

7.39%(44)

8.76%(78)

Average adherence

26.10%(77)

22.18%(132)

23.48%(209)

Good adherence

55.59%(164)

64.37%(383)

61.46%(547)

Over adherence

3.73%(11)

4.20%(25)

4.04%(36)

χ2 = 8.98

0.060

Reg MPR-2: Based on adherence between index prescription and the end of the follow
up period
Depressed
Non-depressed
Total
Test
Sig.
(n = 471)
(n=855)
(n=1326) Statistic
(p)
Mean Reg MPR-2
(Mean + S.D.)

0.66 + 0.31

0.73 + 0.32

0.73 + 0.34

t = -3.82

0.000*

Categories of Reg MPR-2
Very low adherence

35.46%(167)

27.02%(231)

30.02%(398)

Low adherence

12.31%(58)

9.82%(84)

10.71%(142)

Average adherence

14.43%(68)

14.15%(121)

14.25%(189)

Good adherence

32.70%(154)

39.30%(336)

24.51%(325)

Over adherence

5.10%(24)

9.71%(83)

8.07%(107)

* significance at the 0.05 level
t = t -test
χ2 = Chi-square test
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χ2 = 20.57 0.060

Table 14: Ordinary Least Squares (OLS) regression model for the impact of
depression on adherence (Reg MPR-1) to oral hypoglycemics
Beta
S.E.
Test
Sig.
statistic (t) (p)
-0.028

0.010

-2.880 0.004*

0.001

0.000

2.012 0.045*

-0.013

0.009

Whites (ref: non-whites)

0.061

0.020

3.061 0.002*

Urban (ref: rural)

0.004

0.016

0.260 0.795

0.013
-0.003
0.014

0.023
0.022
0.020

0.559 0.577
-0.152 0.879
0.698 0.485

Co-morbid conditions in the pre period
Number of ER/hosp visits
-0.003

0.002

-1.234 0.217

Total health costs

0.000

0.000

2.437 0.015*

Charlson co-morbidity

0.006

0.006

1.167 0.244

Number of therapeutic classes
of medications

-0.027

0.005

-5.627 0.000*

Cardio-vascular

-0.004

0.010

-0.434 0.665

Cancer

-0.009

0.026

-0.351 0.726

Asthma

-0.019

0.014

-1.380 0.168

Ulcers

0.000

0.028

-0.002 0.998

Depression
Demographic characteristics
Age (in years)
Males (ref: females)

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

Provider interaction in the pre period
PAAS enrollment
0.017
0.014
Number of pharmacies visited (ref: multiple pharmacies)
-0.021
0.024
• No pharmacy
0.004
0.009
• Single pharmacy
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-1.381 0.168

1.226 0.221
-0.892 0.373
0.496 0.620

Table 14: Ordinary Least Squares (OLS) regression model for the impact of
depression on adherence (Reg MPR-1) to oral hypoglycemics (Contd.)
Beta
S.E.
Test
Sig.
statistic (t) (p)
Complexity of regimen
0.000
0.002
-0.161 0.872
Number of pills per day for
chronic medications
Number of prescriptions for
chronic medications

0.005

0.001

5.881 0.000*

Number of pills per day for
oral hypoglycemics

-0.018

0.008

-2.188 0.029*

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.011
0.033
• Endocrinologist
0.004
0.010
• Internal medicine

0.328 0.743
0.402 0.688

Total diabetes costs

1.971 0.049*

Number of diabetes related
ER/Hosp visits
Gap between index diagnosis
and prescription
Initial polytherapy

0.000

0.000

-0.015

0.013

-1.156 0.248

0.000

0.000

0.387 0.699

-0.050

0.017

-2.978 0.003*

0.018
0.012
0.036
0.030

-0.389
-0.417
0.226
2.422

0.042

19.225 0.000

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.007
• Thiazolidenedione
-0.005
• Biguanides
0.008
• Alpha-glucosidase
0.073
• Meglitinides
Constant

0.814

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 13.8%; F = 4.026; P = 0.000
Durbin-Watson: 1.980
White test for heteroskedasticity: Chi-square = 480.33 p=0.7073
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0.697
0.677
0.821
0.016*

Table 15: Ordinary Least Squares (OLS) regression model for the impact of
depression on adherence (Reg MPR-2) to oral hypoglycemics
Beta
S.E. Test statistic Sig.
(t)
(p)
-0.057

0.019

-2.916 0.004*

Demographic characteristics
Age (in years)

0.002

0.001

2.115 0.035*

Males (ref: females)

0.004

0.020

0.209 0.834

Whites (ref: non-whites)

0.062

0.041

1.512 0.131

Urban (ref: rural)

0.018

0.034

0.527 0.598

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

0.064
0.102
0.059

0.050
0.047
0.044

1.276 0.202
2.170 0.030*
1.320 0.187

Co-morbid conditions in the pre period
Number of ER/hosp visits
-0.018

0.004

-4.727 0.000*

Total health costs

0.000

0.000

2.467 0.014*

Charlson co-morbidity

-0.008

0.011

-0.755 0.450

Number of therapeutic classes
of medications
Cardio-vascular

-0.018

0.010

-1.700 0.089

0.030

0.021

1.406 0.160

Cancer

-0.075

0.052

-1.433 0.152

Asthma

-0.053

0.029

-1.843 0.066

Ulcers

-0.060

0.056

-1.072 0.284

0.018

0.029

0.631 0.528

Number of pharmacies visited (ref: multiple pharmacies)
-0.057
0.048
• No pharmacy
0.025
0.019
• Single pharmacy

-1.195 0.232
1.276 0.202

Depression

Provider interaction in the pre period
PAAS enrollment
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Table 15: Ordinary Least Squares (OLS) regression model for the impact of
depression on adherence (Reg MPR-2) to oral hypoglycemics (Contd.)
Beta
S.E. Test statistic Sig.
(t)
(p)
Complexity of regimen
-0.003
0.004
-0.782 0.434
Number of pills per day for
chronic medications
Number of prescriptions for
chronic medications
Number of pills per day for
oral hypoglycemics

0.009

0.002

-0.004

0.017

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.089
0.075
• Endocrinologist
-0.009
0.020
• Internal medicine

4.724 0.000*
-0.227 0.820

1.185 0.236
-0.423 0.673

Total diabetes costs

0.000

0.000

1.854 0.064

Number of diabetes related
ER/Hosp visits

0.013

0.027

0.487 0.626

Gap between index diagnosis
and prescription

0.000

0.000

1.509 0.131

Initial polytherapy

0.007

0.041

0.167 0.867

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.004
• Thiazolidenedione
-0.057
• Biguanides
0.091
• Alpha-glucosidase
-0.017
• Meglitinides
Constant

0.473

0.040
0.025
0.078
0.079
0.089

* significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 11.4%; F = 4.906; P = 0.000
Durbin-Watson: 1.934
White test for heteroskedasticity: Chi-square=540.83; p= 0.2963
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0.101
-2.287
1.162
-0.213

0.919
0.022*
0.245
0.832

5.306 0.000

Table 16A: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-1) to oral hypoglycemics
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Very low adherence vs. Good adherence
0.648
0.626 0.301
1.911 0.560
6.521
Depression
Demographic characteristics
Age (in years)

-0.035

0.029 0.216

0.965

0.913

1.021

0.281

0.594 0.636

1.324

0.414

4.240

Whites (ref: non-whites)

-0.836

1.142 0.464

0.433

0.046

4.063

Urban (ref: rural)

-0.388

0.925 0.675

0.678

0.111

4.159

1.378 0.025*
1.364 0.009*
1.366 0.007*

0.046
0.029
0.025

0.003
0.002
0.002

0.680
0.419
0.365

0.127 0.047*

1.287

1.003

1.652

0.000

0.000 0.411

1.000

1.000

1.000

Charlson co-morbidity

-0.319

0.555 0.566

0.727

0.245

2.156

Number of therapeutic
classes of medications

1.086

0.323 0.001*

2.961

1.571

5.583

-0.499

0.629 0.428

0.607

0.177

2.082

Cancer

0.922

1.527 0.546

2.514

0.126

50.158

Asthma

0.798

0.981 0.416

2.222

0.325

15.197

0.000 .

0.000

0.000

0.000

Provider interaction in the pre period
PAAS enrollment
-19.477 9459.151 0.998

0.000

0.000

.

Number of pharmacies visited (ref: multiple pharmacies)
1.129
1.357 0.405
• No pharmacy
0.803
0.627 0.200
• Single pharmacy

3.093
2.232

0.216
0.653

44.207
7.625

Males (ref: females)

Year of index prescription (ref: 2001)
-3.088
• 1998
-3.542
• 1999
-3.686
• 2000
Co-morbid conditions in the pre period
Number of ER/hosp visits
0.253
Total health costs

Cardio-vascular

Ulcers

-18.067
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Table 16A: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-1) to oral hypoglycemics (Contd.)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Complexity of regimen
0.045
0.147 0.758
1.046 0.784
1.396
Number of pills per day for
chronic medications
-0.265

0.076 0.001*

0.767

0.660

0.891

0.684

0.381 0.073

1.983

0.939

4.187

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
-17.438
0.000 .
0.000
• Endocrinologist
0.050
0.632 0.937
1.051
• Internal medicine

0.000
0.304

0.000
3.628

Total diabetes costs

Number of prescriptions for
chronic medications
Number of pills per day for
oral hypoglycemics

0.000

0.000 0.879

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

-0.986

1.455 0.498

0.373

0.022

6.468

Gap between index diagnosis
and prescription

-0.003

0.002 0.201

0.997

0.993

1.001

1.455

0.777 0.061

4.284

0.934

19.642

Initial polytherapy

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.387
1.251
• Thiazolidenedione
0.010
0.684
• Biguanides
-18.235
0.000
• Alpha-glucosidase
-20.527
0.000
• Sulfonyl-biguanides
2.739
1.593
• Meglitinides
Constant

0.631

0.757
0.988
.
.
0.086

2.535 0.804
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0.679
1.010
0.000
0.000
15.464

0.059
7.877
0.264
3.863
0.000
0.000
0.000
0.000
0.681 351.022

Table 16B: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-1) to oral hypoglycemics
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Low adherence vs. Good adherence
0.649
0.301 0.031*
1.913 1.061
3.448
Depression
Demographic characteristics
Age (in years)
-0.013

0.015 0.388

0.987

0.958

1.017

Males (ref: females)

0.408

0.293 0.163

1.504

0.848

2.669

-1.243

0.522 0.017*

0.288

0.104

0.803

0.309

0.530 0.560

1.362

0.482

3.850

Year of index prescription (ref: 2001)
-0.076
• 1998
0.191
• 1999
0.145
• 2000

0.753 0.919
0.703 0.786
0.661 0.826

0.927
1.211
1.157

0.212
0.305
0.316

4.050
4.807
4.229

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.050

0.070 0.475

1.052

0.916

1.207

Total health costs

0.000

0.000 0.325

1.000

1.000

1.000

Charlson co-morbidity

-0.488

0.265 0.066

0.614

0.365

1.033

Number of therapeutic
classes of medications
Cardio-vascular

0.651

0.149 0.000*

1.917

1.433

2.565

0.202

0.317 0.523

1.224

0.658

2.278

Cancer

0.334

0.927 0.718

1.397

0.227

8.591

Asthma

1.206

0.424 0.004*

3.341

1.454

7.676

Ulcers

0.088

0.930 0.924

1.092

0.177

6.757

0.457 0.458

0.712

0.291

1.744

Number of pharmacies visited (ref: multiple pharmacies)
0.105
0.832 0.900
• No pharmacy
0.062
0.282 0.827
• Single pharmacy

1.110
1.064

0.217
0.612

5.671
1.848

Whites (ref: non-whites)
Urban (ref: rural)

Provider interaction in the pre period
PAAS enrollment
-0.340
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Table 16B: Multinomial Logistic regression for the impact of depression on adherence
(Reg MPR-1) to oral hypoglycemics (Contd.)
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Complexity of regimen
0.070 0.575
0.962 0.839
1.102
Number of pills per day for -0.039
chronic medications
-0.110

0.031 0.000*

0.896

0.843

0.952

0.568

0.220 0.010*

1.765

1.146

2.717

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
1.060
0.926 0.252
2.886
• Endocrinologist
0.068
0.300 0.821
1.070
• Internal medicine

0.470
0.594

17.720
1.926

Total diabetes costs

0.000

0.000 0.356

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.383

0.431 0.374

1.467

0.630

3.418

Gap between index diagnosis
and prescription

0.000

0.001 0.795

1.000

0.999

1.002

Initial polytherapy

1.393

0.418 0.001*

4.028

1.775

9.141

1.532
1.151
0.448
0.237
4.801

0.555
0.573
0.036
0.046
0.543

4.232
2.315
5.555
1.219
42.439

Number of prescriptions for
chronic medications
Number of pills per day for
oral hypoglycemics

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.427
0.518 0.410
• Thiazolidenedione
0.141
0.356 0.692
• Biguanides
-0.802
1.284 0.532
• Alpha-glucosidase
-1.440
0.836 0.085
• Sulfonyl-biguanides
1.569
1.112 0.158
• Meglitinides
Constant

-2.570

1.321 0.052
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Table 16C: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-1) to oral hypoglycemics
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Average adherence vs. Good adherence
0.338
0.201 0.092
1.403 0.946
2.079
Depression
Demographic characteristics
Age (in years)
-0.018

0.010 0.056

0.982

0.964

1.000

Males (ref: females)

0.242

0.187 0.196

1.273

0.883

1.837

-0.803

0.390 0.039*

0.448

0.209

0.962

0.188

0.343 0.582

1.207

0.617

2.364

Year of index prescription (ref: 2001)
-0.084
• 1998
0.321
• 1999
-0.001
• 2000

0.517 0.870
0.487 0.509
0.464 0.997

0.919
1.379
0.999

0.334
0.531
0.402

2.532
3.584
2.478

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.069

0.054 0.204

1.071

0.963

1.192

Total health costs

0.000

0.000 0.016*

1.000

1.000

1.000

Charlson co-morbidity

-0.063

0.125 0.613

0.939

0.735

1.199

Number of therapeutic
classes of medications
Cardio-vascular

0.300

0.103 0.004*

1.350

1.103

1.653

-0.181

0.203 0.374

0.835

0.560

1.243

Cancer

0.388

0.557 0.487

1.474

0.494

4.394

Asthma

0.212

0.291 0.467

1.236

0.698

2.188

Ulcers

-0.104

0.572 0.856

0.901

0.294

2.764

0.266 0.896

1.035

0.615

1.742

Number of pharmacies visited (ref: multiple pharmacies)
0.196
0.441 0.658
• No pharmacy
-0.145
0.184
0.433
• Single pharmacy

1.216
0.865

0.512
0.603

2.888
1.242

Whites (ref: non-whites)
Urban (ref: rural)

Provider interaction in the pre period
PAAS enrollment
0.035
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Table 16C: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-1) to oral hypoglycemics (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

0.046

0.042 0.270

1.047

0.965

1.136

Number of prescriptions for
chronic medications

-0.074

0.021 0.000*

0.929

0.892

0.967

Number of pills per day for
oral hypoglycemics

-0.021

0.173 0.902

0.979

0.697

1.374

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.703
0.719 0.328
2.020
• Endocrinologist
0.065
0.198 0.741
1.068
• Internal medicine

0.494
0.724

8.260
1.574

Total diabetes costs

0.000

0.000 0.202

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.478

0.287 0.096

1.613

0.919

2.832

Gap between index diagnosis
and prescription

0.000

0.001 0.772

1.000

0.999

1.001

Initial polytherapy

0.171

0.390 0.662

1.186

0.552

2.548

0.484
0.950
2.120
0.491
9.797

0.200
0.586
0.558
0.123
1.871

1.170
1.541
8.054
1.963
51.297

Complexity of regimen
Number of pills per day for
chronic medications

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.726
0.451 0.107
• Thiazolidenedione
-0.051
0.247 0.835
• Biguanides
0.751
0.681 0.270
• Alpha-glucosidase
-0.712
0.707 0.314
• Sulfonyl-biguanides
2.282
0.845 0.007*
• Meglitinides
Constant

0.441

0.897 0.623
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95% C.I. for
Odds ratio
Lower
Upper

Table 16D: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-1 ) to oral hypoglycemics
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Over adherence vs. Good adherence
0.304
0.422 0.472
1.355 0.593
3.097
Depression
Demographic characteristics
Age (in years)
Males (ref: females)
Whites (ref: non-whites)
Urban (ref: rural)

-0.012

0.020 0.559

0.988

0.950

1.028

0.556

0.384 0.148

1.744

0.821

3.704

15.777

0.000 .

1.293

1.051 0.218

3.644

0.465

28.588

Year of index prescription (ref: 2001)
-0.250
• 1998
0.005
• 1999
-0.102
• 2000

1.018 0.806
0.954 0.996
0.893 0.909

0.779
1.005
0.903

0.106
0.155
0.157

5.730
6.524
5.198

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.040

0.118 0.736

1.041

0.825

1.312

Total health costs

0.000

0.000 0.648

1.000

1.000

1.000

Charlson co-morbidity

-0.210

0.313 0.502

0.811

0.439

1.497

Number of therapeutic
classes of medications
Cardio-vascular

0.080

0.212 0.705

1.083

0.716

1.640

-0.212

0.436 0.627

0.809

0.344

1.902

Cancer

-0.421

1.308 0.748

0.656

0.051

8.527

Asthma

0.190

0.616 0.758

1.209

0.362

4.043

0.000 .

0.000

0.000

0.000

0.582 0.894

1.081

0.346

3.380

Number of pharmacies visited (ref: multiple pharmacies)
-0.323
1.151 0.779
• No pharmacy
0.328
0.399 0.412
• Single pharmacy

0.724
1.388

0.076
0.634

6.906
3.035

Ulcers

-18.605

Provider interaction in the pre period
PAAS enrollment
0.078
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Table 16D: Multinomial Logistic regression for the impact of depression on adherence
(Reg MPR-1) to oral hypoglycemics (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

-0.120

0.106 0.257

0.887

0.721

1.091

Number of prescriptions for
chronic medications

0.013

0.040 0.749

1.013

0.937

1.095

Number of pills per day for
oral hypoglycemics

0.208

0.322 0.518

1.232

0.655

2.316

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
2.342
0.895 0.009*
10.407
• Endocrinologist
0.836
0.400 0.036*
2.307
• Internal medicine

1.800
1.054

60.166
5.049

Total diabetes costs

Complexity of regimen
Number of pills per day for
chronic medications

95% C.I. for
Odds ratio
Lower
Upper

0.000

0.000 0.243

1.000

1.000

1.000

-0.400

0.625 0.522

0.670

0.197

2.281

Gap between index diagnosis
and prescription

0.000

0.001 0.769

1.000

0.997

1.002

Initial polytherapy

1.558

0.512 0.002*

4.752

1.742

12.957

0.364
0.623
1.917
0.158
0.000

0.045
0.233
0.156
0.015
0.000

2.926
1.663
23.543
1.711
0.000

Number of diabetes related
ER/Hosp visits

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-1.011
1.064
• Thiazolidenedione
-0.474
0.501
• Biguanides
0.651
1.280
• Alpha-glucosidase
-1.847
1.216
• Sulfonyl-biguanides
-20.581
0.000
• Meglitinides
Constant

-19.894

0.342
0.345
0.611
0.129
.

1.814 0.000

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
Pseudo R-square = 26.1%
-2 Log Likelihood = 1609.302; χ2 = 226.003; p= 0.00
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Table 17A: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-2) to oral hypoglycemics
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Very low adherence vs. Good adherence
0.484
0.167 0.004*
1.623 1.169
2.252
Depression
Demographic characteristics
Age (in years)
-0.011

0.008 0.150

0.989

0.974

1.004

Males (ref: females)

0.156

0.162 0.333

1.169

0.852

1.605

Whites (ref: non-whites)

-0.413

0.357 0.248

0.662

0.328

1.333

Urban (ref: rural)

-0.018

0.268 0.948

0.983

0.581

1.663

Year of index prescription (ref: 2001)
-0.662
• 1998
-0.889
• 1999
-0.489
• 2000

0.404 0.101
0.383 0.020*
0.361 0.175

0.516
0.411
0.613

0.234
0.194
0.303

1.139
0.871
1.244

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.188

0.041 0.000*

1.207

1.113

1.309

Total health costs

0.000

0.000 0.022*

1.000

1.000

1.000

Charlson co-morbidity

0.119

0.092 0.198

1.126

0.940

1.350

Number of therapeutic
classes of medications
Cardio-vascular

0.156

0.086 0.069

1.169

0.988

1.384

-0.359

0.168 0.033*

0.698

0.502

0.971

Cancer

0.543

0.434 0.211

1.721

0.736

4.026

Asthma

0.417

0.229 0.069

1.518

0.968

2.380

Ulcers

0.336

0.465 0.470

1.399

0.563

3.478

0.232 0.954

0.987

0.626

1.555

Number of pharmacies visited (ref: multiple pharmacies)
0.551
0.370 0.137
• No pharmacy
-0.176
0.156
0.260
• Single pharmacy

1.735
0.839

0.839
0.618

3.584
1.139

Provider interaction in the pre period
PAAS enrollment
-0.013
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Table 17A: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-2) to oral hypoglycemics (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

0.062

0.037 0.095

1.064

0.989

1.144

Number of prescriptions for
chronic medications

-0.087

0.017 0.000*

0.916

0.886

0.948

Number of pills per day for
oral hypoglycemics

-0.006

0.132 0.964

0.994

0.767

1.289

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.266
0.630 0.673
1.304
• Endocrinologist
0.082
0.165 0.619
1.085
• Internal medicine

0.380
0.786

4.481
1.499

Total diabetes costs

Complexity of regimen
Number of pills per day for
chronic medications

95% C.I. for
Odds ratio
Lower
Upper

0.000

0.000 0.221

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

-0.254

0.241 0.293

0.776

0.484

1.245

Gap between index diagnosis
and prescription

-0.001

0.000 0.092

0.999

0.998

1.000

Initial polytherapy

-0.023

0.344 0.947

0.978

0.498

1.918

1.235
1.566
2.174
0.923
2.175

0.654
1.062
0.489
0.300
0.565

2.333
2.309
9.663
2.832
8.370

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.211
0.324 0.515
• Thiazolidenedione
0.449
0.198 0.023*
• Biguanides
0.776
0.761 0.308
• Alpha-glucosidase
-0.081
0.572 0.888
• Sulfonyl-biguanides
0.777
0.688 0.258
• Meglitinides
1.321
0.728 0.070
Constant
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Table 17B: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-2) to oral hypoglycemics
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Low adherence vs. Good adherence
0.389
0.227 0.086
1.475 0.946
2.300
Depression
Demographic characteristics
Age (in years)

0.001

0.011 0.905

1.001

0.980

1.023

Males (ref: females)

0.010

0.222 0.963

1.010

0.654

1.560

-0.998

0.396 0.012*

0.369

0.170

0.801

0.354

0.409 0.387

1.425

0.639

3.177

Year of index prescription (ref: 2001)
-0.117
• 1998
-0.335
• 1999
-0.235
• 2000

0.557 0.834
0.530 0.527
0.503 0.641

0.890
0.715
0.791

0.299
0.253
0.295

2.650
2.022
2.119

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.083

0.055 0.133

1.086

0.975

1.210

Total health costs

0.000

0.000 0.973

1.000

1.000

1.000

Charlson co-morbidity

-0.002

0.131 0.988

0.998

0.773

1.289

Number of therapeutic
classes of medications
Cardio-vascular

0.262

0.110 0.017*

1.299

1.048

1.611

0.067

0.234 0.773

1.070

0.677

1.691

Cancer

0.293

0.600 0.625

1.341

0.413

4.349

Asthma

0.243

0.310 0.433

1.275

0.695

2.339

Ulcers

0.271

0.626 0.665

1.311

0.385

4.470

Provider interaction in the pre period
PAAS enrollment
-0.366

0.349 0.294

0.693

0.350

1.374

Number of pharmacies visited (ref: multiple pharmacies)
0.368
0.545 0.499
• No pharmacy
-0.019
0.211
0.929
• Single pharmacy

1.445
0.981

0.497
0.649

4.205
1.484

Whites (ref: non-whites)
Urban (ref: rural)
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Table 17B: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-2) to oral hypoglycemics (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

0.025

0.048 0.608

1.025

0.933

1.126

-0.068

0.022 0.002*

0.934

0.895

0.975

0.117

0.171 0.493

1.124

0.804

1.572

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
-19.987
0.000 .
0.000
• Endocrinologist
0.292
0.215 0.174
1.339
• Internal medicine

0.000
0.879

0.000
2.039

Total diabetes costs

0.000

0.000 0.123

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.152

0.321 0.636

1.164

0.621

2.182

-0.001

0.001 0.256

0.999

0.998

1.001

0.617

0.395 0.118

1.854

0.856

4.018

1.430
1.590
1.509
0.698
2.841

0.614
0.946
0.223
0.171
0.600

3.328
2.675
10.237
2.853
13.452

Complexity of regimen
Number of pills per day for
chronic medications
Number of prescriptions for
chronic medications
Number of pills per day for
oral hypoglycemics

Gap between index diagnosis
and prescription
Initial polytherapy

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.358
0.431
• Thiazolidenedione
0.464
0.265
• Biguanides
0.412
0.977
• Alpha-glucosidase
-0.359
0.718
• Sulfonyl-biguanides
1.044
0.793
• Meglitinides
Constant

-1.167

0.407
0.080
0.673
0.617
0.188

0.977 0.232
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95% C.I. for
Odds ratio
Lower
Upper

Table 17C: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-2) to oral hypoglycemics
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Average adherence vs. Good adherence
0.308
0.205 0.133
1.360 0.911
2.033
Depression
Demographic characteristics
Age (in years)
-0.005

0.009 0.583

0.995

0.976

1.013

Males (ref: females)

0.249

0.194 0.199

1.283

0.877

1.878

-0.659

0.393 0.093

0.517

0.239

1.117

0.325

0.360 0.366

1.385

0.684

2.804

Year of index prescription (ref: 2001)
-0.219
• 1998
-0.243
• 1999
-0.204
• 2000

0.523 0.675
0.494 0.623
0.472 0.666

0.803
0.784
0.816

0.288
0.298
0.324

2.238
2.065
2.055

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.091

0.055 0.100

1.095

0.983

1.220

Total health costs

0.000

0.000 0.004*

1.000

1.000

1.000

Charlson co-morbidity

0.148

0.115 0.199

1.159

0.925

1.452

Number of therapeutic
classes of medications
Cardio-vascular

0.042

0.103 0.686

1.043

0.852

1.276

-0.260

0.204 0.201

0.771

0.517

1.149

Cancer

0.004

0.557 0.994

1.004

0.337

2.990

Asthma

-0.040

0.296 0.892

0.961

0.537

1.717

Ulcers

-0.285

0.645 0.658

0.752

0.213

2.659

0.259 0.054*

1.645

0.991

2.730

0.951
0.711

0.365
0.491

2.480
1.030

Whites (ref: non-whites)
Urban (ref: rural)

Provider interaction in the pre period
PAAS enrollment
0.498

Number of pharmacies visited (ref: multiple pharmacies)
-0.050
0.489 0.919
• No pharmacy
-0.341
0.189 0.072
• Single pharmacy
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Table 17C: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-2) to oral hypoglycemics (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

0.074

0.042 0.082

1.076

0.991

1.169

Number of prescriptions for
chronic medications

-0.032

0.020 0.107

0.969

0.933

1.007

Number of pills per day for
oral hypoglycemics

-0.152

0.169 0.367

0.859

0.616

1.196

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.636
0.690 0.356
1.889
• Endocrinologist
0.015
0.204 0.940
1.016
• Internal medicine

0.489
0.681

7.306
1.515

Total diabetes costs

0.000

0.000 0.860

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.137

0.274 0.618

1.146

0.670

1.961

Gap between index diagnosis
and prescription

-0.001

0.001 0.086

0.999

0.998

1.000

0.119

0.416 0.775

1.126

0.498

2.543

1.397
1.666
5.338
1.199
3.469

0.642
1.030
1.136
0.308
0.757

3.037
2.695
25.077
4.669
15.901

Complexity of regimen
Number of pills per day for
chronic medications

Initial polytherapy

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.334
0.396 0.399
• Thiazolidenedione
0.510
0.245 0.038*
• Biguanides
1.675
0.789 0.034*
• Alpha-glucosidase
0.181
0.694 0.794
• Sulfonyl-biguanides
1.244
0.777 0.109
• Meglitinides
Constant

0.058

0.906 0.949
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95% C.I. for
Odds ratio
Lower
Upper

Table 17D: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-2) to oral hypoglycemics
Beta
S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower
Upper
Over adherence vs. Good adherence
-0.399
0.281 0.156
0.671 0.386
1.164
Depression
Demographic characteristics
Age (in years)
0.018

0.013 0.144

1.019

0.994

1.044

Males (ref: females)

0.228

0.235 0.333

1.256

0.792

1.991

Whites (ref: non-whites)

0.002

0.581 0.997

1.002

0.321

3.129

Urban (ref: rural)

0.084

0.397 0.833

1.087

0.500

2.367

Year of index prescription (ref: 2001)
-0.529
• 1998
-0.621
• 1999
-0.145
• 2000

0.562 0.347
0.526 0.238
0.485 0.765

0.589
0.537
0.865

0.196
0.192
0.335

1.773
1.506
2.236

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.137

0.054 0.011*

1.147

1.032

1.274

Total health costs

0.000

0.000 0.565

1.000

1.000

1.000

Charlson co-morbidity

0.002

0.127 0.986

1.002

0.781

1.286

Number of therapeutic
classes of medications
Cardio-vascular

-0.053

0.126 0.678

0.949

0.741

1.216

-0.284

0.260 0.275

0.753

0.452

1.253

Cancer

0.515

0.621 0.407

1.673

0.495

5.653

Asthma

-0.277

0.368 0.452

0.758

0.369

1.559

Ulcers

0.550

0.717 0.443

1.733

0.425

7.063

0.393 0.816

0.913

0.422

1.973

Number of pharmacies visited (ref: multiple pharmacies)
0.514
0.589 0.382
• No pharmacy
0.208
0.237 0.380
• Single pharmacy

1.673
1.231

0.528
0.774

5.302
1.960

Provider interaction in the pre period
PAAS enrollment
-0.091
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Table 17D: Multinomial Logistic regression for the impact of depression on
adherence (Reg MPR-2) to oral hypoglycemics (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

0.005

0.049 0.913

1.005

0.912

1.108

0.011

0.022 0.602

1.011

0.969

1.056

-0.262

0.226 0.246

0.769

0.494

1.198

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
1.075
0.765 0.160
2.929
• Endocrinologist
0.282
0.240 0.241
1.326
• Internal medicine

0.654
0.827

13.129
2.124

Total diabetes costs

Complexity of regimen
Number of pills per day for
chronic medications
Number of prescriptions for
chronic medications
Number of pills per day for
oral hypoglycemics

95% C.I. for
Odds ratio
Lower
Upper

0.000

0.000 0.435

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

-0.306

0.379 0.420

0.736

0.350

1.548

Gap between index diagnosis
and prescription

0.000

0.001 0.983

1.000

0.999

1.001

Initial polytherapy

0.172

0.462 0.709

1.188

0.480

2.939

1.701
1.234
6.147
0.545
2.095

0.753
0.667
1.038
0.092
0.199

3.843
2.286
36.393
3.215
22.099

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.531
0.416 0.201
• Thiazolidenedione
0.210
0.314 0.503
• Biguanides
1.816
0.907 0.045*
• Alpha-glucosidase
-0.607
0.906 0.503
• Sulfonyl-biguanides
0.740
1.202 0.538
• Meglitinides
Constant

-2.113

1.128 0.061

*Significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
Pseudo R-square = 20.0%
-2 Log Likelihood = 3480.436; χ2 = 270.066; p= 0.000
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Discussion for objective 6

The study results indicated that newly diagnosed patients who continued oral
hypoglycemic therapy had an adherence rate of 88.00%. If patients who discontinued
therapy were assumed to be non-adherent and included in the computation of adherence,
rates of around 73.00% were found in the first year of oral hypoglycemic therapy.
Results for adherence rates in the 12-month follow up period were found to be
comparable to studies in the literature computing adherence rates for newly diagnosed
patients using prescription claims data. In a study conducted by Spoelstra and
associates161 using retrospective claims data of newly diagnosed type 2 diabetes patients,
adherence rates of around 86.00% were found. These numbers are very similar to the
ones obtained in this study. An adherence rate of 86.00% was also found in a study
conducted in seniors in Nova Scotia, Canada.164 In more than 52,000 patients on
sulfonylurea, Boccuzzi and associates16 determined an average adherence rate of
approximately 79.00%. Similar estimates of 70-80% were found for newly diagnosed
type 2 diabetes patients in Tayside, Scotland.17 Slight differences in the reported
adherence rates may reflect differences in methods, length of follow-up periods, inclusion
criteria, and demographic distribution of the patient population.
Results of this study indicated that patients with depression had significantly
lower adherence (Reg MPR-1 = 86.00%; Reg MPR-2 = 66.00%) to oral hypoglycemics
as compared to patients without depression (Reg MPR-1 = 89.00%; Reg MPR-2 =
73.00%). The impact of depression on adherence remained significant in the multivariate
framework. However, the magnitude of difference in adherence was not large. In the
only other study examining the impact of depression on adherence with oral
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hypoglycemics, Ciechanowski and colleagues28 found that depressive symptom severity
was significantly associated with decreased adherence to dietary recommendations and
approximately twice as many interruptions in refills of oral hypoglycemics. If these
results are converted to make them comparable to findings from this study, rates of
93.00% adherence were found for patients with low depressive symptomatology as
compared to adherence rates of 85.00% for patients with high depression severity. If
patients with medium and high depression severity levels from this study are combined to
form a group of depressed patients, adherence rates of 88% are estimated for depressed
patients. Thus, the difference in adherence rates between depressed and non-depressed
patients in the study by Ciechanowski and associates was around 5.00%; similar to the
results obtained from our study. However, this study was not restricted to patients who
were newly diagnosed patients and included a mix of type 1 and type 2 diabetes patients.
Also, the study measured adherence with oral hypoglycemics over a 12-month period,
including a period of six months before the assessment of depressive symptoms. This
study along with others in the literature demonstrating significantly lower adherence in
depressed patients were co-relational in nature and failed to determine whether
depression causes non-adherence or non-adherence causes depression. The estimation
models could be biased due to endogeneity and failed to control for a number of
confounding variables.
In addition to the study by Ciechanowski and associates28 in diabetes patients,
depression has been reported to have an effect on adherence with other medications
across a number of other disease conditions. In a study of adherence with aspirin among
elderly patients with coronary heart disease, depressed patients adhered to their regimen
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on a significantly lower proportion of days (45.00%) than those without depression
(69.00%).112 Studies of adherence in a variety of other conditions including AIDS, renal
failure, and asthma have also identified depression as a risk factor for non-adherence. In
a study using prescription refill information from claims data of a large HMO and
Veterans Affairs (VA) medical center, depression was significantly associated with
adherence of antihypertensive medications.165 However, similar to this study’s results, the
magnitude of decrease in adherence with every unit increase in depression severity was
low.
The strength of this study lies in the use of actual prescription refill information
from claims data rather than patient reported adherence. Using such an objective
measure of adherence was especially important in this study as a pessimistic attitude in
depressed patients can cause under-reporting of drug use among these patients and thus
show an artificial association between depression and adherence. In addition, data were
adjusted for a range of baseline variables such as demographics, co-morbidity, diabetes
severity, complexity of regimen, and interaction with health care providers that could
confound the impact of depression on adherence with oral hypoglycemics. The study
design was also able to avoid the issue of endogeneity by examining adherence in newly
diagnosed type 2 diabetes patients who had pre-existing depression.
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Results for Objective 7
To estimate the impact of preexisting depression on type 2 diabetes related utilization
and costs

Claims including either a primary or secondary diagnosis code for type 2 diabetes
and prescriptions for insulin, oral hypoglycemics and diabetic supplies were identified in
assessing total resource utilization associated with type 2 diabetes. In addition to total
type 2 diabetes costs, separate costs in terms of ER/hospitalization costs, outpatient costs,
and pharmacy costs were also assessed. Along with expenditures in terms of dollar
amounts, utilization related to type 2 diabetes such as number of ER/hospitalization
episodes, number of physician office visits, and number of diabetes prescriptions were
also compared between depressed and non-depressed patients.
Type 2 diabetes related costs

Univariate results for type 2 diabetes related costs are reported in Table 18.
Results indicated that in the 12 month follow up period total type 2 diabetes related costs
were significantly higher for depressed patients ($3,290.85 +7,060.05) as compared to
non-depressed patients ($2,186.24 +5,142.13). This difference in total type 2 diabetes
costs was primarily due to difference in ER/hospitalization costs, with depressed patients
incurring nearly twice the amount of ER/hospitalization costs as non-depressed patients.
Type 2 diabetes related outpatient costs were also slightly higher for depressed patients
($507.42 +678.48) as compared to non-depressed patients ($407.82 +629.57). However,
no differences in diabetes prescription costs were observed. However, these effects could
also be a result of confounders such as demographics, co-morbidity, diabetes severity,
and interaction with health care providers. Hence, multivariate econometric models were
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used to determine the impact of depression on type 2 diabetes related expenditures
controlling for baseline confounding factors.
Semi-log Ordinary Least Squares (OLS) regression techniques were used for the
estimation of the impact of preexisting depression on total costs associated with type 2
diabetes controlling for other confounding factors. The semi-log OLS model was found
to be significant with a R-square value of 15.60%. The model results are summarized in
Table 19. Results of the multivariate model indicated that controlling for confounding
covariates, patients with depression incurred 21.30% higher type 2 diabetes costs as
compared to non-depressed patients in the 12 month follow up period (p= 0.013). These
estimates were computed by applying the correction of Halverson and Palmquist with a
modification by Kennedy. This method was used for interpreting the estimates in all
semi-log OLS models. Retransformation using smearing estimated that an excess of
$451.27 in type 2 diabetes costs were attributable to depression.
In models where the dependent variables are specific costs such as those due to
ER/hospitalization visits and outpatient costs, a two-part model was used to estimate the
impact of depression on diabetes related ER/hospitalization and outpatient costs. Results
for the two-part model estimating the impact of depression on ER/hospitalization costs
are summarized in Table 20A-20B. An initial multivariate logistic regression model to
estimate the impact of depression on a type 2 diabetes related ER/hospitalization episode
demonstrated that depressed patients were nearly 1.4 times more likely to have a
ER/hospitalization episode as compared to non-depressed patients (p=0.028). A
subsequent semi-logarithmic OLS model, which was conducted only on those patients
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incurring type 2 diabetes related ER/hospitalization revealed no significant differences in
ER/hospitalization costs between depressed and non-depressed patients.
Two-part models for type 2 diabetes related outpatient costs revealed no
significant differences in either the probability or expenditures for type 2 diabetes related
outpatient visits between patients with and without depression (Tables 21A-21B). A
semi-log OLS model in a multivariate framework also failed to reveal any significant
differences in prescription costs between depressed and non-depressed patient controlling
for baseline covariates (Table 22).
Type 2 diabetes related utilization
Univariate results for type 2 diabetes related utilization in the 12-month follow up
period are presented in Table 18. The most notable difference between the 2 groups was
in the number of ER/Hospitalization episodes, with depressed patients (0.79 +1.57)
having significantly higher ER/Hospitalization episodes as compared to non-depressed
patients (0.40 +1.09). Patients with depression (9.81 +5.49) had significantly less
number of prescriptions for diabetes medications as compared to non-depressed patients
(10.76 +6.01), primarily due to decreased adherence with medications. However, the
results did not indicate any differences in number of physician office visits between
depressed and non-depressed patient.
As the dependent variable in this case is count data, a Poisson or Negative
binomial model could be used to estimate the impact of depression on type 2 diabetes
related utilization in a multivariate framework. In a Poisson regression, the probability of
a count is determined by a Poisson distribution, which has the defining characteristic that
the conditional mean of the outcome is equal to the conditional variance. However, most
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of the models for utilization were overdispersed (i.e the variance being greater than the
mean) with a high proportion of zero counts. Hence, a negative binomial model was used
for estimation of all the utilization related variables.
Results of the negative binomial models indicated that the only significant
difference between the two groups in the multivariate framework was in terms of number
of type 2 diabetes related ER/Hospitalizations with depressed patients incurring 57.78%
higher number of visits as compared to non depressed patients (p= 0.000). Results of this
negative binomial model and the fit statistics are summarized in Table 23. Table 24
reports the results of the negative binomial model, which demonstrates no significant
impact of depression on number of diabetes related physician office visits. The
multivariate framework also failed to reveal any significant impact of depression on
number of diabetes related prescriptions in the 12-month follow up period (Table 25).

190

Table 18: Utilization and expenditures for type 2 diabetes in the 12-month follow up
period
Depressed
Non-depressed
Mann-Whitney Sig.
(Mean+ S.D.)
(Mean+ S.D.)
U test
(p)
(N = 471)
(N = 855)
Type 2 diabetes related costs

Outpatient costs
ER/Hosp costs

507.42
+678.48

407.82
+629.57

184897.00

0.014*

2,276.38
+6,932.74

1,271.08
+4,939.85

174006.50

0.000*

507.05
+436.31

507.33
+475.01

195443.00

0.376

3,290.85
+7,060.05

2,186.24
+5,142.13

173041.00

0.000*

Pharmacy costs
Total costs

Type 2 diabetes related utilization

Number of physician
office visits

2.76 +3.34

2.55 +3.08

197218.50

0.525

Number of ER/hosp
visits

0.79 +1.57

0.40 +1.09

172425.50

0.000*

Number of prescriptions 9.81 +5.49

10.76 +6.01

182867.00

0.005*

* significance at the 0.05 level
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Table 19: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on total diabetes costs
Beta
S.E. Test statistic Sig.
(t)
(p)
Depression

0.196

0.079

2.492 0.013*

Demographic characteristics
Age (in years)

0.005

0.004

1.419 0.156

Males (ref: females)

0.048

0.075

0.633 0.527

Whites (ref: non-whites)

0.078

0.155

0.505 0.614

-0.184

0.129

-1.431 0.153

0.044
0.478
0.340

0.187
0.177
0.166

0.233 0.815
2.705 0.007*
2.045 0.041*

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.050

0.014

3.509 0.000*

Total health costs

0.000

0.000

Charlson co-morbidity

0.123

0.042

2.947 0.003*

Number of therapeutic classes
of medications

0.077

0.022

3.443 0.001*

Cardio-vascular

0.074

0.079

0.935 0.350

Cancer

-0.409

0.197

-2.074 0.038*

Asthma

-0.017

0.106

-0.163 0.871

Ulcers

0.170

0.212

0.801 0.423

Provider interaction in the pre period
PAAS enrollment

0.125

0.109

1.146 0.252

Number of pharmacies visited (ref: multiple pharmacies)
-0.035
0.179
• No pharmacy
-0.001
0.073
• Single pharmacy

-0.193 0.847
-0.020 0.984

Urban (ref: rural)
Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000
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-1.370 0.171

Table 19: Semi-log Ordinary Least Squares (OLS) regression model for the
impact of depression on total diabetes costs (Contd.)
Beta

S.E. Test statistic Sig.
(t)
(p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.290
0.283
• Endocrinologist
0.061
0.076
• Internal medicine

1.026 0.305
0.803 0.422

Total diabetes costs

0.000

0.000

0.608 0.543

Number of diabetes related
ER/hosp visits

0.261

0.103

2.524 0.012*

Gap between index diagnosis
and prescription

0.000

0.000

1.605 0.109

Initial polytherapy

0.696

0.155

4.486 0.000*

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.611
• Thiazolidenedione
0.150
• Biguanides
-0.075
• Alpha-glucosidase
-0.758
• Sulfonyl-biguanides
0.464
• Meglitinides
Constant

5.781

0.149
0.077
0.284
0.265
0.277

4.108
1.940
-0.264
-2.863
1.672

0.326

17.728 0.000

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics
R-square: 15.6%; F = 8.331; P = 0.000
Durbin-Watson: 1.988
White test for heteroskedasticity: Chi-square= 409.1604; P = 0.1625
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0.000*
0.053*
0.792
0.004*
0.095

TWO-PART MODEL-PART1
Table 20A: Logistic regression for the impact of depression on having a diabetes
related ER/hospitalization episode in the 12-month follow-up period
Beta S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.331 0.150 0.028*
1.392 1.037 1.868
Depression
Demographic characteristics
Age (in years)

0.002 0.007 0.752

1.002

0.988

1.017

Males (ref: females)

-0.047 0.150 0.753

0.954

0.712

1.279

Whites (ref: non-whites)

-0.057 0.309 0.853

0.944

0.515

1.731

0.118 0.258 0.647

1.126

0.679

1.867

Year of index prescription (ref: 2001)
-0.274 0.370 0.459
• 1998
0.418 0.342 0.222
• 1999
0.316 0.323 0.328
• 2000

0.760
1.519
1.372

0.368
0.777
0.728

1.570
2.971
2.583

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.230 0.038 0.000*

1.259

1.169

1.355

Total health costs

0.000 0.000 0.510

1.000

1.000

1.000

Charlson co-morbidity

0.139 0.077 0.071

1.149

0.988

1.337

Number of therapeutic classes
of medications
Cardio-vascular

0.106 0.042 0.012*

1.111

1.023

1.207

-0.017 0.156 0.916

0.984

0.724

1.336

Cancer

-0.474 0.385 0.217

0.622

0.293

1.323

Asthma

0.242 0.193 0.209

1.274

0.873

1.858

Ulcers

0.673 0.392 0.085

1.961

0.910

4.224

Provider interaction in the pre period
PAAS enrollment
-0.065 0.215 0.761

0.937

0.614

1.428

Number of pharmacies visited (ref: multiple pharmacies)
0.193 0.375 0.606
• No pharmacy
0.065 0.144 0.649
• Single pharmacy

1.213
1.068

0.582
0.806

2.529
1.415

Urban (ref: rural)
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Table 20A: Logistic regression for the impact of depression on having a diabetes
related ER/Hosp episode the 12-month follow-up period (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

95% C.I. for
Odds ratio
Lower Upper

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.306 0.517 0.553
1.359
• Endocrinologist
0.150
0.146
0.304
1.162
• Internal medicine

0.493
0.873

3.742
1.547

Total diabetes costs

0.000 0.000 0.664

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.464 0.199 0.020*

1.590

1.077

2.348

Gap between index diagnosis
and prescription

0.000 0.000 0.978

1.000

0.999

1.001

Initial polytherapy

0.249 0.289 0.389

1.283

0.728

2.261

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.005 0.279 0.985
• Thiazolidenedione
-0.066 0.151 0.662
• Biguanides
-0.928 0.672 0.168
• Alpha-glucosidase
-0.595 0.519 0.251
• Sulfonylurea-biguanide
-0.036 0.540 0.947
• Meglitinides

1.005
0.936
0.395
0.552
0.965

0.582
0.696
0.106
0.200
0.335

1.737
1.259
1.477
1.524
2.778

-2.247 0.646 0.001

0.106

Constant

* Significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
Pseudo R-square = 19.6%
-2 Log Likelihood = 1350.585; χ2 = 189.547, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 4.653; p= 0.794
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TWO-PART MODEL-PART 2
Table 20B: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on diabetes related ER/hospitalization costs
Beta
S.E. Test statistic Sig.
(t)
(p)
Depression

0.232

0.209

1.109 0.268

Demographic characteristics
Age (in years)

0.024

0.011

2.277 0.023*

Males (ref: females)

0.246

0.213

1.155 0.249

Whites (ref: non-whites)

0.025

0.448

0.056 0.955

-0.618

0.377

-1.638 0.102

0.610
0.599
0.256

0.483
0.440
0.421

1.263 0.208
1.360 0.175
0.610 0.543

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.015

0.027

0.550 0.583

Total health costs

0.000

0.000

0.645 0.519

Charlson co-morbidity

0.017

0.090

0.188 0.851

Number of therapeutic classes
of medications
Cardio-vascular

0.123

0.057

2.141 0.033*

0.098

0.229

0.428 0.669

Cancer

-0.064

0.490

-0.131 0.896

Asthma

-0.194

0.246

-0.789 0.431

Ulcers

0.415

0.429

0.967 0.334

Provider interaction in the pre period
PAAS enrollment

0.184

0.295

0.623 0.534

Number of pharmacies visited (ref: multiple pharmacies)
0.444
0.560
• No pharmacy
-0.036
0.200
• Single pharmacy

0.793 0.428
-0.178 0.859

Urban (ref: rural)
Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000
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Table 20B: Semi-log Ordinary Least Squares (OLS) regression model for the
impact of depression on diabetes related ER/Hospitalization costs (Contd.)
Beta

S.E. Test statistic Sig.
(t)
(p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.035
0.652
• Endocrinologist
-0.009
0.200
• Internal medicine

0.053 0.957
-0.044 0.965

Total diabetes costs

0.000

0.000

0.388 0.698

Number of diabetes related
ER/Hosp visits

0.181

0.217

0.833 0.405

Gap between index diagnosis
and prescription

0.000

0.001

0.792 0.429

-0.711

0.417

-1.705 0.089

0.373
0.211
0.928
0.771
0.772

0.358
0.028
-2.277
0.384
0.619

Initial polytherapy

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.133
• Thiazolidenedione
0.006
• Biguanides
-2.114
• Alpha-glucosidase
0.296
• Sulfonyl-biguanides
0.478
• Meglitinides
Constant

5.671

0.887

* significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 13.5%; F = 1.748; P = 0.010
Durbin-Watson: 2.004
White test for heteroskedasticity: Chi-square = 272.42; p= 0.7762
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0.721
0.978
0.023*
0.701
0.536

6.390 0.000

TWO-PART MODEL-PART1
Table 21A: Logistic regression for the impact of depression on having a diabetes
related outpatient episode
Beta S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
-0.118 0.221 0.594
0.889 0.576 1.371
Depression
Demographic characteristics
Age (in years)

-0.008 0.010 0.402

0.992

0.972

1.011

Males (ref: females)

0.223 0.215 0.299

1.250

0.821

1.903

Whites (ref: non-whites)

0.289 0.381 0.448

1.335

0.633

2.814

-0.181 0.382 0.635

0.834

0.395

1.763

Year of index prescription (ref: 2001)
-0.995 0.612 0.104
• 1998
-0.013 0.598 0.983
• 1999
0.288 0.586 0.623
• 2000

0.370
0.987
1.333

0.111
0.306
0.423

1.228
3.188
4.206

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.045 0.048 0.349

1.046

0.952

1.148

Total health costs

0.000 0.000 0.000*

1.000

1.000

1.000

Charlson co-morbidity

0.051 0.155 0.742

1.052

0.777

1.425

-0.078 0.061 0.203

0.925

0.820

1.043

0.802 0.222 0.000*

2.230

1.444

3.446

Cancer

0.910 0.832 0.274

2.484

0.487 12.675

Asthma

-0.028 0.329 0.933

0.973

0.511

1.852

Ulcers

-0.006 0.665 0.993

0.994

0.270

3.659

Provider interaction in the pre period
PAAS enrollment
0.256 0.325 0.431

1.292

0.683

2.443

Number of pharmacies visited (ref: multiple pharmacies)
-0.648 0.446 0.147
• No pharmacy
-0.414 0.210 0.049*
• Single pharmacy

0.523
0.661

0.218
0.438

1.254
0.997

Urban (ref: rural)

Number of therapeutic classes
of medications
Cardio-vascular
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Table 21A: Logistic regression for the impact of depression on having a diabetes
related outpatient episode (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

95% C.I. for
Odds ratio
Lower Upper

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.607 1.065 0.568
1.836
• Endocrinologist
0.334 0.230 0.147
1.396
• Internal medicine

0.228 14.788
0.890 2.192

Total diabetes costs

0.000 0.000 0.793

1.000

1.000

1.000

-0.068 0.332 0.838

0.934

0.487

1.791

Gap between index diagnosis
and prescription

0.001 0.001 0.504

1.001

0.999

1.002

Initial polytherapy

1.092 0.619 0.078

2.981

0.886 10.028

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.049 0.508 0.924
• Thiazolidenedione
-0.013 0.221 0.954
• Biguanides
-0.276 0.669 0.680
• Alpha-glucosidase
• Sulfonylurea-biguanide -0.314 1.208 0.795
-0.526 0.680 0.440
• Meglitinides

0.953
0.987
0.759
0.730
0.591

0.352
0.640
0.205
0.068
0.156

2.589 0.968 0.007

13.320

Number of diabetes related
ER/Hosp visits

Constant

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
Pseudo R-square = 14.9%
-2 Log Likelihood = 759.410; χ2 = 97.180, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 5.411; p= 0.713
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2.576
1.524
2.814
7.788
2.243

TWO-PART MODEL-PART 2
Table 21B: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on diabetes related outpatient costs
Beta
S.E. Test statistic Sig.
(t)
(p)
0.065

0.091

0.717 0.473

Demographic characteristics
Age (in years)

-0.007

0.004

-1.519 0.129

Males (ref: females)

-0.054

0.087

-0.619 0.536

0.120

0.183

0.654 0.513

Urban (ref: rural)

-0.176

0.148

-1.190 0.234

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

-0.095
0.056
0.308

0.214
0.199
0.188

-0.445 0.656
0.279 0.780
1.639 0.101

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.030

0.017

1.721 0.085

Total health costs

0.000

0.000

-1.157 0.247

Charlson co-morbidity

0.102

0.047

2.154 0.031

Number of therapeutic classes
of medications
Cardio-vascular

0.000

0.026

-0.012 0.990

0.293

0.093

Cancer

-0.036

0.222

-0.162 0.872

Asthma

0.005

0.122

0.043 0.966

Ulcers

0.123

0.243

0.508 0.611

Provider interaction in the pre period
PAAS enrollment

0.398

0.125

3.183 0.001*

Depression

Whites (ref: non-whites)

Number of pharmacies visited (ref: multiple pharmacies)
-0.329
0.212
• No pharmacy
-0.017
0.084
• Single pharmacy
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3.147 0.002*

-1.554 0.121
-0.201 0.841

Table 21B: Semi-log Ordinary Least Squares (OLS) regression model for the
impact of depression on diabetes related outpatient costs (Contd.)
Beta

S.E. Test statistic Sig.
(t)
(p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.199
0.318
• Endocrinologist
-0.125
0.088
• Internal medicine
Total diabetes costs

0.628 0.530
-1.427 0.154

0.000

0.000

0.921 0.357

-0.013

0.116

-0.116 0.908

Gap between index diagnosis
and prescription

0.000

0.000

1.823 0.069

Initial polytherapy

0.428

0.175

2.455 0.014*

Number of diabetes related
ER/Hosp visits

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.175
• Thiazolidenedione
-0.104
• Biguanides
-0.072
• Alpha-glucosidase
-0.813
• Sulfonyl-biguanides
-0.073
• Meglitinides
Constant

5.498

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 7.6%; F = 3.080; P = 0.010
Durbin-Watson: 2.009
White test for heteroskedasticity: χ2= 328.00; p= 0.8161
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0.168
0.089
0.336
0.296
0.328

-1.044
-1.175
-0.215
-2.747
-0.222

0.297
0.240
0.830
0.006*
0.824

0.378

14.531 0.000

Table 22: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on diabetes prescription costs
Beta
S.E. Test statistic Sig.
(t)
(p)
Depression

0.067

0.065

1.033 0.302

Demographic characteristics
Age (in years)

0.005

0.003

1.714 0.087

Males (ref: females)

0.040

0.062

0.649 0.517

Whites (ref: non-whites)

0.124

0.127

0.972 0.331

Urban (ref: rural)

0.009

0.106

0.081 0.935

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

0.315
0.521
0.200

0.154
0.145
0.137

2.046 0.041*
3.586 0.000*
1.463 0.144

Co-morbid conditions in the pre period
Number of ER/hosp visits
-0.030

0.012

-2.554 0.011*

Total health costs

0.000

0.000

0.319 0.750

Charlson co-morbidity

0.010

0.034

0.279 0.780

Number of therapeutic classes
of medications

0.042

0.018

2.285 0.022*

Cardio-vascular

0.028

0.065

0.427 0.670

Cancer

-0.218

0.162

-1.342 0.180

Asthma

-0.162

0.088

-1.848 0.065

Ulcers

-0.238

0.174

-1.363 0.173

0.004

0.090

0.042 0.966

Number of pharmacies visited (ref: multiple pharmacies)
-0.057
0.148
• No pharmacy
0.058
0.060
• Single pharmacy

-0.388 0.698
0.954 0.340

Provider interaction in the pre period
PAAS enrollment
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Table 22: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on diabetes prescription costs (Contd.)
Beta

S.E. Test statistic Sig.
(t)
(p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.413
0.233
• Endocrinologist
0.047
0.063
• Internal medicine

1.777 0.076
0.742 0.458

Total diabetes costs

0.000

0.000

0.873 0.383

Number of diabetes related
ER/Hosp visits

0.063

0.085

0.746 0.456

Gap between index diagnosis
and prescription

0.000

0.000

0.680 0.497

Initial polytherapy

1.210

0.128

9.482 0.000*

Index class of oral hypoglycemic (ref: Sulfonyl urea)
1.270
• Thiazolidenedione
0.568
• Biguanides
0.544
• Alpha-glucosidase
-0.552
• Sulfonyl-biguanides
0.893
• Meglitinides
Constant

4.527

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 19.9%; F = 10.450; P = 0.00
Durbin-Watson: 1.939
White test for heteroskedasticity: χ2 = 398.14; p= 0.0705
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0.122
0.064
0.233
0.218
0.228

10.368
8.935
2.330
-2.534
3.913

0.000*
0.000*
0.020*
0.011*
0.000*

0.268

16.868 0.000

Table 23: Negative binomial model for the impact of depression on number of
diabetes related ER/Hosp episodes
Estimate
S.E. Test statistic Sig.
(Chi-square) (p)
Depression

0.456

0.123

13.740 0.000*

Demographic characteristics
Age (in years)

0.001

0.006

0.020 0.902

Males (ref: females)

0.173

0.123

2.000 0.157

-0.284

0.244

1.350 0.245

0.146

0.225

0.420 0.517

-0.090
0.364
0.368

0.300
0.275
0.264

0.090 0.764
1.750 0.186
1.940 0.164

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.149

0.024

37.880 0.000*

Total health costs

0.000

0.000

0.290 0.589

Charlson co-morbidity

0.059

0.058

1.050 0.306

Number of therapeutic classes
of medications

0.062

0.034

3.280 0.070

Cardio-vascular

-0.060

0.131

0.210 0.648

Cancer

-0.308

0.299

1.060 0.303

Asthma

0.192

0.153

1.580 0.208

Ulcers

0.202

0.305

0.440 0.507

-0.095

0.175

0.290 0.587

Number of pharmacies visited (ref: multiple pharmacies)
0.081
0.306
• No pharmacy
0.076
0.119
• Single pharmacy

0.070 0.792
0.410 0.524

Whites (ref: non-whites)
Urban (ref: rural)
Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

Provider interaction in the pre period
PAAS enrollment
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Table 23: Negative binomial model for the impact of depression on number of diabetes
related ER/Hosp episodes (Contd.)
Estimate

S.E.

Test statistic Sig.
(Chi-square) (p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.457
0.392
• Endocrinologist
0.197
0.120
• Internal medicine

1.360 0.243
2.710 0.100

Total diabetes costs

0.000

0.000

1.060 0.303

Number of diabetes related
ER/Hosp visits

0.452

0.135

11.210 0.001*

Gap between index diagnosis
and prescription

0.000

0.000

0.350 0.555

Initial polytherapy

0.318

0.240

1.760 0.185

0.222
0.123
0.533
0.452
0.440

0.150
0.320
2.020
1.600
0.020

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.085
• Thiazolidenedione
-0.070
• Biguanides
-0.758
• Alpha-glucosidase
-0.573
• Sulfonyl-biguanides
0.059
• Meglitinides
Constant

-1.782

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
-2log likelihood= 2281.1894; χ2= 205.37; p= 0.000
Dispersion estimate: 1.4288; χ2= 236.39; p = 0.000
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0.523

0.701
0.572
0.155
0.205
0.893

11.620 0.001

Table 24: Negative binomial model for the impact of depression on number of
diabetes related physician office visits
Estimate
S.E.
Test statistic Sig.
(Chi-square) (p)
Depression

0.063

0.081

0.610 0.435

Demographic characteristics
Age (in years)

0.008

0.004

4.070 0.044*

-0.042

0.078

0.290 0.592

Whites (ref: non-whites)

0.195

0.166

1.380 0.240

Urban (ref: rural)

0.037

0.137

0.070 0.788

-0.374
-0.031
0.080

0.193
0.180
0.170

3.750 0.053*
0.030 0.865
0.220 0.639

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.006

0.016

0.150 0.694

Total health costs

0.000

0.000

5.420 0.020*

Charlson co-morbidity

0.031

0.043

0.520 0.469

-0.020

0.023

0.750 0.385

0.055

0.085

0.420 0.517

Cancer

-0.029

0.198

0.020 0.886

Asthma

-0.030

0.108

0.080 0.782

Ulcers

0.138

0.211

0.430 0.512

Provider interaction in the pre period
PAAS enrollment

0.055

0.112

0.240 0.626

Number of pharmacies visited (ref: multiple pharmacies)
-0.185
0.193
• No pharmacy
-0.013
0.077
• Single pharmacy

0.920 0.337
0.030 0.863

Males (ref: females)

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

Number of therapeutic classes
of medications
Cardio-vascular

206

Table 24: Negative binomial model for the impact of depression on number of
diabetes related physician office visits (Contd.)
Estimate

S.E.

Test statistic Sig.
(Chi-square) (p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.474
0.280
• Endocrinologist
0.149
0.080
• Internal medicine

2.870 0.090
3.480 0.062

Total diabetes costs

0.000

0.000

0.550 0.457

-0.023

0.106

0.050 0.829

Gap between index diagnosis
and prescription

0.000

0.000

0.610 0.434

Initial polytherapy

0.337

0.156

4.660 0.031*

0.150
0.080
0.289
0.268
0.292

3.900
0.840
1.630
0.650
0.050

0.348

0.910 0.340

Number of diabetes related
ER/Hosp visits

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.295
• Thiazolidenedione
0.074
• Biguanides
0.369
• Alpha-glucosidase
-0.217
• Sulfonyl-biguanides
-0.065
• Meglitinides
Constant

0.332

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
-2loglikelihood= 5437.492; χ2= 58.82; p = 0.0013
Dispersion estimate: 1.2206; χ2= 1510.38; p= 0.000
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0.048*
0.358
0.202
0.419
0.825

Table 25: Negative binomial model for the impact of depression on number of
diabetes prescriptions
Estimate
S.E.
Test statistic Sig.
(Chi-square) (p)
-0.059

0.035

2.850 0.091

Demographic characteristics
Age (in years)

0.004

0.002

4.460 0.035*

Males (ref: females)

0.003

0.033

0.010 0.940

Whites (ref: non-whites)

0.111

0.070

2.530 0.112

Urban (ref: rural)

0.044

0.057

0.580 0.446

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

0.045
0.104
0.086

0.083
0.078
0.073

0.300 0.584
1.780 0.183
1.370 0.241

Co-morbid conditions in the pre period
Number of ER/hosp visits
-0.023

0.007

11.490 0.001*

Total health costs

0.000

0.000

2.010 0.156

-0.023

0.019

1.480 0.224

Number of therapeutic classes
of medications

0.027

0.010

7.390 0.007*

Cardio-vascular

0.023

0.036

0.400 0.528

Cancer

-0.144

0.089

2.640 0.104

Asthma

-0.078

0.048

2.670 0.103

Ulcers

-0.063

0.096

0.420 0.515

0.023

0.048

0.230 0.635

Number of pharmacies visited (ref: multiple pharmacies)
-0.028
0.080
• No pharmacy
0.038
0.033
• Single pharmacy

0.120 0.727
1.340 0.247

Depression

Charlson co-morbidity

Provider interaction in the pre period
PAAS enrollment
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Table 25: Negative binomial model for the impact of depression on number of diabetes
prescriptions (Contd.)
Estimate

S.E.

Test statistic Sig.
(Chi-square) (p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.241
0.122
• Endocrinologist
0.001
0.034
• Internal medicine

3.920 0.048*
0.000 0.985

Total diabetes costs

0.000

0.000

4.060 0.044*

Number of diabetes related
ER/Hosp visits

0.011

0.045

0.060 0.808

Gap between index diagnosis
and prescription

0.000

0.000

1.580 0.209

Initial polytherapy

0.672

0.064

111.710 0.000*

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.043
• Thiazolidenedione
-0.065
• Biguanides
0.082
• Alpha-glucosidase
-0.627
• Sulfonyl-biguanides
-0.115
• Meglitinides
Constant

1.866

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
-2loglikelhiood = 7956.926; χ2= 197.66; p= 0.000
Dispersion estimate: 0.1987; χ2 =943.91; p=0.000
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0.065
0.034
0.125
0.114
0.125
0.146

0.440
3.530
0.440
30.380
0.840

0.507
0.060
0.509
0.000*
0.359

164.030 0.000

Discussion for Objective 7

The study results demonstrated that patients with depression had nearly 21.00%
higher type 2 diabetes related costs as compared to patients without depression. These
estimates were obtained after adjusting for a number of baseline confounding factors such
as demographics, co-morbidity, diabetes severity, and interaction with health care
providers. This is to our knowledge the first study in literature to examine the impact of
depression on type 2 diabetes related utilization and expenditures. Adjusted smearing
estimates indicated that an excess of $ 451.27 type 2 diabetes costs were attributable to
presence of depression in the 12-month follow up period.
Most of the studies in this area have examined the impact of depression on total
health care costs. One of the reasons that our study examined type 2 diabetes related
costs was that we hypothesized that excess type 2 diabetes related costs in depressed
patients could be attributable to the impact of depression on decreasing adherence with
oral hypoglycemics. Also, our study examined the breakdown of these excess
expenditures in detail. This can help us identify cost drivers and provide an explanation
for any observed differences in type 2 diabetes expenditures. Our results indicated that
increased type 2 diabetes costs in patients with depression were primarily due to
increased probability of diabetes related ER/hospitalization episodes. This information
may be an important lead for exploring future research in this area.
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Results for Objective 8
To estimate the impact of preexisting depression on overall health care utilization and
costs

All medical and prescription claims in the follow up period were identified for
this analysis, irrespective of diagnosis codes (except those due to depressive diagnosis).
The costs were also examined separately in terms of ER/ hospitalization costs, outpatient
costs, and pharmacy costs. Along with expenditures in terms of dollar amounts, overall
utilization such as number of ER/hospitalization episodes, number of physician office
visits, and number of prescriptions were also compared between depressed and nondepressed patients.
Overall health care costs

Univariate results for the overall health care costs in the 12-month follow up
period are reported in Table 26. The results indicated that health care costs were
significantly higher for depressed patients ($9,809.07 +12,293.26) as compared to nondepressed patients ($6,833.37 +12,369.62). Significant differences were observed in all
categories of costs such as outpatient costs, ER/hospitalization costs, and prescription
costs. Patients with depression ($3,057.74 +7,764.26) had significantly higher
ER/hospitalization costs as compared to non-depressed patients ($1,909.12 + 6,429.12).
Outpatient costs were also higher for depressed patients ($3,654.98 +7087.62) as
compared to non-depressed patients ($2,808.49 + 9,424.36). Differences in prescription
costs were also observed with depressed patients ($3,096.35 +2,479.97) incurring
significantly higher prescription costs as compared to non-depressed patients ($2,115.76
+ 1,912.47).
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Semi-log Ordinary Least Squares (OLS) regression techniques were used for the
estimation of the impact of preexisting depression on total costs associated with type 2
diabetes controlling for other confounding factors. The semi-log OLS model was found
to be significant with a R-square value of 36.90%. The model results are summarized in
Tables 27. Robust standard errors are reported as the model was found to be
heteroskedastic. Results of the multivariate model indicated that controlling for
confounding covariates, patients with depression incurred 32.11% higher health care
costs as compared to non-depressed patients in the 12-month follow up period (p= 0.000).
Retransformation using smearing estimates indicated that an excess of $1,864.52 in total
health care costs (excluding those due to depressive diagnosis) are due to depression.
In models where the dependent variables are specific costs such as those due to
ER/hospitalization visits, a two-part model was used in this case to estimate the impact of
depression on ER/hospitalization (Tables 28A-28B). An initial multivariate logistic
regression model to estimate the impact of depression on a ER/hospitalization episode
demonstrated that depressed patients were nearly 1.7 times more likely to have a
ER/hospitalization episode as compared to non-depressed patients (p=0.000). A
subsequent semi-logarithmic OLS model, which was conducted only on those patients
having an ER/hospitalization episode revealed no significant differences in
ER/hospitalization costs between depressed and non-depressed patients.
As all patients incurred outpatient and prescription costs, semi-log OLS models
were used to estimate the impact of depression on these costs in a multivariate
framework. The semi-log OLS model for outpatient costs was found to be significant
with a R-square value of 28.00%. The model results are summarized in Table 29.
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Results of the multivariate model indicated that controlling for confounding covariates,
patients with depression incurred nearly 38.00% higher outpatient costs as compared to
non-depressed patients in the 12-month follow up period (p= 0.000). Retransformation
using smearing estimates indicated that an excess of $732.65 in total outpatient costs
(excluding those due to depressive diagnosis) were attributed to depression.
The semi-log OLS model for prescription costs was found to be significant with a
R-square value of 33.5%. The model results are summarized in Table 30. Results of the
multivariate model indicated that controlling for confounding covariates, patients with
depression incurred nearly 30.85% higher prescription costs as compared to nondepressed patients in the 12-month follow up period (p= 0.000). Retransformation using
smearing estimates indicated that an excess of $627.75 in total prescription costs
(excluding those due to depressive diagnosis) were attributed to depression.
Health care utilization
In the 12-month follow up period, significant differences were observed in terms
of all the utilization related variables (Table 26). Depressed patients (2.33 +3.88) had
twice as many ER/hospitalization episodes as compared to non-depressed patients (1.14
+2.20). Patients with depression (71.35 +36.42) also had significantly higher number of
prescriptions as compared to non-depressed patients (53.79 +32.99). Univariate results
also indicated that the number of physician office visits were significantly higher for
depressed patients (10.44 +9.98) as compared to non-depressed patients (6.63 +6.27).
Negative binomial models were used for estimation of all the utilization related
variables. Results of the negative binomial models indicated that significant differences
were observed on all the utilization parameters between the two groups in a multivariate
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framework (Tables 31-33). Multivariate results indicated that controlling baseline
covariates, patients with depression had 48.14% higher number of ER/Hospitalization
episodes as compared to non-depressed patients (p= 0.000). Patients with depression also
had 28.78% higher number of physician office visits as compared to non-depressed
patients (p=0.000). Similar results were observed in terms of prescription utilization with
depression patients filling 16.76% higher number of prescriptions in the 12-month follow
up period (p=0.000).
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Table 26: Utilization and expenditures for overall health care
(excluding those due to depression ) in the 12-month follow up period
Depressed
Non-depressed
Mann-Whitney
(Mean + S.D.)
U test
(Mean +S.D.)
(N = 471)
(N = 855)

Sig.
(p)

Overall health care costs (in dollars)
Outpatient costs

3,654.98
+7,087.62

2,808.49
+ 9,424.36

146647.00 0.000*

ER/Hosp costs

3,057.74
+7,764.26

1,909.12
+ 6,429.12

158711.50 0.000*

Pharmacy costs

3,096.35
+2,479.97

2,115.76
+ 1,912.47

141544.00 0.000*

9,809.07
+12,293.26

6,833.37
+12,369.62

140387.00 0.000*

Total costs

Overall health care utilization

Number of physician
office visits

10.44 +9.98

6.63 +6.27

149043.50

0.000*

Number of ER/hosp
visits

2.33 +3.88

1.14 +2.20

154814.50

0.000*

53.79 +32.99

141781.50

0.000*

Number of Rxs

71.35 +36.42

*Significance at the 0.05 level

215

Table 27: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on total healthcare costs (excluding depression costs)
Beta
Robust Test statistic Sig.
S.E.
(t)
(p)
Depression

0.280

0.055

5.133 0.000*

Demographic characteristics
Age (in years)

0.006

0.003

2.245 0.025*

-0.025

0.055

-0.462 0.644

0.056

0.099

0.566 0.572

-0.203

0.093

-2.185 0.029*

0.164
0.174
0.156

0.121
0.115
0.103

1.350 0.177
1.520 0.129
1.523 0.128

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.023

0.012

1.935 0.053*

Total health costs

0.000

0.000

9.967 0.000*

Charlson co-morbidity

0.060

0.027

2.204 0.028*

Number of therapeutic classes
of medications
Cardio-vascular

0.107

0.015

7.162 0.000*

0.029

0.055

0.524 0.601

Cancer

-0.134

0.114

-1.172 0.241

Asthma

0.108

0.066

1.654 0.098

Ulcers

0.209

0.138

1.515 0.130

Provider interaction in the pre period
PAAS enrollment

0.062

0.078

0.801 0.423

Number of pharmacies visited (ref: multiple pharmacies)
-0.156
0.163
• No pharmacy
-0.043
0.050
• Single pharmacy

-0.960 0.337
-0.863 0.388

Males (ref: females)
Whites (ref: non-whites)
Urban (ref: rural)
Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000
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Table 27: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on total healthcare costs (excluding depression costs) (Contd.)
Beta

Robust Test statistic Sig.
S.E.
(t)
(p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.188
0.187
• Endocrinologist
0.053
0.053
• Internal medicine

1.008 0.314
0.989 0.323

Total diabetes costs

0.000

0.000

-1.970 0.049*

Number of diabetes related
ER/Hosp visits

0.141

0.066

2.133 0.033*

Gap between index diagnosis
and prescription

0.000

0.000

1.033 0.302

Initial polytherapy

0.228

0.086

2.649 0.008*

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.182
• Thiazolidenedione
0.058
• Biguanides
0.060
• Alpha-glucosidase
-0.296
• Sulfonyl-biguanides
0.063
• Meglitinides
Constant

7.357

0.103
0.052
0.143
0.164
0.176

1.765
1.129
0.423
-1.804
0.357

0.231

31.907 0.000

* Significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 36.9%; F = 24.536; P = 0.000
Durbin-Watson: 1.931
White test for heteroskedasticity: Chi-square = 495.31; P= 0.0001
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0.078
0.259
0.672
0.071
0.721

TWO-PART MODEL-PART 1
Table 28A: Logistic regression for the impact of depression on having an
ER/Hospitalization episode (excluding depression)
Beta S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.524 0.139 0.000*
1.689 1.285 2.220
Depression
Demographic characteristics
Age (in years)

-0.005 0.007 0.406

0.995

0.982

1.007

Males (ref: females)

-0.170 0.133 0.200

0.844

0.651

1.094

Whites (ref: non-whites)

-0.124 0.272 0.648

0.883

0.518

1.505

Urban (ref: rural)

-0.080 0.225 0.722

0.923

0.594

1.435

Year of index prescription (ref: 2001)
0.103 0.337 0.761
• 1998
0.239 0.319 0.453
• 1999
0.241 0.300 0.422
• 2000

1.108
1.270
1.273

0.572
0.680
0.707

2.147
2.371
2.294

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.411 0.053 0.000*

1.508

1.359

1.674

Total health costs

0.000 0.000 0.511

1.000

1.000

1.000

Charlson co-morbidity

0.198 0.085 0.019*

1.219

1.033

1.440

Number of therapeutic classes
of medications
Cardio-vascular

0.041 0.040 0.310

1.041

0.963

1.126

-0.238 0.140 0.090

0.788

0.599

1.038

Cancer

-0.449 0.364 0.217

0.638

0.313

1.303

Asthma

0.355 0.198 0.073

1.427

0.968

2.103

Ulcers

0.291 0.435 0.504

1.338

0.570

3.140

Provider interaction in the pre period
PAAS enrollment
0.157 0.195 0.422

1.169

0.798

1.713

Number of pharmacies visited (ref: multiple pharmacies)
0.119 0.308 0.699
• No pharmacy
-0.131 0.129 0.309
• Single pharmacy

1.126
0.877

0.616
0.681

2.058
1.129
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Table 28A: Logistic regression for the impact of depression on having an
ER/hospitalization episode (excluding depression) (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

95% C.I. for
Odds ratio
Lower Upper

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.013 0.509 0.980
1.013
• Endocrinologist
0.155
0.137
0.259
1.168
• Internal medicine

0.373
0.892

2.747
1.529

Total diabetes costs

0.000 0.000 0.902

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.015 0.216 0.945

1.015

0.665

1.549

Gap between index diagnosis
and prescription

0.000 0.000 0.457

1.000

0.999

1.000

Initial polytherapy

0.112 0.268 0.676

1.119

0.661

1.892

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.155 0.268 0.564
• Thiazolidenedione
0.103 0.137 0.450
• Biguanides
-0.374
0.522 0.474
• Alpha-glucosidase
-0.189 0.459 0.681
• Sulfonylurea-biguanide
0.104 0.476 0.827
• Meglitinides

1.167
1.109
0.688
0.828
1.109

0.691
0.848
0.247
0.336
0.436

1.972
1.451
1.915
2.036
2.821

-0.378 0.584 0.517

0.685

Constant

*Significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
Pseudo R-square = 21.8%
-2 Log Likelihood = 1559.939; χ2 = 230.150, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 16.207; p= 0.040
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TWO-PART MODEL-PART 2
Table 28B: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on total ER/hospitalization costs (excluding depression)
Beta
S.E. Test statistic Sig.
(t)
(p)
Depression

0.154

0.155

0.994 0.321

Demographic characteristics
Age (in years)

0.022

0.007

2.890 0.004*

Males (ref: females)

0.194

0.159

1.217 0.224

Whites (ref: non-whites)

0.238

0.316

0.752 0.452

-0.170

0.265

-0.643 0.520

0.605
0.462
0.267

0.379
0.356
0.339

1.599 0.110
1.300 0.194
0.786 0.432

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.087

0.023

3.774 0.000*

Total health costs

0.000

0.000

2.119 0.034*

Charlson co-morbidity

0.079

0.075

1.056 0.291

Number of therapeutic classes
of medications
Cardio-vascular

0.115

0.044

2.622 0.009*

0.157

0.162

0.966 0.334

Cancer

-0.442

0.383

-1.155 0.248

Asthma

-0.030

0.190

-0.155 0.877

Ulcers

0.873

0.365

-0.009

0.214

-0.043 0.966

Number of pharmacies visited (ref: multiple pharmacies)
0.543
0.401
• No pharmacy
-0.045
0.150
• Single pharmacy

1.355 0.176
-0.300 0.764

Urban (ref: rural)
Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

Provider interaction in the pre period
PAAS enrollment
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2.388 0.017*

Table 28B: Semi-log Ordinary Least Squares (OLS) regression model for the
impact of depression on total ER/hospitalization costs (excluding depression)
Beta

S.E. Test statistic Sig.
(t)
(p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.516
0.536
• Endocrinologist
-0.007
0.151
• Internal medicine

0.963 0.336
-0.045 0.964

Total diabetes costs

0.000

0.000

-0.091 0.928

Number of diabetes related
ER/Hosp visits

0.288

0.189

1.526 0.128

Gap between index diagnosis
and prescription

0.000

0.000

0.503 0.615

-0.230

0.323

-0.711 0.478

0.291
0.158
0.587
0.559
0.563

0.911
0.123
-1.593
0.111
-0.819

Initial polytherapy

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.265
• Thiazolidenedione
0.019
• Biguanides
-0.935
• Alpha-glucosidase
0.062
• Sulfonyl-biguanides
-0.461
• Meglitinides
Constant

4.436

*Significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 17.0%; F = 4.321; P = 0.000
Durbin-Watson: 2.109
White test for heteroskedasticity: χ2= 408.66; p= 0.3850
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0.660

0.363
0.902
0.112
0.912
0.413

6.722 0.000

Table 29: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on total outpatient costs (excluding depression)
Beta
S.E. Test statistic Sig.
(t)
(p)
0.325

0.077

Demographic characteristics
Age (in years)

-0.006

0.004

-1.607 0.108

Males (ref: females)

-0.168

0.074

-2.278 0.023*

0.070

0.151

0.464 0.643

-0.271

0.126

-2.158 0.031*

0.315
0.203
0.294

0.183
0.172
0.162

1.720 0.086
1.177 0.240
1.808 0.071

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.013

0.014

0.951 0.342

Total health costs

0.000

0.000

14.360 0.000*

Charlson co-morbidity

0.092

0.041

2.256 0.024*

Number of therapeutic classes
of medications

0.008

0.022

0.345 0.730

Cardio-vascular

0.187

0.078

2.401 0.017*

Cancer

0.073

0.192

0.379 0.705

Asthma

0.233

0.104

2.243 0.025*

Ulcers

0.363

0.209

1.736 0.083

Provider interaction in the pre period
PAAS enrollment

0.312

0.106

2.937 0.003*

Depression

Whites (ref: non-whites)
Urban (ref: rural)
Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

Number of pharmacies visited (ref: multiple pharmacies)
-0.263
0.176
• No pharmacy
-0.051
0.072
• Single pharmacy
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4.226 0.000*

-1.494 0.135
-0.712 0.476

Table 29: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on total outpatient costs (excluding depression) (Contd.)
Beta

S.E. Test statistic Sig.
(t)
(p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.183
0.276
• Endocrinologist
0.033
0.075
• Internal medicine

0.665 0.506
0.435 0.663

Total diabetes costs

0.000

1.6E-05

-1.291 0.197

Number of diabetes related
ER/Hosp visits

0.046

0.10086

0.456 0.648

Gap between index diagnosis
and prescription

0.000

0.0002

1.455 0.146

Initial polytherapy

0.277

0.15132

1.834 0.067

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.099
• Thiazolidenedione
-0.046
• Biguanides
0.244
• Alpha-glucosidase
-0.430
• Sulfonyl-biguanides
-0.094
• Meglitinides
Constant

0.14598
0.07555
0.27655
0.25836
0.27056

6.640

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 28.0%; F = 16.254; P = 0.000
Durbin-Watson: 1.925
White test for heteroskedasticity: χ2 = 390.70; p= 0.9330
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0.319

-0.676
-0.614
0.881
-1.665
-0.346

0.499
0.539
0.379
0.096
0.729

20.845 0.000

Table 30: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on total prescription costs (excluding depression)
Beta
S.E. Test statistic Sig.
(t)
(p)
Depression

0.270

0.048

5.668 0.000*

Demographic characteristics
Age (in years)

0.009

0.002

3.969 0.000*

-0.006

0.046

-0.132 0.895

0.030

0.094

0.319 0.750

-0.057

0.078

-0.735 0.463

0.018
0.121
0.068

0.113
0.107
0.101

0.159 0.874
1.134 0.257
0.673 0.501

Co-morbid conditions in the pre period
Number of ER/hosp visits
-0.006

0.009

-0.700 0.484

Total health costs

0.000

0.000

5.715 0.000*

Charlson co-morbidity

0.008

0.025

0.327 0.743

Number of therapeutic classes
of medications

0.183

0.013

13.533 0.000*

Cardio-vascular

0.068

0.048

1.406 0.160

Cancer

-0.129

0.119

-1.081 0.280

Asthma

0.059

0.064

0.910 0.363

Ulcers

0.010

0.128

0.079 0.937

-0.050

0.066

-0.757 0.449

Males (ref: females)
Whites (ref: non-whites)
Urban (ref: rural)
Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

Provider interaction in the pre period
PAAS enrollment

Number of pharmacies visited (ref: multiple pharmacies)
-0.275
0.109
• No pharmacy
-0.048
0.044
• Single pharmacy
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-2.528 0.012*
-1.087 0.277

Table 30: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of depression on total prescription costs (excluding depression) (Contd.)
Beta

S.E. Test statistic Sig.
(t) (p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.133
0.171
• Endocrinologist
0.014
0.046
• Internal medicine

0.776 0.438
0.298 0.766

Total diabetes costs

0.000

0.000

0.028 0.978

Number of diabetes related
ER/Hosp visits

0.025

0.063

0.396 0.692

Gap between index diagnosis
and prescription

0.000

0.000

0.979 0.328

Initial polytherapy

0.386

0.094

4.110 0.000*

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.336
• Thiazolidenedione
0.126
• Biguanides
0.117
• Alpha-glucosidase
-0.223
• Sulfonyl-biguanides
0.224
• Meglitinides
Constant

6.281

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 33.5%; F = 21.204; P = 0.000
Durbin-Watson: 2.004
White test for heteroskedasticity: χ2 = 459.76; p= 0.1633
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0.090
0.047
0.172
0.160
0.168

3.728
2.680
0.682
-1.391
1.334

0.000*
0.007*
0.495
0.164
0.182

0.198

31.796 0.000

Table 31: Negative binomial model for the impact of depression on number of
overall ER/hospitalization episodes (excluding depression)
Estimate
S.E.
Test statistic Sig.
(Chi-square) (p)
0.393

0.085

21.200 0.000*

Demographic characteristics
Age (in years)

-0.002

0.004

0.290 0.592

Males (ref: females)

-0.002

0.085

0.000 0.981

0.044

0.181

0.060 0.810

-0.009

0.146

0.000 0.948

0.126
0.059
0.132

0.216
0.204
0.195

0.340 0.560
0.080 0.773
0.460 0.499

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.197

0.017

127.470 0.000*

Total health costs

0.000

0.000

0.160 0.688

Charlson co-morbidity

0.089

0.043

4.390 0.036*

Number of therapeutic classes
of medications

0.052

0.024

4.630 0.031*

Cardio-vascular

-0.185

0.089

4.350 0.037*

Cancer

-0.210

0.216

0.950 0.330

Asthma

0.073

0.110

0.440 0.508

Ulcers

0.099

0.219

0.210 0.650

-0.060

0.123

0.240 0.626

Depression

Whites (ref: non-whites)
Urban (ref: rural)
Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

Provider interaction in the pre period
PAAS enrollment

Number of pharmacies visited (ref: multiple pharmacies)
0.201
0.204
• No pharmacy
-0.173
0.083
• Single pharmacy
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0.970 0.324
4.350 0.037*

Table 31: Negative binomial model for the impact of depression on number of overall
ER/hospitalization episodes (excluding depression) (Contd.)
Estimate

S.E.

Test statistic Sig.
(Chi-square) (p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.118
0.298
• Endocrinologist
0.103
0.085
• Internal medicine

0.160 0.692
1.450 0.229

Total diabetes costs

0.000

0.000

2.130 0.144

Number of diabetes related
ER/Hosp visits

0.206

0.102

4.100 0.043*

Gap between index diagnosis
and prescription

0.000

0.000

0.270 0.604

Initial polytherapy

0.230

0.170

1.840 0.175

0.161
0.086
0.355
0.309
0.323

1.140
0.000
3.260
2.620
0.170

0.369

0.690 0.407

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.172
• Thiazolidenedione
-0.003
• Biguanides
-0.641
• Alpha-glucosidase
-0.500
• Sulfonyl-biguanides
-0.134
• Meglitinides
Constant

-0.306

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
-2loglikelihood = 3948.0036 χ2= 377.59; p= 0.00
Dispersion estimate: 1.0099; χ2= 799.89; p = 0.000
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0.286
0.971
0.071
0.106
0.678

Table 32: Negative binomial model for the impact of depression on number of
overall physician office visits (excluding depression)
Estimate
S.E.
Test statistic Sig.
(Chi-square) (p)
Depression

0.253

0.060

17.770 0.000*

Demographic characteristics
Age (in years)

0.002

0.003

0.260 0.613

-0.121

0.058

4.330 0.037*

0.107

0.121

0.770 0.380

Urban (ref: rural)

-0.083

0.100

0.690 0.406

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

-0.077
0.021
0.059

0.145
0.136
0.129

0.280 0.596
0.020 0.879
0.210 0.649

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.038

0.012

10.700 0.001*

Total health costs

0.000

0.000

3.250 0.072

Charlson co-morbidity

0.046

0.030

2.350 0.125

Number of therapeutic classes
of medications

0.043

0.017

6.820 0.009*

Cardio-vascular

0.069

0.061

1.310 0.253

Cancer

0.042

0.150

0.080 0.781

Asthma

0.053

0.078

0.470 0.495

Ulcers

0.402

0.156

6.630 0.010*

Provider interaction in the pre period
PAAS enrollment

0.076

0.083

0.830 0.362

Males (ref: females)
Whites (ref: non-whites)

Number of pharmacies visited (ref: multiple pharmacies)
-0.316
0.146
• No pharmacy
-0.089
0.057
• Single pharmacy
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4.720 0.030*
2.420 0.120

Table 32: Negative binomial model for the impact of depression on number of overall
physician office visits (excluding depression) (Contd.)
Estimate

S.E.

Test statistic Sig.
(Chi-square) (p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.501
0.210
• Endocrinologist
0.138
0.059
• Internal medicine

5.710 0.017*
5.440 0.020*

Total diabetes costs

0.000

0.000

0.000 0.951

Number of diabetes related
ER/Hosp visits

0.008

0.080

0.010 0.925

Gap between index diagnosis
and prescription

0.000

0.000

0.690 0.405

Initial polytherapy

0.115

0.120

0.920 0.336

0.114
0.060
0.213
0.203
0.214

3.190
1.600
3.460
0.000
0.200

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.204
• Thiazolidenedione
0.076
• Biguanides
0.396
• Alpha-glucosidase
-0.014
• Sulfonyl-biguanides
0.096
• Meglitinides
Constant

1.522

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
-2loglikelihood= 7909.38; χ2= 205.05; p= 0.000
Dispersion estimate: 0.7588; χ2 = 3819.72; p= 0.000
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0.252

0.074
0.206
0.063
0.946
0.653

36.590 0.000

Table 33: Negative binomial model for the impact of depression on number of
overall prescriptions (excluding depression)
Estimate
S.E.
Test statistic Sig.
(Chi-square) (p)
Depression

0.155

0.031

25.390 0.000*

Demographic characteristics
Age (in years)

0.008

0.002

28.870 0.000*

-0.079

0.029

7.240 0.007*

0.028

0.061

0.210 0.643

Urban (ref: rural)

-0.022

0.050

0.180 0.669

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

-0.027
0.003
-0.042

0.074
0.069
0.065

0.140 0.710
0.000 0.968
0.420 0.518

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.001

0.006

0.030 0.862

Total health costs

0.000

0.000

18.150 0.000*

-0.002

0.016

0.010 0.916

Number of therapeutic classes
of medications

0.153

0.009

303.320 0.000*

Cardio-vascular

0.048

0.031

2.410 0.120

Cancer

-0.146

0.077

3.620 0.057

Asthma

0.051

0.041

1.540 0.215

Ulcers

0.060

0.082

0.540 0.464

Provider interaction in the pre period
PAAS enrollment

0.012

0.043

0.070 0.786

Males (ref: females)
Whites (ref: non-whites)

Charlson co-morbidity

Number of pharmacies visited (ref: multiple pharmacies)
-0.181
0.072
• No pharmacy
-0.059
0.029
• Single pharmacy
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6.260 0.012*
4.170 0.041*

Table 33: Negative binomial model for the impact of depression on number of overall
prescriptions (excluding depression) (Contd.)
Estimate

S.E.

Test statistic Sig.
(Chi-square) (p)

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.142
0.110
• Endocrinologist
0.034
0.030
• Internal medicine

1.670 0.197
1.320 0.251

Total diabetes costs

0.000

0.000

0.080 0.775

Number of diabetes related
ER/Hosp visits

0.019

0.041

0.220 0.637

Gap between index diagnosis
and prescription

0.000

0.000

0.210 0.648

Initial polytherapy

0.246

0.061

16.380 0.000*

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.024
• Thiazolidenedione
-0.025
• Biguanides
0.027
• Alpha-glucosidase
-0.272
• Sulfonyl-biguanides
-0.132
• Meglitinides
Constant

3.205

0.058
0.030
0.111
0.104
0.108
0.128

*Significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
-2loglikelhood: 1192.86; χ2= 664.45; p= 0.000
Dispersion estimate: 0.2128 (0.1956 – 02316); χ2= 3599.54; p= 0.000
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0.170
0.690
0.060
6.880
1.480

0.683
0.406
0.805
0.009*
0.224

632.110 0.000

Discussion for Objective 8

Our study results indicated that patients with depression had nearly 32.10% higher
health care costs as compared to patients without depression. These estimates were
obtained after adjusting for a number of baseline confounding factors such as
demographics, co-morbidity, diabetes severity, and interaction with health care providers.
A few studies in the literature have examined the impact of depression on health care
costs in patients with type 2 diabetes. Ciechanowski and associates28 showed that after
controlling for demographics, medical comorbidity, and diabetes severity, higher levels
of depression severity were associated with a significantly greater probability of having
an emergency department, primary care, specialty care, medical inpatient, and mental
health costs compared to patients with low severity depression. The total costs of the
high tertile group were $3,654 versus $ 2,653 in the medium depression tertile and
$2,094 in the low tertile groups. However, these reported costs were unadjusted and
were calculated for a six-month period. Also, it was a population-based study from two
primary care clinics with relatively small sample sizes, especially for assessing costs.
Egede and associates125 used the Medical Expenditure Panel Survey (MEPS) and showed
that patients with depression and diabetes incurred 4.5 times greater health care costs than
patients with diabetes alone. However, the numbers reported for excess costs seemed
unreasonably large thus raising concerns regarding the validity of the study results. Both
the above studies relied on self-reported data and had small sample sizes. Most
importantly, these studies examined total health care costs that included costs due to
depressive diagnosis, which will be higher for depressed patients irrespective of the
impact of depression on other chronic illnesses.
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The only study in literature which examined the impact of depression on nondepression related health care costs in type 2 diabetes patients was conducted by
Finklestein and associates127 using claims data from the 1997 Medicare 5% Standard
Analytic Files. The study results indicated that controlling for age, gender, race, and
comorbidities non-mental health care costs were approximately 21.00% higher for
depressed diabetics as compared to non-depressed diabetics. The authors also concluded
that depressed patients seek treatment for more services and when admitted, spend more
time in inpatient facilities than patients without depression. These differences in terms of
non-depression health costs between depressed and non-depressed diabetic patients were
lower than those obtained in our study (32.10%). Numbers in this study may be higher
since a more comprehensive utilization data was available for the study population as
opposed to Medicare claims which may not be furnish information related to some
expenditures such as prescription costs. The cost differences may also be due to a
younger population in this study (18-64 years of age) comprising of only newly
diagnosed type 2 diabetes patients.
The findings of higher health care costs among depressed patients in this study
corresponds with the literature that in patients with diverse medical illnesses, depression
makes a significant independent contribution to increased health care costs.113 Studies
have shown depression to be a good predictor of symptoms commonly associated with
worsening glucose control such as polyphagia and polydipsia. Depressive symptoms
may also be associated with a perception of impaired health and thus simulate worsening
diabetes symptoms.119 Such perceptions on the part of the patient may prompt both the
patient and provider to increase diagnostic testing, medical testing, and pursue aggressive
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treatment strategies. Adherence to medications and other behaviors can also be a
mediator between depression and health care expenditures.
Results for Objective 9
To examine the causal pathways between preexisting depression, adherence, and
outcomes such as resource utilization and costs for type 2 diabetes

Earlier objectives have examined the role that depression can play in affecting
adherence to oral hypoglycemics and type 2 diabetes related utilization and expenditures.
The following 4 steps were used to identify whether adherence with oral hypoglycemics
mediates the relationship between depression and type 2 diabetes outcomes. The
mediating relation is going to be tested using the four steps mentioned in the
methodology section.
Step 1: If depression is a significant predictor of type 2 diabetes outcomes

Results of a multivariate Semi-log Ordinary Least Squares (OLS) model indicated
that controlling for confounding covariates, patients with depression incurred 21.27%
higher type 2 diabetes costs as compared to non-depressed patients in the 12 month
follow up period (Table 19). These cost differences were primarily due to increased
likelihood of ER/hospitalization episodes for depressed patients. Results from a
multivariate logistic regression model indicated that depressed patients were nearly 1.4
times more likely to have an ER/hospitalization episode as compared to non-depressed
patients (Table 20A).
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Step 2: If depression significantly predicts adherence with oral hypoglycemics

Results indicated that patients with depression had significantly lower adherence
to oral hypoglycemics than non-depressed patients on the basis of both Reg MPR-1 and
Reg MPR-2. However, although the differences were significant the magnitude of
difference was not large with depressed patients being only 3.00% and 6.00% less
adherent than non-depressed patients on the Reg MPR-1 and Reg MPR-2 index
respectively. These estimates were found to be similar in both the univariate and
multivariate framework (Tables 14 and 15).
The multinomial logistic regression model for the impact of depression on
categories of adherence (Reg MPR-1 and Reg MPR-2) also indicated similar results.
Results of the multivariate model for Reg MPR-1 indicated that controlling for
confounding covariates, patients with depression were 1.9 times more likely to have low
adherence to oral hypoglycemics as compared non-depressed patients (Table 16B).
Results from the model for Reg MPR-2 demonstrated that depressed patients were 1.6
times more likely to be in the very low adherence group as compared to non-depressed
patients (Table 17A).
Step 3: If adherence significantly predicts outcomes while controlling for depression.

Results from the semi-log OLS models for the effect of adherence (Reg MPR-1
and Reg MPR-2) on type 2 diabetes related total costs were inconclusive. A non-linear
pattern of the effect of adherence on costs was observed with results indicating that
patients who had very low adherence have lower costs and patients with over adherence
have higher costs than patients with good adherence.
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The semi-log OLS model for the impact of Reg MPR-1 on type 2 diabetes costs
indicated that patients who were over adherent to their oral hypoglycemics medications
incurred nearly 65.00% greater type 2 diabetes related costs than patients who were
adherent to their medications (p=0.004) (Table 34). However, adherence with oral
hypoglycemics was not associated with the probability of a type 2 diabetes related
ER/hospitalization episode (Tables 35).
The semi-log OLS model estimating the impact of Reg MPR-2 on type 2 diabetes
costs demonstrated that patients with very low adherence had nearly 57.00% lower costs
as compared to patients who were adherent to their medications (p=0.000)(Table 36).
The logistic regression model to estimate the impact of adherence (Reg MPR-2) on
ER/hospitalization costs (Table 37) demonstrated that patients with low adherence were
nearly 1.6 times more likely to have a diabetes related ER/hospitalization episode
(p=0.029).
Step 4: If adherence mediates the impact of depression on type 2 diabetes outcomes

To establish that adherence completely mediates the relationship between
depression and outcomes, the effect of depression on outcomes controlling for adherence
should be zero. If partial mediation is exhibited then the effect of depression on outcomes
controlling for adherence should reduce in size. However, in both the models to estimate
effect of adherence on type 2 diabetes costs, depression demonstrated a significant effect
on outcomes without reducing its effect size as compared to models not controlling for
the effect of adherence.
A multivariate model indicated that controlling for confounding covariates other
than adherence, patients with depression incurred 21.27% higher type 2 diabetes costs as
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compared to non-depressed patients (Table 19). The impact of depression on type 2
diabetes costs remained significant even in models adjusted for adherence. The effect
size of depression also remained similar to the original model with adherence-adjusted
models indicating that patients with depression incurred 23%-31% higher costs than nondepressed patients (Table 34, 36).
Controlling for confounding covariates other than adherence, depressed patients
were nearly 1.4 times more likely to have an ER/hospitalization episode as compared to
non-depressed patients (p=0.028). (Table 20A) This effect of depression was maintained
in adherence-adjusted models with odds ratio of 1.537 and 1.390 for Reg MPR-1 and Reg
MPR-2 adjusted models respectively (Table 35, 37). The presence of mediation was
statistically tested by comparing the estimated effects of depression on type 2 diabetes
outcomes with and without controlling for adherence using a Hausman type statistic.
This statistic displayed no significant differences between the estimates confirming the
absence of adherence to oral hypoglycemic agents as a mediator between depression and
type 2 diabetes outcomes.
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Table 34: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of adherence (MPR-1) on total diabetes related costs
Beta
S.E. Test statistic Sig.
(t)
(p)
0.210

0.081

-0.199
-0.164
-0.024
0.520

0.248
0.129
0.087
0.181

Demographic characteristics
Age (in years)

0.001

0.004

0.221 0.825

Males (ref: females)

0.024

0.075

0.324 0.746

Whites (ref: non-whites)

-0.027

0.163

-0.165 0.869

Urban (ref: rural)

-0.157

0.128

-1.225 0.221

-0.252
0.184
0.093

0.190
0.178
0.167

-1.325 0.185
1.032 0.303
0.555 0.579

0.059

0.019

3.068 0.002*

Total health costs

0.000

0.000

-2.091 0.037*

Charlson co-morbidity

0.141

0.045

3.127 0.002*

Number of therapeutic classes
of medications
Cardio-vascular

0.043

0.023

1.910 0.057

0.031

0.083

0.371 0.711

Cancer

-0.078

0.215

-0.363 0.716

Asthma

0.050

0.111

0.453 0.651

Ulcers

0.352

0.231

1.521 0.129

Depression

2.579 0.010*

Adherence (Ref: Good adherence)
•
•
•
•

Very low adherence
Low adherence
Average adherence
Over adherence

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000
Co-morbid conditions in the pre period
Number of ER/hosp visits
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-0.801
-1.263
-0.277
2.870

0.423
0.207
0.782
0.004*

Table 34: Semi-log Ordinary Least Squares (OLS) regression model for the impact of
adherence (Reg MPR-1) on total diabetes related costs (Contd.)
Beta

Provider interaction in the pre period
PAAS enrollment

0.252

S.E. Test statistic Sig.
(t)
(p)

0.111

Number of pharmacies visited (ref: multiple pharmacies)
-0.059
0.194
• No pharmacy
-0.024
0.074
• Single pharmacy

2.268 0.024*
-0.306 0.760
-0.324 0.746

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.292
0.274
• Endocrinologist
0.044
0.079
• Internal medicine

1.066 0.287
0.564 0.573

Total diabetes costs

0.000

0.000

1.399 0.162

Number of diabetes related
ER/Hosp visits

0.125

0.104

1.203 0.229

Gap between index diagnosis
and prescription

0.000

0.000

0.467 0.641

Initial polytherapy

0.565

0.140

4.030 0.000*

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.553
• Thiazolidenedione
0.279
• Biguanides
0.177
• Alpha-glucosidase
-0.643
• Sulfonyl-biguanides
0.676
• Meglitinides
Constant

6.646

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 20.8%; F = 6.422; P = 0.000
Durbin-Watson: 2.050
White test for heteroskedasticity: χ2 = 465.86; p= 0.7675
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0.151
0.079
0.282
0.248
0.285

3.665
3.534
0.627
-2.597
2.370

0.000*
0.000*
0.531
0.010*
0.018*

0.339

19.602 0.000

Table 35: Logistic regression for the impact of adherence (Reg MPR-1) on having a
type 2 diabetes related ER/hospitalization episode
Beta S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.430 0.189 0.023*
1.537 1.061 2.226
Depression
Adherence (Ref: Good adherence)
•
•
•
•

Very low adherence
Low adherence
Average adherence
Over adherence

Demographic characteristics
Age (in years)

Males (ref: females)
Whites (ref: non-whites)
Urban (ref: rural)

0.566
0.137
0.266
0.378

0.307
0.653
0.202
0.362

1.761
1.147
1.304
1.459

0.594
0.630
0.867
0.647

5.223
2.088
1.961
3.290

0.006 0.010 0.520

1.006

0.987

1.026

-0.125 0.185 0.499

0.882

0.614

1.268

0.141 0.420 0.738

1.151

0.505

2.625

-0.033 0.310 0.915

0.968

0.527

1.776

0.461 0.266
0.424 0.539
0.398 0.902

0.599
1.298
1.050

0.243
0.565
0.481

1.477
2.981
2.294

0.055 0.000*

1.318

1.183

1.468

Year of index prescription (ref: 2001)
-0.513
• 1998
0.261
• 1999
0.049
• 2000
Co-morbid conditions in the pre period
Number of ER/hosp visits
0.276

0.555
0.305
0.208
0.415

Total health costs

0.000 0.000 0.971

1.000

1.000

1.000

Charlson co-morbidity

0.161 0.105 0.126

1.175

0.956

1.445

Number of therapeutic classes
of medications
Cardio-vascular

0.106 0.053 0.043*

1.112

1.003

1.233

0.009 0.203 0.965

1.009

0.678

1.501

Cancer

-0.623 0.525 0.236

0.536

0.191

1.502

Asthma

0.376 0.247 0.127

1.457

0.898

2.364

Ulcers

1.125 0.529 0.034*

3.081

1.091

8.697
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Table 35: Logistic regression for the impact of adherence (Reg MPR-1) on having a
type 2 diabetes related ER/Hospitalization episode
Beta

S.E. Sig.
(p)

Odds
ratio

95% C.I. for
Odds ratio
Lower Upper

Provider interaction in the pre period
PAAS enrollment
0.114 0.265 0.666

1.121

0.667

1.883

Number of pharmacies visited (ref: multiple pharmacies)
-0.037 0.550 0.946
• No pharmacy
0.170 0.179 0.343
• Single pharmacy

0.963
1.185

0.328
0.834

2.829
1.683

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.341 0.610 0.577
1.406
• Endocrinologist
0.178
0.185
0.334
1.195
• Internal medicine

0.425
0.832

4.646
1.716

Total diabetes costs

0.000 0.000 0.978

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.409 0.241 0.090

1.505

0.938

2.414

Gap between index diagnosis
and prescription

0.000 0.000 0.825

1.000

0.999

1.001

Initial polytherapy

0.249 0.321 0.438

1.283

0.683

2.408

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.158 0.365 0.666
• Thiazolidenedione
0.128 0.189 0.499
• Biguanides
-1.008
0.871 0.247
• Alpha-glucosidase
-0.484 0.602 0.422
• Sulfonylurea-biguanide
0.420 0.630 0.505
• Meglitinides

0.854
1.137
0.365
0.616
1.521

0.418
0.784
0.066
0.189
0.443

1.746
1.648
2.012
2.006
5.230

-2.671 0.834 0.001

0.069

Constant

*Significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
Pseudo R-square = 23.5%
-2 Log Likelihood = 871.069; χ2 = 153.705, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 8.552; p= 0.381
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Table 36: Semi-log Ordinary Least Squares (OLS) regression model for the impact
of adherence (Reg MPR-2) on total diabetes related costs
Beta
S.E. Test statistic Sig.
(t)
(p)
0.275

0.076

-0.840
0.023
-0.061
0.166

0.084
0.115
0.103
0.128

Demographic characteristics
Age (in years)

0.003

0.004

0.753 0.452

Males (ref: females)

0.056

0.072

0.776 0.438

Whites (ref: non-whites)

0.066

0.148

0.449 0.653

Urban (ref: rural)

-0.197

0.123

-1.600 0.110

Year of index prescription (ref: 2001)
• 1998
• 1999
• 2000

-0.014
0.393
0.306

0.179
0.168
0.159

-0.077 0.938
2.331 0.020*
1.932 0.054*

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.072

0.014

5.206 0.000*

Total health costs

0.000

0.000

-2.343 0.019*

Charlson co-morbidity

0.137

0.040

3.438 0.001*

Number of therapeutic classes
of medications
Cardio-vascular

0.053

0.021

2.489 0.013*

0.026

0.076

0.339 0.735

Cancer

-0.337

0.188

-1.797 0.073

Asthma

0.052

0.102

0.513 0.608

Ulcers

0.235

0.202

1.165 0.244

Depression

3.639 0.000*

Adherence (Ref: Good adherence)
•
•
•
•

Very low adherence
Low adherence
Average adherence
Over adherence
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-9.980
0.197
-0.593
1.294

0.000*
0.844
0.554
0.196

Table 36: Semi-log Ordinary Least Squares (OLS) regression model for the impact of
adherence (Reg MPR-2) on total diabetes related costs (Contd.)
Beta

Provider interaction in the pre period
PAAS enrollment

0.128

S.E. Test statistic Sig.
(t)
(p)

0.104

1.235 0.217

Number of pharmacies visited (ref: multiple pharmacies)
0.031
0.171
• No pharmacy
-0.034
0.070
• Single pharmacy

0.182 0.855
-0.484 0.628

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.307
0.270
• Endocrinologist
0.057
0.073
• Internal medicine

1.137 0.256
0.781 0.435

Total diabetes costs

0.000

0.000

0.467 0.641

Number of diabetes related
ER/Hosp visits

0.217

0.099

2.205 0.028*

Gap between index diagnosis
and prescription

0.000

0.000

1.309 0.191

Initial polytherapy

0.665

0.148

4.496 0.000*

Index class of oral hypoglycemic (ref: Sulfonyl urea)
0.612
• Thiazolidenedione
0.192
• Biguanides
-0.073
• Alpha-glucosidase
-0.735
• Sulfonyl-biguanides
0.506
• Meglitinides
Constant

6.259

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
R-square: 23.7%; F = 11.479; P = 0.000
Durbin-Watson: 1.995
White test for heteroskedasticity: χ2= 596.11; p= 0.0678
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0.142
0.074
0.271
0.252
0.265

4.312
2.593
-0.269
-2.914
1.914

0.000*
0.010*
0.788
0.004*
0.056

0.316

19.794 0.000

Table 37: Logistic regression for the impact of adherence (Reg MPR-2) on having a
type 2 diabetes related ER/hospitalization episode
Beta S.E. Sig.
Odds
95% C.I. for
(p)
ratio
Odds ratio
Lower Upper
0.330 0.151 0.029*
1.390 1.034 1.871
Depression
Adherence (Ref: Good adherence)
-0.025
• Very low adherence
0.485
• Low adherence
-0.070
• Average adherence
0.037
• Over adherence

0.975
1.624
0.932
1.038

0.692
1.051
0.609
0.615

1.374
2.510
1.428
1.752

0.002 0.007 0.804

1.002

0.987

1.016

Males (ref: females)

-0.038 0.150 0.802

0.963

0.718

1.292

Whites (ref: non-whites)

-0.013 0.311 0.965

0.987

0.536

1.815

0.095 0.258 0.713

1.100

0.663

1.824

Year of index prescription (ref: 2001)
-0.287 0.372 0.439
• 1998
0.419 0.344 0.223
• 1999
0.320 0.324 0.323
• 2000

0.750
1.520
1.377

0.362
0.775
0.730

1.554
2.983
2.598

Co-morbid conditions in the pre period
Number of ER/hosp visits
0.232 0.038 0.000*

1.261

1.170

1.359

Total health costs

0.000 0.000 0.493

1.000

1.000

1.000

Charlson co-morbidity

0.143 0.077 0.065

1.154

0.991

1.343

Number of therapeutic classes
of medications
Cardio-vascular

0.104 0.042 0.014*

1.110

1.021

1.206

-0.034 0.157 0.831

0.967

0.711

1.316

Cancer

-0.483 0.388 0.213

0.617

0.288

1.319

Asthma

0.238 0.194 0.220

1.268

0.868

1.854

Ulcers

0.663 0.394 0.092

1.941

0.898

4.199

Demographic characteristics
Age (in years)

Urban (ref: rural)

0.175
0.222
0.217
0.267
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0.885
0.029*
0.748
0.890

Table 37: Logistic regression for the impact of adherence (Reg MPR-2) on having a
type 2 diabetes related ER/hospitalization episode (Contd.)
Beta

S.E. Sig.
(p)

Odds
ratio

95% C.I. for
Odds ratio
Lower Upper

Provider interaction in the pre period
PAAS enrollment
-0.047 0.216 0.828

0.954

0.625

1.457

Number of pharmacies visited (ref: multiple pharmacies)
0.197 0.376 0.601
• No pharmacy
0.063 0.145 0.664
• Single pharmacy

1.217
1.065

0.583
0.802

2.541
1.413

Diabetes severity
Index oral hypoglycemic prescription by: (ref: Family medicine)
0.370 0.519 0.476
1.447
• Endocrinologist
0.139 0.147 0.344
1.149
• Internal medicine

0.523
0.862

4.002
1.532

Total diabetes costs

0.000 0.000 0.720

1.000

1.000

1.000

Number of diabetes related
ER/Hosp visits

0.455 0.199 0.022*

1.577

1.067

2.329

Gap between index diagnosis
and prescription

0.000 0.000 0.955

1.000

0.999

1.001

Initial polytherapy

0.213 0.290 0.463

1.237

0.701

2.184

Index class of oral hypoglycemic (ref: Sulfonyl urea)
-0.006 0.280 0.983
• Thiazolidenedione
-0.085 0.152 0.577
• Biguanides
-0.918 0.672 0.172
• Alpha-glucosidase
-0.572 0.520 0.271
• Sulfonylurea-biguanide
-0.078
0.546 0.887
• Meglitinides
-2.266 0.658 0.001
Constant

0.994
0.918
0.399
0.564
0.925
0.104

0.574
0.681
0.107
0.204
0.317

1.722
1.238
1.491
1.563
2.698

*significance at the 0.05 level
PAAS: Physician Assured Access System

Model fit statistics:
Pseudo R-square = 20.2%
-2 Log Likelihood = 1344.536; χ2 = 195.596, p= 0.000
Hosmer and Lemeshow’s goodness of fit: χ2 = 4.848; p= 0.774
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Discussion for Objective 9

The four step method for determining mediation indicated that adherence to oral
hypoglycemics is not a mediator in the relationship between depression and type 2
diabetes. Lustman and associates122,123 and Gary and associates131 conducted studies
using different methodological approaches to determine the mediating role of adherence
in the impact of depression on diabetes outcomes. Their findings were similar to our
study results with depression affecting diabetes outcomes without adherence being a
mediating variable.
As for the effect of adherence on type 2 diabetes related costs, our results
indicated lack of a strong association. However, the effect was non-linear with results
indicating that patients who had very low adherence have lower costs and patients with
over adherence have higher costs than patients with good adherence. For the middle
group, there seemed to be a linear trend with improving adherence decreasing type 2
diabetes costs. An interesting finding is the effect of over adherence on costs. Over
adherence is ignored in a lot of adherence studies by truncating the adherence levels at
1.0. In some situations over adherence may not be serious, while in other situations it
may result in serious conditions such as hypoglycemia or may be indicative of over
aggressive pharmacotherapy. The study also examined the effect of over adherence
separately on non-prescription type 2 diabetes costs. The effects remained the same
indicating higher type 2 diabetes costs in patients who are over adherent to their oral
hypoglycemics. Low costs for patients with low adherence may possibly be due to the
fact that these patients have achieved glycemic control through diet and exercise and
hence did not regularly filled their prescriptions. These results were similar to those of a
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recent retrospective cohort study conducted in a non-managed care setting, wherein a
non-linear effect was observed with significantly lower costs for patients with less than
20% adherence and significantly higher costs for patients with more than 100%
adherence. Adherence levels somewhere in between showed a weak negative linear
association with type 2 diabetes costs.84
The study had a short follow up period of one year. Diabetes is a chronic illness
and complications of diabetes normally arise years after diagnosis. Improved adherence
with oral hypoglycemics is likely to increase pharmaceutical costs in the short term. The
decreases in medical costs due to improved adherence may not be enough to offset the
high costs of pharmaceuticals in the short term. However, a couple of sub-analyses were
conducted to explore these issues. The objectives were examined in a sub-sample with a
24-month follow up period. Also, the impact of adherence on type 2 diabetes related
costs excluding those due to pharmaceutical expenditures were examined. However,
these sub-analyses provided identical results. It may take many years of improved
glycemic control through adherence to oral hypoglycemics to reduce medical costs
associated with treatment of long-term complications. Thus, the relationship between
depression, adherence, and type 2 diabetes related expenditures might differ with a longer
measurement period.
These results of this study could be possible as one failed to measure adherence to
other aspects of diabetes therapy such as diet, exercise, or glucose monitoring. Also, the
relation between depression and type 2 diabetes outcomes might occur via physiological
pathways that are independent of behavioral factors. It is possible that a common
neuroendocrine factor leads to both depression and diabetes. The increased expenditures
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may be a direct result of worsening glucose control due to changes in the autonomic
nervous system, the hypothalamic-pituitary adrenal axis, or neurotransmitters.
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CHAPTER FIVE
SUMMARY AND CONCLUSIONS
This chapter provides and overview of the study findings, draws conclusions,
presents implications of the study, lists limitations, and provides recommendations for
future research.
Phase 1

The potential effects of depression on outcomes associated with management of
type 2 diabetes may be significant when one considers that depression is highly prevalent
in patients with diabetes. In addition to the increased prevalence of co-morbid depression
in patients with type 2 diabetes, a few studies have also indicated an increased incidence
of type 2 diabetes in patients with depression. Depression is related to changes in
nutrition and exercise that may contribute to risk for diabetes; and there may be somatic
aspects of depression such as a change in the immune or vascular system that contributes
to enhanced risk for diabetes onset. Phase 1 of the study examined the epidemiological
relationship between depression and type 2 diabetes. Objectives of this phase included
determining the prevalence of co-morbid depression in patients with type 2 diabetes and
the incidence of type 2 diabetes in patients with pre-existing depression.
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Conclusions for Phase 1
Objective 1: To estimate prevalence of co-morbid depression in patients with type 2
diabetes

The null hypothesis for this objective was that there is no difference between the
prevalence of co-morbid depression in patients with type 2 diabetes and without type 2
diabetes. The study results indicated that co-morbid depression was more prevalent in
patients with type 2 diabetes as compared to enrollees without type 2 diabetes. The
higher prevalence of depression was primarily due to the higher number of co-morbid
conditions associated with type 2 diabetes. However, one can attribute these co-morbid
conditions and subsequent depression to type 2 diabetes and thus reasonably conclude
that type 2 diabetes is associated with a higher prevalence of co-morbid depression.

Objective 2: To estimate the incidence of type 2 diabetes in patients with pre-existing
depression

The null hypothesis for this objective was that there is no difference in the
incidence rate of type 2 diabetes in patients with pre-existing depression as compared to
patients without pre-existing depression. The results indicated that female patients with
pre-existing depression are more likely to develop type 2 diabetes as compared to
enrollees without pre-existing depression controlling for baseline confounding factors
such as demographics and co-morbidity. No differences in incident rates were observed
in males.
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Phase 2

Phase 2 of the study examined the impact of depression on patterns of oral
hypoglycemic use, initiation of insulin therapy, and adherence with oral hypoglycemics.
The effect of depression on utilization and expenditures related to type 2 diabetes and
overall health care (excluding those due to depressive diagnosis) was also estimated. In
addition, the study also tested the mediating influence of adherence with oral
hypoglycemics between depression and outcomes related to management of type 2
diabetes.

Conclusions for Phase 2
Objective 3: To examine the impact of preexisting depression on patterns of oral
hypoglycemic use in new patients with type 2 diabetes

The null hypothesis for this objective was that there is no difference in the pattern
of oral hypoglycemic use between newly diagnosed type 2 diabetes patients who have
pre-existing depression and those who do not have pre-existing depression. The study
findings indicated that patients without depression had a significantly favorable pattern of
oral hypoglycemic use as compared to non-depressed patients. A significantly higher
proportion of depressed patients, switched, augmented or discontinued their index oral
hypoglycemic therapy as compared to non –depressed patients.
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Objective 4: To examine the impact of preexisting depression on modification of oral
hypoglycemic therapy

The null hypothesis for this objective was that there is no difference in the rate of
modification of oral hypoglycemics between newly diagnosed type 2 diabetes patients
who have pre-existing depression and those who do not have pre-existing depression.
The results indicated that patients with depression had a significantly higher rate of
modification of oral hypoglycemic therapy and had a relatively shorter time to
modification as compared to non-depressed patients.

Objective 5: To estimate the impact of preexisting depression on initiation of insulin
therapy in patients with type 2 diabetes

The null hypothesis for this objective was that there is no difference in the rate of
initiation of insulin therapy between newly diagnosed type 2 diabetes patients who have
pre-existing depression and those who do not have pre-existing depression. The null
hypothesis for this objective was accepted as no differences were seen in rates of insulin
initiation and time to insulin therapy between depressed and non-depressed patients in the
12-month follow up period.

Objective 6: To estimate the impact of preexisting depression on adherence to oral
hypoglycemic agents

The null hypothesis for this objective was that there is no difference in adherence
to oral hypoglycemics between newly diagnosed type 2 diabetes patients who have preexisting depression and those who do not have pre-existing depression. The findings
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demonstrated that depressed patients had significantly lower adherence to oral
hypoglycemic agents as compared to non-depressed patients. However, the magnitude of
difference was not large with results indicating that patients with depression were 3-6%
less adherent than non-depressed patients.

Objective 7: To estimate the impact of preexisting depression on type 2 diabetes related
utilization and costs

The null hypothesis for this objective was that there is no difference in type 2
diabetes related utilization and costs between newly diagnosed type 2 diabetes patients
who have pre-existing depression and those who do not have pre-existing depression.
Patients with depression had significantly higher type 2 diabetes related costs as
compared to non-depressed patients. Results indicated that controlling for confounding
covariates, patients with depression incurred around 21.30% higher type 2 diabetes costs
as compared to non-depressed patients. These cost differences were primarily due to a
higher probability of an ER/hospitalization episode in depressed patients as compared to
non-depressed patients. Also, a significant difference between the two groups was in
terms of number of type 2 diabetes related ER/hospitalizations with depressed patients
incurring nearly 57.80% higher number of visits as compared to non depressed patients.

Objective 8: To estimate the impact of preexisting depression on overall health care
utilization and costs (excluding those due to depressive diagnosis)

The null hypothesis for this objective was that there is no difference in overall
health care utilization and costs between newly diagnosed type 2 diabetes patients who
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have pre-existing depression and those who do not have pre-existing depression. Patients
with depression had nearly 32.10% higher overall health care costs (excluding those due
to depressive diagnosis) as compared to patients without depression. Depression was
associated with increased costs in all areas of health care such as ER/hospitalization,
outpatient, and prescription costs. A similar increase in health care utilization was
observed for depressed patients in terms of number of ER/hospitalization episodes,
physician office visits, and prescriptions in the 12-month follow up period.

Objective 9: To examine the causal pathways between preexisting depression,
adherence, and outcomes such as resource utilization and costs for type 2 diabetes

The null hypothesis for this objective was that adherence to oral hypoglycemics is
not a mediating variable between the presence of pre-existing depression and outcomes
related to management of type 2 diabetes. Mediation analysis indicated that depression
had a significant impact on both, type 2 diabetes related expenditures and adherence with
oral hypoglycemics. However, adherence to oral hypoglycemics was not a mediator
between depression and type 2 diabetes related expenditures. Depression could have
impacted type 2 diabetes related outcomes directly through a physiological effect on
glycemic levels or indirectly through its impact on adherence to other behaviors such as
diet or exercise.
Limitations
Although our database study revealed the patterns of oral hypoglycemic use such

as switching, augmentation, discontinuation, it gives no indication of the reasons for
these patterns. These patterns could be a result of variety of reasons such as side effects,
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lack of efficacy, adequate glycemic control, or co-morbid conditions. Determining these
reasons from claims data without additional clinical or patient/physician reported
information is not possible. The study could have classified some patients who achieved
glycemic control through diet and exercise and were taken off their oral hypoglycemic
prescriptions as discontinuers and non-adherent. Also, the adherence measures were
based on refill information from prescription claims data. Hence, the study makes the
assumption that the prescriptions filled by patients were used appropriately. These
indirect measures of adherence from claims data may not be considered the most accurate
and reliable, but several studies have found significant associations between adherence
measured from refill information and other methods such as self-report, pill count,
medication diary.166
Adherence to medications can be affected by a number of factors, which were not
measured in this study such as social support, perceived risk of the outcomes of being
non-adherent, and others. One of the primary factors affecting adherence to oral
hypoglycemics is diabetes severity. All our estimation models were controlled for
severity of diabetes, which was measured from the information available from claims
data. Although large variations in diabetes severity were not expected in this study
population of newly diagnosed type 2 diabetes patients, additional laboratory values such
as A1C and blood glucose levels would have been helpful in determining disease
severity. These laboratory values could also have been very useful as clinical outcome
measures of diabetes therapy in addition to economic outcomes such as type 2 diabetes
related expenditures.
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One of the primary limitations of this study is the absence of measurement of
depression severity though a structured diagnostic interview. Depressed patients in this
study are identified on the basis of seeking treatment for depression. Hence, it is possible
that patients in this study classified as non-depressed may have depression
symptomatology but not been diagnosed with depression. This issue of
undiagnosed/unrecognized depression can potentially lead to misclassification bias as
patient classified as non-depressed could be patients with undiagnosed depression.
However, one can assume that diagnosed patients will have more severe depressive
symptoms as compared to an undiagnosed population. Also, this misclassification could
only lead to underestimation of the effect of depression on adherence to medications and
related outcomes. The significant impact of depression found in this study’s results
would remain significant, but have a bigger magnitude of effect in absence of this
misclassification.
The mediation analyses indicated that adherence to oral hypoglycemics had a
non-linear and insignificant impact on type 2 diabetes related costs. However, diabetes is
a chronic illness and complications of diabetes arise after several years of diagnosis.
Improved adherence with oral hypoglycemics is likely to increase pharmaceutical costs in
the short term. The decreases in medical costs due to improved adherence may not be
enough to offset the high costs of pharmaceuticals in the short term. This study used a
12-month follow up period since the initial diagnosis of type 2 diabetes. It may take
many years of improved glycemic control through adherence to oral hypoglycemics to
reduce medical costs associated with treatment of long-term complications. Thus the
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relationship between depression, adherence, and type 2 diabetes related expenditures
might differ with a longer measurement period.

Implications

Study results indicated that depression is associated with significantly higher type
2 diabetes and overall health care costs. Also, the rate of occurrence of depression in
patients with type 2 diabetes was significantly higher as compared to Medicaid enrollees
without type 2 diabetes. These results should encourage West Virginia Medicaid,
national credentialing committees, large insurers, and employers to screen for depression
in patients with type 2 diabetes and improve clinical management of depression in these
patients. The implications of untreated depression on long-term type 2 diabetes
complications can be even more significant when one considers that depression may be
recurrent in diabetes patients. This data suggests that interventions are needed to screen
diabetes patients for depression and use effective and aggressive therapies for treatment
of depression. These data may provide an impetus for improving the detection and
treatment of depression. Such increased effort in detecting and treating depression may
be associated with additional non-psychiatric health benefits due to improved adherence,
glycemic control, and decreased health care utilization.
Also, the observed higher risk of type 2 diabetes among female patients with
depression may suggest that physicians need to monitor diabetic metabolic changes in
females with depression for early detection and treatment of type 2 diabetes. Undetected
and untreated type 2 diabetes can aggravate diabetic complications thus resulting in
increased costs associated with management of type 2 diabetes. Considering the high
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prevalence of depression in West Virginia Medicaid, an improved screening and
detection of type 2 diabetes may result in better disease management and cost saving.
In addition to improving depression screening for patients with type 2 diabetes,
one must systematically identify patients who have both type 2 diabetes and depression to
ensure appropriate quality of care and the need for more aggressive treatment. The
recognition of depression as a risk factor for decreasing adherence with oral
hypoglycemics and increasing type 2 diabetes related expenditures has the potential to
improve diabetes management and related outcomes. A potential barrier to effective
depression management among type 2 diabetes patients is the lack of an overall unified
view of a patient’s condition encompassing both the conditions. Although the Health
Plan Employer Data and Information Set (HEDIS) has included performance measures
for both depression and diabetes care, separate standards should also be set for the
treatment of type 2 diabetes with co-morbid depression. Programs addressing such
multiple disorders must search for commonalities in treatment.167 A good example can be
the emphasis on increased physical activity for management of both diabetes and
depression. Also, given the crucial role of depression in diabetes, mental health
professionals can play an important role in the care of these patients. This also calls for
mental health professionals to create working relations with diabetes health care
providers, including physicians, nurses, dietitians, pharmacists, and others.
Physicians can help improve patient adherence to treatment regimens by
addressing adherence issues with their patients regularly and providing them with
educational materials. Pharmacists can also assume a proactive role, especially in type 2
diabetes patients with co-morbid depression. These data suggest that patients with
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depressive symptoms should have their adherence to oral hypoglycemics monitored
particularly closely and may require special encouragement from health care providers.
Recognizing that a patient might be depressed could help a physician fathom the reasons
for a patient’s non-adherence and thus improve patient-physician relationship. For
patients initiating treatment for type 2 diabetes, presence of depression might prove to be
a useful indicator of possible future non-adherence and might suggest closer monitoring
and assistance to achieve adherence to treatment. Alternatively, a lack of adherence with
diabetes pharmacotherapy should cause concern for a possible presence of co-morbid
depression.

Directions for Future Research

One of the main limitations of this study was the lack of clinical information
regarding glycemic control and depression severity. The study also failed to measure
adherence to other behaviors such as diet, exercise, and glucose monitoring that can
affect management of type 2 diabetes. Incorporation of this clinical and adherence
information in the study design can increase the validity of the findings. The relationship
between depression and type 2 diabetes can be better explained in such a large scale
longitudinal study that measure indicators such as adherence to medications, diet, and
exercise, alterations in neurohormonal levels, depression severity, and glycemic levels at
several points in time. Similar research can be conducted in patients with type 2 diabetes
developing depression over the course of their diabetes management. The effect of the
onset of depression on changing adherence with oral hypoglycemics and related
outcomes in a prevalent type 2 diabetes patient should also be examined.
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There are a number of approaches to measure adherence with medications. Refill
information using claims data seems a relatively valid and non-intrusive method to
measure adherence. However, future studies can use multiple methods of adherence
measurement such as pill count, self-report, or MEMS cap to validate the results from
refill information. One of the main problems with refill data is the absence of
information on free samples provided by physicians, which can especially invalidate the
patterns of oral hypoglycemic use computed in our study. Similar studies in literature
have measured patterns of use in terms of discontinuation, augmentation, modification,
and switching from claims data. Future research needs to examine the extent of free
samples being provided by physicians and adjustments be made to findings from claims
data.
The excess costs attributable to depression in patients with type 2 diabetes or
other chronic illness may be more significant if costs due to sick leave, missed
productivity, or absenteeism from the work force are accounted. Thus, the impact of
depression may more substantial from a societal perspective, which includes costs outside
of the health care system. In future research, the policy discussion related to the impact
of depression on costs should be expanded to include such indirect costs.
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• Developed a smoking-specific quality of life instrument for adolescents and
assessed the cost-effectiveness of the adolescent smoking cessation program in
collaboration with the Centers for Disease Control and Prevention (CDC)
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RESEARCH EXPERIENCE
11/2003-06/2004
Cardiovascular events and expenditures in patients with type 2 diabetes
Primary consultant on a grant funded by Takeda pharmaceuticals to assess the burden of
cardiovascular conditions in patients with type 2 diabetes and the differential effect of
choice of therapy on expenditures related to type 2 diabetes
08/2001- 04/2002
QT lengthening in patients with schizophrenia
Principal investigator of an unrestricted educational grant provided by Eli Lilly & Co. to
explore the utilization of QT lengthening drugs in patients with schizophrenia in West
Virginia Medicaid
08/2000 – 08/200
Burden of Barrett’s esophagus: prevalence and cost estimates
Research assistant on a study funded by Pharmacia & Co. to assess the economic burden
of Barrett’s esophagus and esophageal cancer in the West Virginia Medicaid population.
Assisted in the study design, analyses and publication of the study results
06/2000 – 07/2001
Assessing the need for smoking cessation programs in West Virginia Medicaid
Research assistant on a study funded by the West Virginia Bureau of Medical Services to
assess the prevalence, attitudes, and preferences of smokers to aid in developing smoking
cessation programs. Assisted in study design, survey development, analyses and
publication of the study results

TEACHING EXPERIENCE
08/1998 - 12/1999
Teaching Assistant at the School of Pharmacy, West Virginia University
• Pharmacy as a Profession: Responsibilities included grading, management of
course materials, and facilitation of student projects
• Pharmacy Care Lab & Patient Health Education: Responsibilities included
conducting communication skills exercises, evaluating student verbal and nonverbal patient consultation skills, and grading group presentations
• Outcomes Assessment and Quality Improvement. Responsibilities included
lecturing and preparing handouts on topics in pharmacoeconomics such as cost
utility analyses
01/10/2002
Evidence-based decision making workshop
Conducted a decision-making workshop on economic evaluations in public health for the
employees of West Virginia Bureau for Public Health
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RELEVANT COURSES
Pharmacoeconomics, Econometrics, SAS, Quality of Life Assessment, Epidemiology,
Data Management and Analyses, Survey Research, Health Services Marketing, and
Health Behavior Theories
COMPUTER SKILLS
Statistical packages: SPSS, SAS, HLM
Decision analysis software: DATA TreeAge, @ RISK, Precision Tree

PUBLICATIONS
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15 months later. American Journal of Public Health 2004; 94(2): 181-184
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Prevention Science 2004; 5(2): 113-26
Dino GA, Kamal KM, Horn KA, Kalsekar I, Fernandes AW. Stage of change and
smoking cessation outcomes among adolescents. Addictive Behaviors 2004; 29(5): 93540
Kalsekar I, Makela E, Moeller K. Analysis of West Virginia Medicaid claims data for
the prevalence of medical conditions and use of drugs likely to cause QT prolongation in
patients with schizophrenia. Current Therapeutic Research 2003; 64(8): 538-550
Horn K, Fernandes A, Dino G, Massey CJ, Kalsekar I. Adolescent nicotine dependence
and smoking cessation outcomes. Addictive Behaviors 2003; 28(4): 769-776
Amonkar M, Kalsekar I, Boyer JG. The economic burden of Barrett’s esophagus in a
Medicaid population. The Annals of Pharmacotherapy 2002; 36(4): 605-611
Massey CJ, Horn K, Goldcamp J, McCracken A, Dino G, Kalsekar I. School-based teen
smoking cessation programs: Recruitment issues in research. Journal of School Health
2003; 73(2): 58-63
Dino G, Horn K, Goldcamp J, Fernandes A, Kalsekar I, Massey CJ. A two-year
efficacy study of Not-On- Tobacco in Florida: An overview of program successes in
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Horn K, Dino G, Kalsekar I, Mody R. The impact of Not On Tobacco on teen smoking
cessation: End-of-program evaluation results, 1998-2003. Journal of Adolescent
Research. (In press)
Mody R, Kalsekar I, Madhavan S, Hassan M, Amonkar M. Assessing smoking behavior
and attitudes towards smoking cessation in a state Medicaid population. Journal of
Health Care for the Poor and Underserved. (Under review)
Hassan M, Kalsekar I, Madhavan S, Mody R, Amonkar M. Determinants of smoking
among women of childbearing age in West Virginia Medicaid. Journal of Women’s
Health. (Under review)
SELECTED POSTER PRESENTATIONS
Kalsekar I, Makela E, Moeller K. Assessment of utilization of drugs and prevalence of
conditions leading to QT lengthening in patients with schizophrenia. Presented at the
annual meeting of the American Pharmaceutical Association (APhA), New Orleans, LA,
March 2003
Horn KA, Dino GA, Goldcamp J, Kalsekar I, Mody R. The Not On Tobacco teen
smoking cessation program: A review of end-of-program findings from 1998-2002.
Presented at the annual meeting of the Society for Prevention Research, Washington,
D.C., June 2003
Kamal KM, Kalsekar I, Fernandes A, Horn K, Dino G. "Stages of Change and Smoking
Cessation Outcomes in Adolescents." Presented at the annual meeting of the National
Conference on Tobacco and Health, San Francisco, CA, November 2002
Fernandes A, Kalsekar I, Horn K, Massey CJ, Dino G. Adolescent nicotine dependence
and smoking cessation outcomes. Presented at the annual meeting of the Society for
Prevention Research, Washington, D.C., May 2001
Joshi AV, Nau D, Kalsekar I. An appraisal of health-related quality of life instruments
for use in patients diagnosed with Human Immunodeficiency Virus (HIV) disease.
Presented at the annual meeting of the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR), Arlington, VA, May 2001
Rosenbluth SA, Kalsekar I, Ma JK. Pharmacy Student Research Conference - Eastern
States: A study of presenter’s interests, opinions, and careers. Presented at the Annual
Meeting of the American Association of Colleges of Pharmacy (AACP), Toronto,
Canada, July 2001
Dino G, Horn K, Goldcamp G, Fernandes A, Kalsekar I, Massey CJ. A two-year
efficacy study of NOT-ON- TOBACCO in Florida: An overview of program successes in
changing teen smoking behavior. Presented at the annual meeting of the Society for
Prevention Research, Washington, D.C., May 2001
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REVIEWER
American Journal of Managed Care
Social Science and Medicine
HONORS/AFFILIATIONS
Recipient of Graduate Teaching Award, School of Pharmacy, West Virginia University
Recipient of Graduate Research Award, School of Pharmacy, West Virginia University
Member of Rho Chi Honor Society
Member of International Society for Pharmacoeconomics & Outcomes Research
(ISPOR)
Member of American Pharmaceutical Association (APhA)
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